PLVAP as the gatekeeper of endothelial cell permeability and leukocyte migration by Jäppinen, Norma
A
N
N
A
LES U
N
IV
ERSITATIS TU
RK
U
EN
SIS
N
orm
a Jäppinen
D
 1445
ISBN 978-951-29-7780-2 (PRINT)
ISBN 978-951-29-7781-9 (PDF)
ISSN 0355-9483 (PRINT) ISSN 2343-3213 (ONLINE)
Pa
in
os
al
am
a 
O
y, 
Tu
rk
u 
, F
in
la
nd
  2
01
9
PLVAP AS THE 
GATEKEEPER OF 
ENDOTHELIAL CELL 
PERMEABILITY AND 
LEUKOCYTE MIGRATION
Norma Jäppinen
TURUN YLIOPISTON JULKAISUJA – ANNALES UNIVERSITATIS TURKUENSIS
SARJA – SER. D OSA – TOM. 1445 | MEDICA – ODONTOLOGICA | TURKU 2019
 
TURUN YLIOPISTON JULKAISUJA – ANNALES UNIVERSITATIS TURKUENSIS 
SARJA - SER. D OSA – TOM. 1445 | MEDICA – ODONTOLOGICA | TURKU 2019 
 
 
 
 
 
Norma Jäppinen 
PLVAP AS THE 
GATEKEEPER OF 
ENDOTHELIAL CELL 
PERMEABILITY AND 
LEUKOCYTE MIGRATION 
University of Turku 
Faculty of Medicine 
Institute of Biomedicine 
Medical Microbiology and Immunology 
Turku Doctoral Programme of Molecular Medicine 
Supervised by 
Academician MD, PhD, Sirpa Jalkanen 
Institute of Biomedicine 
MediCity Research Laboratory 
University of Turku 
Turku, Finland 
 
Docent, PhD, Pia Rantakari 
Institute of Biomedicine 
University of Turku 
Turku, Finland 
Professor, MD, PhD Marko Salmi 
Institute of Biomedicine 
MediCity Research Laboratory 
University of Turku 
Turku, Finland 
 
 
 
 
 
Reviewed by 
Professor, MD, PhD, Risto Renkonen 
Department of Bacteriology and 
Immunology 
Transplantation Laboratory 
University of Helsinki 
Helsinki, Finland 
Docent, PhD, Marja Mikkola 
Institute of Biotechnology 
University of Helsinki 
Helsinki, Finland 
Opponent 
Professor, MD, PhD, Mika Rämet 
PEDEGO Research Unit 
University of Oulu 
Oulu, Finland 
Laboratory of Experimental Immunology 
University of Tampere 
Tampere, Finland  
The originality of this publication has been checked in accordance with the University 
of Turku quality assurance system using the Turnitin OriginalityCheck service. 
ISBN 978-951-29-7780-2 (PRINT) 
ISBN 978-951-29-7781-9 (PDF) 
ISSN 0355-9483 (Print) 
ISSN 2343-3213 (Online) 
Painosalama, Turku, Finland 2019 
 3 
 
 
Perheelleni  
4 
UNIVERSITY OF TURKU 
Faculty of Medicine 
Institute of Biomedicine 
Medical Microbiology and Immunology 
NORMA JÄPPINEN: PLVAP as the Gatekeeper of Endothelial Cell 
Permeability and Leukocyte Migration 
Doctoral Dissertation, 214 pp. 
Turku Doctoral Programme of Molecular Medicine  
October 2019 
ABSTRACT 
Endothelial cells (EC) line the lymphatic and vascular vessels of the body, forming 
a barrier between the lumen and surrounding tissue. ECs actively coordinate the 
exchange of migrating cells, fluids and molecules thus regulating tissue 
homeostasis. Correctly working endothelium is also important during the 
embryonic development, as progenitor cells have tight time windows to reach and 
colonize target tissues. Failures to do so lead to perturbed cell composition and 
lasting adverse effects in the adulthood. In the blood endothelium, plasmalemma 
vesicle-associated protein (PLVAP) forms diaphragms on specific plasma 
membrane structures (transendothelial channels, fenestrae and caveolae) and has 
been showed to regulate the EC permeability in blood vessels. However, the role of 
PLVAP in the lymphatic endothelium is not characterized, nor its role in the 
immune system during development. 
The aim of this thesis was to use in vivo and in vitro -methods to investigate 
endothelial cells in the lymph node and liver. The results of this thesis show that 
PLVAP is unexpectedly expressed in distinct lymphatic ECs of the lymph node and 
there, PLVAP regulates the antigen and lymphocyte entry to the lymph node. 
During development PLVAP expression is crucial for migration of macrophage 
progenitors and the emerging of a F4/80Hi tissue-resident macrophage population in 
several organs. In mammary gland, the F4/80Hi macrophages form a major 
population of the steady state macrophage pool and that their unique functions 
cannot be performed by other macrophage types. 
KEYWORDS: Endothelium, PLVAP, lymph node, cell traffic, tissue specific 
macrophage, mammary gland   
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TIIVISTELMÄ 
Kehon veri- ja imusuonistoa vuoraa endoteelisoluista koostuva kerros, joka toimii 
aktiivisena rajapintana suonten sisätilan ja ympäröivien kudosten välillä. 
Endoteelisolut suodattavat lävitseen soluja, nesteitä sekä molekyylejä ja säätelevät 
näin kehon fysiologista tasapainoa. Endoteelisolujen toiminta on tärkeää aikuisten 
kudosten homeostaasin ylläpidon säätelyssä, mutta myös sikiönkehityksen aikana 
ohjaamassa solujen esiasteiden kulkua kohdekudoksiinsa. Plasmalemma vesicle-
associated protein (PLVAP) on veriendoteelisolujen pinnalla ilmentyvä proteiini, 
joka muodostaa siivilämäisiä suodattimia endoteelisoluihin. PLVAP:n on 
aikaisemmin osoitettu vaikuttavan endoteelisolujen läpäisevyyteen verisuonistossa. 
Tämän väitöskirjan tarkoituksena on tutkia in vivo ja in vitro-metodeja 
käyttäen imusolmukkeen ja maksan endoteelisoluja ja selvittää, kuinka PLVAP-
riippuvainen endoteelisolupermeabiliteetti säätelee soluliikennettä ja miten 
soluliikenteen häiriintyminen sikiönkehityksen aikana vaikuttaa myöhemmin 
kudoksissa.  
Väitöskirjatutkimuksessa selvitettiin, että PLVAP esiintyy odottamattomasti 
imusolmukkeen sinuksen endoteelisoluissa, joissa se säätelee antigeenien ja solujen 
pääsyä imusolmukkeeseen. Lisäksi selvisi, että sikiökautisessa maksassa PLVAP 
säätelee makrofagien esiasteiden pääsyä verenkierron kautta kohdekudoksiinsa. 
Näytimme, että normaalitilassa rintakudoksen makrofagipopulaatio koostuu 
merkittävin osin sikiöperäisistä kudosmakrofageista, joilla on erityistehtäviä, joita 
muut makrofagit eivät pysty suorittamaan. 
AVAINSANAT: Endoteeli, PLVAP, imusolmuke, soluliikenne, kudosspesifiset 
makrofagit, rintakudos  
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1 Introduction 
The wellbeing of an individual largely depends on the ability to maintain effi-
ciently working defense systems in the body, be it during the physiological steady 
state or under threats during pathological conditions like inflammation or cancer. 
Well-functioning communication between organs, facilitated by vasculature, is the 
cornerstone of immunity. The network of vessels provides a highway for the 
signals from the periphery to be distributed to the vital lymphoid organs where they 
are interpreted and reacted to accordingly. The vasculature can be divided to two 
distinct parts, the blood vasculature and the lymphatic vasculature. The two are 
intertwined, and have structural similarities among the dividing factors. The 
innermost layer of both vasculatures consists of endothelium, a cell layer that not 
only acts as a barrier between the lumen of the vessel and surrounding tissues, but 
also actively regulates the permeability of the vessels. Disturbances in the vessel 
permeability can lead to disturbed exchange of fluids, molecules and cells. 
(Cleaver and Krieg, 2010, Escobedo and Oliver, 2016) The regulation of cell traffic 
is especially important during embryogenesis, which is a precisely regulated 
cascade of events within a narrow time window. (Melton and Cleaver, 2003) 
Perturbations in cell trafficking caused by incorrectly working endothelium during 
development can lead to lasting effects on the cellular composition and function of 
tissues. 
Plasmalemma Vesicle Associated Protein (PLVAP) is an endothelial cell 
specific protein which has been shown to regulate cell traffic and the permeability 
of fenestrated blood endothelium. (Stan et al. 2012) However, little is known about 
PLVAPs role in the lymphatics and the cell traffic across the lymphatic 
endothelium. The research projects in this thesis show for the first time that 
PLVAP is also expressed in the lymphatic endothelial cells (LECs) of the lymph 
node and there it regulates the permeability of lymphatic endothelial cells of the 
subcapsular sinus. During the study of the immunological role of PLVAP, it 
became evident that the PLVAP deficient mice have major perturbations in 
macrophage populations in several tissues. The emergence of tissue-resident 
macrophages occurs during embryogenesis, in a process which involves cell 
migration across the liver sinusoidal endothelium. (Rafii et al. 1997) The molecules 
Norma Jäppinen 
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which govern the migration of the fetal macrophage precursors were unknown, 
thus we hypothesized a role for PLVAP as it affects permeability in several other 
tissues. The results showed that the expression of PLVAP during development is 
necessary for the emergence of F4/80Hi tissue-resident macrophages in adulthood. 
Finally, a closer look at the mammary gland was taken, since the macrophage 
dependent ductal development was clearly perturbed in the Plvap−/− mice. It was 
shown that the majority of macrophages in the adult mammary gland originate 
from the fetal era and that the tissue-resident macrophages have a distinct 
phenotype and function in comparison to monocyte-derived macrophages. Detailed 
information about tissue macrophage composition is crucial for the development of 
new treatment strategies that rely on modulation of endogenous immune cells. 
 15 
2 Review of the Literature 
The immune system is an intricate combination of specialized subsystems. This 
literature review will discuss the development and functions of blood and 
lymphatic vasculature, lymph nodes, macrophages and mammary gland. The role 
of endothelium in cell and molecule migration at steady state and the role of 
PLVAP in the permeability of endothelial cells will also be discussed. 
2.1 The immune system 
The immune system is a system of cells and organs working together in order to 
protect against a disease and maintain the host homeostasis. The body comes in 
contact with a vast amount of both new and previously encountered antigens daily. 
Bacteria, viruses, parasites and fungi, or a part of them or their products act as 
antigens that need to be recognized from host cells and, if necessary, destroyed 
efficiently. To achieve this, the body has two systems that work together to protect 
the host: the innate immunity and the adaptive immunity. The innate response is 
rapid, but also less specific and somewhat explosive, whereas the adaptive 
immunity reacts more slowly but counters with specific responses and an 
immunological memory which helps fight a reoccurring infection. (Iwasaki, 
Medzhitov 2015, Wood 2015) 
The body has several tiers of protection against pathogens. Pathogen entry into 
the body is limited by the physical barrier of the intact skin on the outside and 
mucosal barriers on the inside of the body, in addition to commensal bacteria and 
resident immune cells in both barriers. (Naik et al. 2012) If the antigen has been 
able to find its way to the body, the innate immunity is the first responder. The 
initiation of first immune response relies on recognition of highly conserved 
pathogen-associated molecular patterns which are present in large groups of micro-
organisms. (Janeway 1992) The first reaction to infection or injury is usually 
inflammation, driven by local macrophages, fibroblasts, mast cells, and dendritic 
cells (DCs) and accompanied by circulating leukocytes, including neutrophils and 
monocytes. (Newton, Dixit 2012) A more elaborate and targeted response occurs 
shortly after, once the antigen reaches the lymph node and is presented to T cells 
with the help of antigen presenting cells (APCs). Activated T cells differentiate 
Norma Jäppinen 
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into CD4+ T helper cells which can assist other T cells in differentiating into 
cytotoxic T cells which have the ability to kill other cells. T helper cells can also 
promote B cell responses by helping B cells become plasma cells which produce 
large quantities of antibodies. Some of the B cells undergo affinity maturation and 
differentiate into memory cells which remain in the body and can start the 
production of higher affinity antibodies quickly if the same antigen is encountered 
a second time. The APCs, T cells and B cells work together to produce an 
appropriate adaptive immune reaction. (Wood 2015) 
Even though inflammation is often the first appropriate reaction to many 
external or internal threats, like pathogens and tissue injury, it needs to be carefully 
controlled. Correctly working immunity creates a proportional response to antigens 
or infection caused by them and is able to curb the inflammation when the threat 
subsides. (Koh, DiPietro 2011) Problems in controlling the immune response can 
lead to chronic inflammation, autoimmune diseases or immunodeficiency.  
Chronic inflammation is linked to a heightened risk for cardiovascular disease 
(Ridker et al. 1997) and type 2 diabetes (Duncan et al. 2003), both major health 
issues worldwide. Autoimmune diseases are the result of the immune system 
mistakenly attacking healthy tissues and destroying autologous cells. These 
diseases, such as multiple sclerosis, Crohn’s disease and autoimmune thyroiditis 
are becoming more prevalent in the Western societies, perhaps due to 
environmental factors. (Lerner et al. 2016) In addition to the diseases caused by an 
over aggressive immune system, the lack of immune responses can be even more 
dangerous and often lethal. Immunodeficiency caused by genetic mutations 
(Buckley et al. 1999) or the human immunodeficiency virus (Autran et al. 1997) 
leads to loss of immune cells or their function and severely hampers the ability to 
fight infections. Thus, modulation of the immune system is warranted as the 
diseases caused by overly active immune system and immunodeficiency not only 
cause pain and discomfort but also predispose the patients to other diseases and 
cancer. (Grulich et al. 2007, Park et al. 2010) 
Curbing the immune responses in order to control extreme inflammation or 
autoimmune reactions relies on immunosuppressive medication. Drugs in the 
glucocorticoid family (Croxtall et al. 2002) and non-steroidal drugs and biologics 
(Pato et al. 2011) are commonly used for the inhibition of lymphocyte activity. The 
immune system can be activated before the onset of a disease through 
immunization, commonly achieved with vaccinations. Vaccinations, often 
combined with a response enhancing adjuvant (Mosca et al. 2008), activate the 
immunological memory and provide a relatively long term protection against 
certain diseases later in life. (Hammarlund et al. 2016) Boosting the immune 
activity in immunosuppressive conditions can be achieved by a combination of 
drugs to decrease the viral load and allow immune cell recovery (Autran et al. 
Review of the Literature 
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1997) or by hematopoietic stem cell gene therapy (Clarke et al. 2018). Despite the 
various existing methods to modulate the immune system, new approaches are 
needed, because many of the current methods are aggressive and have adverse 
effects due to non-specificity of drug distribution and the development of 
resistance. (Pato et al. 2011, Wilson et al. 2019) 
The protective and homeostasis maintaining effects of the immune system 
often relies on the presence of immune cells. For the purpose of surveilling the 
body and reaching the site of action, the immune cells must travel using the blood 
and lymphatic vessels which act as highways from tissue to another. The next 
sections review the development of the two important vessel systems and the inner 
lining cell compartment of the vessels, the endothelial cells, with particular in-sight 
to the endothelial protein PLVAP. 
2.1.1 The cardiovascular and lymphatic vasculature 
The circulatory system has developed to offer nutrients and oxygen to every cell in 
the body, to transport waste from the tissues and to facilitate cell traffic throughout 
the body. The cardiovascular and lymphatic vasculatures circulate blood and lymph 
respectively, to ensure that the tissues receive nutrients and also to simultaneously 
facilitate immune surveillance. Blood vasculature distributes oxygenated blood 
from the arteries to the vessels which sprout from the larger veins, finally reaching 
the small capillaries. Blood is circulated back towards the lungs to release the 
carbon dioxide and re-oxygenate the blood. (Cleaver and Krieg 2010) Similarly to 
the blood vasculature, the lymphatic vessels traverse most of the body. Even the 
central nervous system, which was thought to be devoid of lymphatic vasculature, 
has been shown to be drained by lymphatic vessels in certain areas, in addition to 
the local microglia-dependent drainage. (Aspelund et al. 2015, Petrova and Koh 
2018) The lymphatic capillaries collect interstitial fluid, antigens and activated 
lymphocytes into larger lymphatic vessels, which transport the lymph to the 
thoracic duct, which empties into the central veins. In addition to lymph drainage, 
the lymphatics contribute to lipid metabolism. (Wang et al. 2017) 
Cells and molecules in the vessels must enter and exit the lumen at suitable 
points to reach their destination within the tissues. Intra- and extravasation 
cascades of lymphocytes are complex multistep processes which involve several 
proteins and interaction between the lumen facing endothelium and the migrating 
lymphocytes. (Vestweber 2015) Structurally, the blood and lymphatic vessels are 
composed of an inner lining of endothelial cells and varying degrees of basement 
membrane (nonexistent in some parts). The vessels are surrounded by different 
widths of smooth muscle cells depending on the vessel type and finally are 
wrapped in elastic tissue and fibrous connective tissue. The contracting smooth 
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muscle cells and luminal valves in the veins and bigger lymphatic vessels help the 
blood and lymph flow going to the right direction. Blood is pumped in a closed 
circuit system that is powered by the heart, while lymph seems to flow in a more 
passive manner due to body movement and respiration. (Cleaver and Krieg 2010, 
Jones and Min 2011, Wang et al. 2017) 
2.1.1.1 Development of blood and lymphatic vasculature 
The cardiovascular system is one of the first functional organ systems to develop in 
the embryo, understandably so because the system provides nutrients and 
transports cells and signals within the developing fetus and thus enables the growth 
of an individual. (Ferrara et al. 1996) In the extra embryonic mouse yolk sac, blood 
islands form from mesoderm-derived hemangioblasts. Hemangioblasts give rise to 
endothelial cell precursors, angioblasts, and hematopoietic precursors. The 
hematopoietic precursors give rise to primitive red blood cells by E8.0 in mice. 
Simultaneously, the aorta and the heart tube form in the embryo proper without 
contact with hematopoietic cells. The angioblasts in the yolk sac produce 
endothelial cells in response to local cues produced by the mesoderm, resulting in 
the growth of the blood islands which then fuse together, forming the rudimentary 
vasculature (primary vascular plexus). The endothelial cells proliferate and form 
new vessels by sprouting from the existing plexus in a process termed 
angiogenesis. Endothelial proliferation and angiogenesis is often prompted by the 
vascular endothelial growth factor (VEGF) signaling, mediated by the receptors 
VEGFR1 (Flt-1) and VEGFR2 (Flk-1) on the endothelial cells. (Ferrara et al. 1996) 
Functional circulation is achieved at E8.5, when the yolk sac and embryo proper 
vasculature are connected, although it takes two more days for the circulation to be 
fully functional. (McGrath et al. 2003) Finally, the vessels mature to be able to 
support the increasing blood flow. The endothelial cells synthesize a thicker 
basement membrane and recruit vascular wall components such as pericytes and 
smooth muscle cells to stabilize the vessels. Later, vessels develop different 
characteristics in response to endothelial cell interaction with the surrounding cells, 
enabling the vessels to transform into arteries, veins and smaller vessels like 
venules and capillaries according to the tissue demands. Advanced techniques have 
revealed that several organs such as liver, lung, pancreas, stomach/intestine, and 
spleen also have hemangioblasts, which contribute to the vasculogenesis (the 
formation of blood vessels, without sprouting from an existing vessel) within the 
organ. (Risau et al. 1988, Risau and Flamme 1995, Shalaby et al. 1995, McGrath et 
al. 2003, Cleaver and Krieg 2010) 
In adult tissues, vasculogenesis is rare. The need for increased blood supply is 
usually met with new blood vessels sprouting from the existing ones (angiogenesis) 
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in response to tissue signals, as opposed to de novo formation of blood vessels. 
VEGF and angiopoietins 1 and 2 are important for the correct migration and 
maturation of the sprouting blood vessels. (Hattori et al. 2001, Lim et al. 2004) 
The development of lymphatic vasculature occurs simultaneously with 
vasculogenesis, but is regulated by different signaling. The majority of lymphatic 
vessels arise from blood vessels, by sprouting from Prox1+ endothelial cells during 
the early development around E10. (Wigle, Oliver 1999, Martinez-Corral et al. 
2015, Escobedo, Oliver 2016) In addition to budding from venous endothelial cells, 
recent research has revealed that some lymphatic endothelium originates from a 
nonhematopoietic precursor, the exact cell type of the lymphatic endothelial cell 
(LEC) progenitor however is not clear. (Martinez-Corral et al. 2015) Once 
established, the primary lymphatic vessels continue to grow and develop into 
initial, blind ended lymphatic vessels, larger smooth muscle cell coated collector 
vessels with valves and finally into lymphatic veins. (Wang et al. 2017) 
2.1.1.2 Endothelial cells 
Both the blood and lymphatic vasculature are lined with a layer of endothelial cells. 
As described above, the endothelium plays a pivotal role in the development of 
new vessels by orchestrating the vessel formation by cell-cell interactions and 
cytokine production. In adulthood, the endothelial cells remain a dynamic 
interphase between the cells and molecules in the vessel lumen and the surrounding 
tissue. Endothelial cells have a heterogeneous gene profile (Chi et al. 2003), 
however, they perform similar functions in many tissues. Endothelium participates 
in cell migration by expressing adhesion molecules like intercellular adhesion 
molecule-1 (ICAM) and AOC3 and producing chemokines. (Stolen et al. 2005, 
Millán et al. 2006) They also control vasodilation by producing substances to 
constrict or dilate the vessel and even have the ability to phagocytose. (Ingerman-
Wojenski et al. 1981, Dini et al. 1995, Anselmo and Mitragotri 2017) In the lymph 
node, the endothelium is important for induction of peripheral tolerance, as the 
LECs are able to present endogenous antigens directly to T cells. (Cohen et al. 
2010) 
In addition to their secretory and interactional functions, endothelium can be 
categorized based on the morphology into continuous, discontinuous or fenestrated 
endothelium (Figure 1A). The different endothelial types differ vastly in their 
permeability. The need for certain type of endothelium highly depends on the 
vessel size, location and function, therefore all types of endothelium can be found 
even within one organ, such as the different compartments of the kidney. (Risau 
1998) The endothelial type can also experience changes brought on by 
developmental maturing. During early development, when the liver is an active 
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hematopoietic organ, the fenestrated liver endothelium is overlaid with 
diaphragms, but the diaphragms are not found in adult liver. (Stan 2007) 
 
Figure 1.  A schematic picture of continuous, discontinuous and fenestrated endothelium (A). 
Plasma membrane structures caveola, transendothelial channel (TEC) and fenestra 
with PLVAP diaphragms are pictured in the insert (B). BM= basement membrane, N= 
nucleus, L= lumen. 
Continuous endothelium is characterized by an uninterrupted layer of endothelial 
cells, where the endothelial cells are joined together by tight, zipper-like junctions, 
accompanied by a continuous basement membrane. This type of endothelium is 
typical for veins, arteries and collecting lymphatics and is the most non-permeable 
endothelium type. The exchange of molecules through the cell is facilitated by 
vesicle transport. (Predescu et al. 1997, Baluk et al. 2007, Aird 2012) 
Small capillaries are often lined with discontinuous endothelium. The typical 
features of discontinuous endothelium are poorly formed basement membrane and 
the lack of tight junctions between endothelial cells. Discontinuous endothelium is 
the most permissive of endothelial types and is often found in capillaries of tissues 
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with extensive molecular traffic such as the liver and bone marrow. (Streeten, 
Brandi 1990, Risau 1995, Aird 2012, Stan et al. 2012) 
Fenestrated endothelium is characterized by transcellular pores which are 
overlaid with diaphragms. The basement membrane however is continuous. 
Fenestrated endothelium can be found in organs that are involved in secretion or 
filtration such as the endocrine glands and intestinal mucosa. (Streeten, Brandi 
1990, Aird 2012) 
Structures such as caveolae, transendothelial channels (TECs) and fenestrae 
can be found on the endothelium plasma membrane. These structures are usually 
found in the peripheral part of the endothelial cell and they are important for the 
transcellular (through the cell) passage of macromolecules and migration of cells. 
Caveolae are invaginations of the plasma membrane, coated by caveolin-1, which 
is an essential protein for the assembly of caveolae. (Razani et al. 2001) Caveolae 
facilitate the uptake and transport of molecules, such as albumin, from the blood to 
the tissue. (Schubert et al. 2001) Unlike caveolae, TECs and fenestrae create a 
direct route through the endothelial cells. Fenestrae are circular openings of the 
endothelial cell, which often organize in groups called sieve plates. (Loannidou et 
al. 2006) Depending on the tissue, the aforementioned plasma membrane structures 
are selectively covered with stomatal diaphragms. (Stan, Kubitza et al. 1999)  
So far, only one protein, Plasmalemma Vesicle Associated Protein (PLVAP), 
has been reported to participate in the formation of the diaphragms. PLVAP 
diaphragms have been shown to regulate the endothelial cell permeability in 
fenestrated blood vasculature. The following section will focus on the biology and 
endothelial functions of PLVAP. 
2.1.1.3 Plasmalemma Vesicle Associated Protein (PLVAP) in 
vasculature 
Plasmalemma Vesicle Associated Protein (PLVAP, PV-1 or MECA-32 antigen and 
in humans PAL-E or FELS) is an endothelial cell specific protein which has only 
been reported in the blood vessel endothelium and thus widely used as a blood 
endothelium specific marker. Electron microscopy studies show that PLVAP forms 
cartwheel like diaphragms on the plasma membrane of endothelial cells. The 
average diameter of the diaphragm is 60-70 nm and the sieve is composed of fibrils 
that are conjoined by a central knob, forming openings with the arc width of 5-6 
nm. PLVAP is the only known component of the diaphragms and is necessary for 
their formation. (Bearer, Orci 1985, Rhodin 1962, Stan et al. 2012). Diaphragms 
are found on endothelium surface structures such as TECs, caveolae and fenestrae 
(Figure 1B) but are notably missing in the intercellular junctions. (Stan, Kubitza et 
al. 1999, Stan, Ghitescu et al. 1999) The caveolae and transendothelial structures 
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form independently of PLVAP and are often encountered in tissues with extensive 
molecular traffic between bloodstream and tissue, such as the liver and endocrine 
glands, suggesting a role for the fenestrae in the cell traffic and molecule exchange. 
(Stan et al. 2012) In in vitro setting, PLVAP diaphragms are needed for the 
formation of correctly organized fenestrae and sieve plates and the fenestra 
formation can be stimulated with VEGF. (Loannidou et al. 2006) In the absence of 
caveolae, TECs and fenestrae, PLVAP is rapidly internalized, which would suggest 
that forming the diaphragm is the only role for PLVAP. (Tkachenko et al. 2012) 
PLVAP has been extensively studied for decades and the distribution of Plvap 
expression has been mapped in rat (Hnasko, McFarland et al. 2002), mouse and 
human (normal and neoplastic) tissues (Stan et al. 2001, Strickland et al. 2005). 
PLVAP mRNA can be found in mouse embryo as early as E7.5, hinting at the fact 
that PLVAP may be important for normal embryonic development. Expression of 
Plvap mRNA is highest in tissues with extensive traffic between blood and tissues, 
such as the lung and kidney and little to no expression was detected in the brain 
and testis. (Stan et al. 2001) 
Precious structural data about PLVAP diaphragms have been acquired from in 
vitro studies, but because endothelial permeability is a complex phenomenon, in 
vivo models are necessary to study the role of PLVAP. Mouse and human Plvap 
mRNA distributions show only quantitative differences, which has corroborated 
the use of mouse models in PLVAP studies. (Stan et al. 2001) Deletion of the gene 
of interest is a common approach to study the role of a specific gene, thus knock 
out mouse models of Plvap have been developed in a few research groups. The 
Plvap−/− mice do not survive on a pure breed genetic background and the models 
are slightly different in regard to their mixed genetic background, but they all show 
the same hallmarks of PLVAP deficiency: embryonic lethality, blood lipid 
perturbations and leaky blood vessels. (Herrnberger et al. 2012, Stan et al. 2012) 
Recently, perturbations in the maintenance of a subpopulation of B cells in the 
peritoneum and spleen of Plvap−/− mice have been described. (Elgueta et al. 2016) 
The severe phenotype of the Plvap−/− mice highlights the importance of PLVAP 
for normal homeostasis. 
PLVAP diaphragms in fenestrated blood endothelium regulate permeability by 
acting as physical sieves. They filter small molecules from the plasma, but leave in 
sizeable (>70 kDa) proteins. (Stan et al. 2012) In addition to passive filtering, 
PLVAP diaphragms have also been shown to interact with several molecules and 
chemokines. Molecules like Neuropilin-1 (Keuschnigg et al. 2012), VEGF 
(Strickland et al. 2005) and heparin (Hnasko et al. 2002) interact with PLVAP in 
vitro, but the biological function of these interactions have not been elucidated. 
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2.1.1.4 PLVAP/PAL-E in humans 
In humans, the monoclonal antibody PAL-E (Patologische Anatomie Leiden 
Endothelium) was discovered in the 1980s as a new staining reagent for 
endothelium. (Schlingemann et al. 1985) In non-pathological tissues, PAL-E was 
reported to stain the endothelium in the capillaries, sinusoids and small and 
medium sized veins. The antibody has been useful to discriminate between 
vascular and lymphatic endothelium, as no signal seems to be detected in the 
lymphatic ducts. In 2005 it was revealed that PAL-E:s target is actually PLVAP 
(Niemelä et al. 2005) and the discovery was further solidified by Keuschnigg et al. 
in 2012 (Keuschnigg et al. 2012). 
Only rare cases of Plvap gene mutations in humans have been reported, 
probably because the effects of complete loss of Plvap function are so severe that 
the development of an affected individual stops very early. So far, only two cases 
of nonsense mutations and two cases of missense mutations have been reported in 
patients with protein-losing enteropathy. The effects of the missense mutations are 
milder, but similarly to mouse models, the lack of functional PLVAP in humans 
leads to severely compromised endothelial barrier function, resulting in edema, 
hypoproteinemia, hypoalbuminemia, hypertriglyceridemia and premature death. 
(Elkadri et al. 2015, Broekaert et al. 2018, Kurolap et al. 2018) The symptoms in 
humans verify the validity of the mouse models and underline the importance of 
PLVAP in human endothelial permeability and intestinal and vascular integrity. 
2.1.1.5 PLVAP is a potential target for drug development and treatment 
Loss of PLVAP is difficult to treat, but many pathological conditions have been 
associated with altered endothelial permeability and increased PLVAP expression. 
Cancer growth demands increased supply of blood and nutrients and therefore 
angiogenesis is often promoted by the tumor produced VEGF, which also induces 
PLVAP expression. Many anti-cancer treatments focus on targeting the tumor 
angiogenesis. Vascular permeability also increases in inflammation, because of the 
increased signaling and immune cell traffic in the inflamed tissue. The expression 
of PLVAP is reported to be increased in many pathological conditions such as 
nephritis in rats and the vasculature of many human tumors. (Strickland et al. 2005, 
Ichimura et al. 2008) In addition to cancer biology, PLVAP has been extensively 
studied in the field of eye and brain research. The blood-brain-barrier and blood-
retinal-barrier are easily affected by changes in PLVAP expression and subsequent 
changes in permeability. (Bosma et al. 2018)  
Inhibiting PLVAP expression has led to positive results in in vitro and in vivo 
experiments. The differential expression in healthy and cancer-associated 
endothelium was utilized by Wang et al. who successfully induced necrosis in 
Norma Jäppinen 
24 
hepatocellular carcinoma by treating the tumor with anti-PLVAP antibody. (Wang 
et al. 2014) Suitably administered PLVAP inhibitors might also become a novel 
target for diabetic macular edema therapy and other retinal diseases. (Wisniewska-
Kruk et al. 2016, Nakagami et al. 2019) Recently, PLVAP was successfully used as 
a target for drug delivery in the lungs. (Shuvaev et al. 2018) Because PLVAP is so 
widely expressed in the body, there is a heightened risk for adverse effects if the 
target tissue or cell type is not limited by selective formulation or administration 
route. Further research in mouse models and humans is needed but these results 
show that the function of PLVAP can be modified with encouraging outcomes. 
2.1.2 The peripheral lymph node 
Lymph nodes (Figure 2) are strategically located encapsulated secondary 
lymphoid organs which are connected to each other via the lymphatic vasculature 
and seeded by blood vessels. Lymph nodes develop during E15-E20.5 in mouse 
from lymphoid tissue inducer cells, which migrate from blood vessels in the 
prospective location of the lymph nodes. (Bovay et al. 2018) Hundreds of lymph 
nodes in the body serve as centrals for stromal components, APCs and circulating 
lymphocytes. The close interaction between the immune cells and the exposure to 
antigens and pathogens promote effective initiation of immune responses. Lymph 
nodes serve as important gatekeepers to prevent the spread of pathogens and 
metastatic cancer cells. (Brown et al. 2018) Therefore the traffic to and from the 
lymph node is carefully regulated. 
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Figure 2.  Schematic view of a peripheral lymph node. The arrowheads represent the direction of 
the lymph flow. HEV= High endothelial venule. 
2.1.2.1 Subcapsular sinus 
The lymph node is encapsulated by a bilayer of Prox1+ LECs which form a sinus 
that can be divided to a ceiling and a floor. LECs in the mouse subcapcular sinus 
(SCS) can be identified by their expression of markers such as Lyve-1, Prox-1 and 
podoplanin. (Baluk, McDonald 2008) The sinus is flushed by the constant flow of 
lymph, arriving via afferent lymphatic vessels from the periphery. The lymph is 
enriched with antigens and antigen presenting DCs, which together indicate the 
immune status of the tissues that drain to the specific lymph node. From the sinus, 
free flowing antigens can enter the parenchyma of the lymph node, but instead of 
pouring through the LEC floor, the entry of unbound antigens is size selective. 
Molecules of the molecular weight of 70 kDa or smaller have been shown to enter 
the lymph node. Exclusion of larger molecules could protect the lymph node 
lymphocytes from substances that might disturb the immune reaction, such as 
microbes and their soluble products. However, even if the lymph node is infected 
with a virus and enlarged in size, the filtering function of the LECs in the SCS 
floor remains unperturbed. (Gretz et al. 2000) Larger antigens need to be 
transported to the lymph node by migrating DCs. (Berney et al. 1999) The LECs in 
the SCS floor and medullary sinus are accompanied by CD169+ macrophages. 
They sample antigens from the lymph and either eliminate the antigens by 
phagocytosis, thus keeping the infections from spreading, or efficiently present the 
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antigens to the underlying B cells, subsequently activating the B cells. (Junt et al. 
2007) The SCS continues all the way to the LEC lined medullary sinus of the 
lymph node and to the adjacent efferent lymphatic vessels. The medulla is 
phenotypically distinct from other parts of the LEC lined sinus, but its detailed 
function is not fully understood. (M'Rini et al. 2003, Iftakhar-E-Khuda et al. 2016) 
The efferent lymphatics facilitate the exit of lymphocytes through a process which 
is regulated by specific mechanisms involving sphingosine 1-phosphate and its 
receptors. (Allende et al. 2004) 
2.1.2.2 Parenchyma 
In addition to BECs and LECs, the lymph node parenchyma is inhabited by 
heterogeneous and functionally versatile stromal cells. Stromal fibroblastic 
reticular cells (FRCs) and follicular dendritic cells offer structural support and 
assist the homeostasis of the compartmentalized structure of the lymph node 
parenchyma. B cells gather together to form follicles directly under the SCS, but T 
cells reside more dispersed in the paracortex. Parenchymal cells define the limits of 
the lymphocyte compartments by controlling B and T cell CCR7-dependent 
movement within the parenchyma. (Bajénoff et al. 2006, Carrasco, Batista 2007) 
Even though the stromal cells and resident lymphocytes actively interact with each 
other, the development of the majority of stromal cells seems to be independent of 
B and T cells. (Fletcher et al. 2011) In addition to structural support, the stromal 
cells also express lymphocyte survival factors and take part in antigen presentation 
and induce self-tolerance among T cells. (Link et al. 2007, Cohen et al. 2010) 
2.1.2.3 Conduit system 
Immediately under the SCS begins the reticular conduit system, a three 
dimensional network of fibroblast reticular cell wrapped collagen strands and 
fibrils. This complex system travels from the SCS to the high endothelial venules 
(HEVs). The network is most dense in the T cell areas, but conduits can be found 
in the B cell areas as well. (Roozendaal et al. 2009) Resident DCs are in contact 
with the conduit system, probing the antigens travelling through the conduits. 
Immigrated DCs however do not seem to make contact with the conduit system. 
(Sixt et al. 2005) The conduit system is specialized in transporting several different 
kinds of cargo. Small antigens, larger IgM produced by resident B cells and even 
viral particles are able to enter the conduit system and be transported to the resident 
immune cells. (Thierry et al. 2018, Reynoso et al. 2019) The conduit system offers 
a pathway for antigens in the lymph to be quickly transported from the SCS to the 
HEV and be sampled on the way. Antigen transport via conduits happens in 
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minutes, in comparison to the hours it takes for an antigen transporting DC to 
arrive from the periphery. (Salomon et al. 1998, Gretz et al. 2000) Rapid import of 
antigens and immunoglobulins within the lymph node and further exit of antigen 
specific lymphocytes ensure an efficient response in peripheral tissues. 
2.1.2.4 Resident leukocytes 
Migration of lymphocytes into the lymph node is a complicated process. In brief, 
Naïve IgM+ B cells and naïve CD44LowCD62LHi T cells travel to the lymph node 
parenchyma from the bone marrow and thymus respectively. (Gorelik et al 2003, 
Mempel et al. 2004) Both enter the PLN via the parenchymal blood vessels, HEVs, 
in a multistep process which is regulated by several factors, such as CCR7 in the 
lymphocytes, the HEVs and HEV associated DCs. (Young 1999, Stein et al. 2003, 
Girard et al. 2012, Veerman et al. 2019) T cells from the periphery arrive to the 
lymph node via the SCS, also this step seems to require assistance from the DCs in 
the lymph. (Braun et al. 2011) It is not clear which specific mechanisms are used 
during the migration of lymph-borne cells through the SCS LEC layer, but in 
general the migration across endothelium can occur between endothelial cells 
(paracellular route) or through an endothelial cell (transcellular route). Both 
migration routes involve distinct tethering of the LEC-layer by the lymphocytes, 
however the compared to paracellular migration, transcellular migration is more 
dependent on podosome function. (Carman et al. 2007) Expression of molecules 
such as CD73 on lymphocytes and Stabilin-1/CLEVER-1 and ICAM-1 on the ECs 
are some of the many molecules that have been shown to be important for 
migration of lymphocytes across the lymphatic and blood endothelium. (Xu et al. 
2001, Ålgars et al. 2011, Shetty et al. 2011) 
The purpose of the lymph node and its compartments is to provide effective 
communication between the immune cells and APCs, which is essential for the 
lymphocyte activation. Local APCs work with migrated DCs to present processed 
parts of encountered antigens to resident lymphocytes. (Allan et al. 2006) Priming 
by DCs induces activation markers such as CD25 and CD44, cytokine secretion 
and proliferation in T cells. T cell interaction is mostly contact-dependent, in 
comparison to the secretory manner in which B cells perform their functions. 
(Mempel et al. 2004) B cell activation occurs within the B cell follicle after 
exposure to the antigen with the help of their B cell receptor or a follicular DC or 
after interaction with an activated T cell. Activated GL7+ B cells in the germinal 
center begin the process of differentiating into plasma cells and long lasting 
memory cells. (Gorelik et al. 2003, McHeyzer-Williams, McHeyzer-Williams 
2005)  
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2.2 Macrophages 
Macrophages are vital participants in several functions within the body, ranging 
from embryonic development to coordinating immune responses and maintaining 
homeostasis. Macrophages are specialized myeloid cells which take part in 
phagocytosis, scavenging, antigen presentation and cytokine production. 
Practically every tissue and organ is colonized with macrophages in the steady state 
and the macrophage counts usually increase in inflamed conditions. (Massberg et 
al. 2007, Ginhoux et al. 2016) Macrophages fight infections using several tactics. 
The initial, innate response sends macrophages among the first immune cells to the 
site of infection or trauma. Initial inflammation, caused in part by the macrophage 
produced cytokines and other cells that are attracted to the site by macrophage-
derived chemokines, is often beneficial for the host and leads to healing. 
Macrophages promote resolving of the inflammation by inducing apoptosis in 
neutrophils and participating in clearing of the apoptotic cells. Excessive 
inflammation can lead to collateral damage in the surrounding tissue, which is why 
the macrophage response needs to be strictly controlled. (Koh, DiPietro 2011) In 
steady state, the macrophages patrol the tissues and phagocytose pathogens, 
bacteria and dead cells. Phagocytosed antigens are digested and the resulting 
peptides are presented to lymphocytes using the major histocompatibility complex 
(MHC) class I and II. Defects in the MHCII (in humans, human leukocyte antigen 
HLA) function can lead to disturbed immune responses, which are the cause for 
many chronic inflammatory and autoimmune diseases. (Menconi et al. 2008, 
Forabosco et al. 2009, Cho et al. 2014) 
Macrophages are classified by many attributes, but many of the classifications 
are rather black and white and include various exceptions. Macrophages are 
notoriously plastic (Sica, Mantovani 2012), so the division that is fitting for the cell 
in one moment might not be accurate by the next. However, in many cases the 
classifications are useful and benefit scientific discussion, once an agreement has 
been reached about the characteristics. One just needs to keep in mind that the 
comparison of two types of macrophages usually leaves many in between. 
A popular classification of macrophages is based on their activation by T cell 
products in in vitro settings. Classically activated M1 macrophages produce 
cytokines like TNFα in response to stimulation with IFNγ and LPS. Alternatively 
activated M2 macrophages are a large group of macrophages which are typically 
activated by cytokines such as IL-4 and IL-13. M1 macrophages are considered 
inflammatory, whereas the M2 macrophages are generally considered anti-
inflammatory. (Sindrilaru et al. 2011) However, the growing knowledge 
concerning the heterogeneity of macrophages has raised questions about the 
broadness of the bipolar M1/M2 division. New classifications have been suggested 
to be based on for example the homeostatic activities of the macrophages. (Mosser, 
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Edwards 2008, Martinez, Gordon 2014) One of the newer ways of defining 
macrophage populations is to inspect their developmental origins. 
Traditionally, macrophages were thought to arise from blood monocytes that 
patrol the body in the blood stream and enter a tissue in order to perform tissue 
surveillance and inflammation control. Mouse macrophages are commonly 
recognized by their “standard” surface markers F4/80, CD64, and MerTK, in 
addition to their ability to phagocytose. (Chakarov et al. 2019, Morris et al. 1991) 
More powerful analysis methods have revealed detailed differences in macrophage 
marker expression, which have been utilized to recognize macrophage subsets. In 
the recent decades, new insights to macrophage biology have come to light. Fate 
mapping studies have revealed that a proportion of macrophages in almost all adult 
tissues originate from the fetal era. These macrophages are not produced by the 
adult HSCs like typical adult macrophages, but self-renew within the tissue by 
downregulating transcription factors MafB and cMaf, and simultaneously 
activating a self-renewal gene network that is controlled by cell type–specific 
enhancers. (Soucie et al. 2016) Both the monocyte-derived and the tissue-resident 
macrophages have specific functions and both are necessary for the well-
functioning immunity and homeostasis. The next sections discuss the origins of 
monocyte and fetal derived macrophages and their functions (see also Box 1). 
Box 1.  What is a monocyte or a macrophage? 
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2.2.1 Monocyte-derived macrophages 
In adults, the bone marrow is the major hematopoietic organ. There, the 
transcription factor Myb –dependent hematopoietic stem cells (HSCs) produce 
different classes of hematopoietic progenitors, which in turn can produce mature 
cells of one or more lineages. (Wolber et al. 2002, Schulz et al. 2012) Monocytes 
and subsequent macrophages derive from a common myeloid precursor (MP), 
which is capable of generating macrophage and DC precursors (MDPs). MDPs, 
which express the chemokine receptor CX3CR1, can give rise to common DC 
precursors and monocytes. (Liu et al. 2009) Monocytes are short lived white blood 
cells, with the half-life of one to two days. In mouse, they are often divided by their 
expression of Ly6C to the Ly6CHigh/+ monocytes and their progeny, the Ly6C- 
monocytes. The short life span means that monocytes need to be constantly 
produced and released to the blood stream, in order to meet the need for active 
patrolling. Monocytes circulate in the blood stream and increase migration to 
tissues once signs of distress are detected. (Yona et al. 2013) Monocytes that have 
entered the tissue begin to differentiate into macrophages and dendritic cells and 
combat threats like inflammation. (Massberg et al. 2007) In the steady state, many 
tissues, such as the intestines, rely on monocyte infiltration to maintain their tissue 
macrophage pool. (Bain et al. 2014) 
2.2.1.1 Molecules that affect monocyte migration 
In addition to the sufficient production of monocytes and monocyte-derived 
macrophages, their number in the circulation and tissues depends on the migration 
from the bone marrow to the blood vessels and from the vessels to the tissues. 
Monocyte traffic is crucial for the resolution of inflammation and therefore their 
migration has been the subject of several studies. Molecules such as CCR2 and 
Nur77 are important for the survival and correct migration of the Ly6C+ and Ly6C- 
monocytes and the knock out mouse models of the two receptors are often used to 
study the monocyte function. The inherent problem of monocyte migration studies 
is the fact that the assays are often conducted under inflammatory conditions to 
promote the quantities of migrating cells. However, it is not always clear how well 
the information from inflammatory settings correspond to steady state. 
The chemokine receptor CCR2 is expressed on a subset of monocytes. Its main 
ligand CCL2 is a major chemoattractant to Ly6CHigh monocytes. The production of 
monocytes in the bone marrow is CCR2 independent, but monocytes need CCR2 to 
exit the bone marrow into the blood circulation. CCR2 is also crucial for the tissue 
entry of monocytes. (Serbina, Pamer 2006, Tsou et al. 2007, Bonapace et al. 2014) 
Deletion of CCR2 inhibits monocyte entry to tissues, which has been shown to be 
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beneficial in protecting the host by curbing excess inflammatory response in 
pathological conditions. (Boring et al. 1998) 
Nur77 (NR4A1) is one of the three members of the NR4A subfamily of orphan 
receptors in the steroid thyroid receptor family. (Martínez-González, Badimon 
2005) Nur77 and the other members of the receptor family seem to have 
overlapping functions in the myeloid system, but the deletion of Nur77 alone has 
significant effects on the bone marrow differentiation and survival of Ly6C- 
monocytes. Loss of Nur77 leads to apoptosis of the Ly6C- monocytes in the bone 
marrow, but had no significant effect on the Ly6C+ monocytes, which have low 
expression of Nur77. (Lee et al. 1995, Mullican et al. 2007, Nackiewicz et al. 2011) 
2.2.2 Tissue-resident macrophages 
Many tissues seem to harbor macrophages that differ from monocyte-derived 
macrophages in terms of their proliferation and persistence after inflammation has 
subsided. (Davies et al. 2011) Among others, the brain microglia (Ajami et al. 
2007), liver Kupffer cells (Gomez Perdiguero et al. 2015) and alveolar 
macrophages in the lung (Guilliams et al. 2013) are all established before birth and 
show distinctive functions within their respective tissues. The composition of tissue 
macrophages seems to vary from tissue to another as some tissue-resident 
macrophages, such as macrophages of the heart, originate from several sources. 
Dick et al. revealed that the heart myocardium harbors distinct subsets of 
macrophages, some of which are maintained independently of blood monocytes 
and some partially or fully replaced by blood monocytes. (Dick et al. 2019) 
2.2.2.1 The development of tissue-resident macrophages 
The emergence of tissue-resident macrophages occurs in sequential waves during 
embryonic development (Figure 3.) and has been studied in vivo with mice in 
detailed fate-mapping studies. The first erythro-myeloid progenitors (EMPs) can be 
found in the extraembryonic yolk sac (YS) at embryonic day 7.0 (E7.0). (Palis et 
al. 1999) The CSF1R-dependent EMPs differentiate to macrophages in the YS. 
After the establishment of blood circulation at E8.5 the EMPs and the macrophages 
migrate from the YS to all tissues, including the brain and the liver before E10.5. 
EMPs in the fetal liver generate myeloid precursors, which give rise to fetal liver 
fetal erythrocytes, macrophages, granulocytes and monocytes until at least E16.5. 
(Gomez Perdiguero et al. 2015) At E10.5 the fetal liver is also seeded by HSCs 
from the aorta-gonad-mesonephros (AGM). HSCs in the developing embryo 
participate in the production of macrophages via monocyte intermediates and from 
this point onwards, the main hematopoiesis shifts from the YS to the fetal liver. 
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From the fetal liver, the monocytes enter the blood stream and seed all tissues at 
E12.5, excluding the brain which has been closed off by the blood-brain-barrier. 
(Ginhoux, Guilliams 2016) The brain is the only tissue, where the macrophage 
population, also known as microglia, exclusively originates from the YS. (Ginhoux 
et al. 2010) In other tissues, the YS-derived macrophages are at least partially 
superseded by the fetal liver -derived macrophages by E16.5 (and supplemented 
with bone marrow monocyte-derived macrophages postnatally). Finally, the 
macrophage production shifts from the liver to the bone marrow during E16 to 4 
days postpartum. (Wolber et al. 2002) Around the time of birth and thereafter the 
HSC-derived monocytes in the bone marrow can participate to tissue-resident 
macrophage production as is the case with arterial macrophages. (Ensan et al. 
2015) From this point onwards, the tissue-resident macrophages proliferate locally, 
but the postnatal systemic distribution of macrophages depends on the HSCs, the 
precursor cells and the rate of monocyte migration to the tissues. (Soucie et al. 
2016) 
 
Figure 3.  Macrophages in adult tissues originate from different developmental origins. Tissue-
resident macrophages develop throughout embryonic development. In adulthood, 
macrophages replenishment relies on self-renewal of tissue macrophages, bone 
marrow HCSs and bone marrow -derived monocytes. AGM= aorta-gonad-
mesonephros, EMP= erythro-myeloid progenitor, HCS= hematopoietic stem cell, Mac= 
macrophage, Mono= monocyte, PP= postpartum.view of a peripheral lymph node. The 
arrowheads represent the direction of the lymph flow. HEV= High endothelial venule. 
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Thus, in a simplistic view, tissue-resident macrophages originate mainly from the 
YS or fetal liver. In the adulthood, the two embryonic macrophage populations 
begin to resemble each other in their surface marker expression pattern. This makes 
it difficult to study the exact phenotypes and functions of the two embryonic 
populations in adult tissues. To some extent, cells of a distinct origin can be 
recognized with the help of inducible reporter mice. A conditional Cre-
recombinase enzyme can be activated with tamoxifen to allow the transcription of a 
fluorescent protein in cells with a desired promoter, such as CX3CR1 or CSF1R. 
Timed tamoxifen pulsation will result in fluorescent cells of interest which can be 
followed until the life span of the cells or their progeny come to an end. (Yona et 
al. 2013) 
The differences in macrophage characteristics between tissue-resident and 
monocyte-derived macrophages are partly explained by their developmental origin, 
but it has been suggested that the tissue environment could have an even greater 
effect on the macrophage phenotype. (Gautier et al. 2012, Lavin et al. 2014) 
Macrophages colonize the tissues early in the development, so it is reasonable that 
the populations are sculpted in part by the interactions with the tissue environment. 
Interestingly, the epigenetic programming by the tissue is able to mold the tissue-
resident macrophages even from another tissue to resemble the organic population. 
(Lavin et al. 2014) Van de Laar however showed that the tissue-resident alveolar 
macrophages cannot be replaced by tissue-resident macrophages from any other 
tissue, but they can be replenished by adult donor alveolar macrophages or 
macrophage precursors from the YS or fetal liver (but not from the adult bone 
marrow). (Van de Laar et al. 2016) In myocardium, a small proportion of 
monocyte-derived macrophages is shown to be able to assume a nearly identical 
transcriptional profile to the resident macrophage populations. However, they are 
not able to redeem the spatially localized cardioprotective functions of the tissue-
resident macrophages. (Dick et al. 2019) 
These results indicate that the embryonic macrophages retain some level of 
plasticity throughout their life span. The unique profiles of the tissue-resident 
macrophages are affected by the tissue environment, but it seems unlikely that the 
tissue signals alone are capable of sculpting cells into functioning tissue-resident 
macrophages. Further research is needed to fully elucidate the contribution of the 
tissue environment and inherent genetic properties to the development of tissue-
resident macrophages. 
2.2.2.2 Tissue-resident macrophage functions 
In addition to the task of fighting inflammation and infection when needed, tissue-
resident macrophages take part in other functions. It is not surprising that the 
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tissue-resident macrophages, which are established during embryonic development, 
have a role in the development of organs. In the developing brain, microglia sculpts 
synaptic network and promotes synaptic maturation. (Paolicelli et al. 2011) During 
adulthood, the tissue-resident macrophages have many homeostasis maintaining 
functions, unique for their anatomical location. Peritoneal macrophages interact 
with peritoneal B1 cells and control the IgA production in the gut. (Okabe, 
Medzhitov 2014) The recycling of heme takes place in the spleen and the resident 
red pulp macrophages maintain iron homeostasis by phagocytosing red blood cells. 
(Haldar et al. 2014) Finally, the resident macrophages of the lung, alveolar 
macrophages participate in surfactant homeostasis. (Jubinville et al. 2019) These 
examples highlight the diverse tissue-specific functions that tissue-resident 
macrophages perform.  
2.3 Mammary gland development and function 
The mammary gland is a complex tissue that consists of adipocytes, mammary 
stem cells, epithelial cells, mesenchymal cells, vascular endothelial cells and 
immune cells. (Oakes et al. 2006, Inman et al. 2015) One of the most important 
functions of the mammary gland is to produce and distribute milk for offspring 
after pregnancy. To serve this purpose, the mature mammary gland stroma is a 
network of ducts, which are essentially hollow tubes lined with contractile 
epithelium. The ducts traverse the mammary gland and terminate in milk secreting 
alveoli (Figure 4.). The stroma between the ducts is comprised mainly of white 
adipocytes and fibroblasts. (Hennighausen and Robinson 2001, Gouon-Evans and 
Pollard 2002)  
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Figure 4.  A schematic representation of mammary gland ductal development in different 
developmental stages (A). The blue arrows point to terminal end buds. The inserts 
show the budding alveolar structures (white arrow heads) during lactation (B) and the 
disappearance of the alveoli during involution (C). LN= lymph node. 
The majority of the information on breast development and function originates 
from studies on mice. Clear differences between mouse and man include the 
number of mammary gland pairs per individual (one pair in humans compared to 
the five pairs in mice) and the extent of male mammary development. Unlike in 
mice, the human male breasts grow similarly to female breasts until puberty, until 
male hormones determine the smaller size of the breast. (Howard and Gusterson 
2000) Additionally there is variation in the stromal architecture and the number of 
main ducts. Nonetheless, the developmental processes in the two species are 
similar and the mouse studies provide important insight to mammary gland cell 
interactions, signaling and function. (Parmar and Cunha 2004, Inman et al. 2015) 
2.3.1 Prenatal development 
The mammary gland development starts around halfway of pregnancy at E10 in 
mouse, in both sexes and is sparked by tissue interaction between epithelium and 
mesenchyme. Early breast development is largely regulated with local signaling 
and cell contact within the mammary tissue. Milk lines running along the ventral 
sides of the torso break apart to form placodes at E11, in response to avid signaling 
from the likes of Wnt ligands, Tbx3, Fgf10 from the surrounding epithelium and 
mesenchyme. (Chu et al. 2004, Jerome-Majewska et al. 2005, Veltmaat et al. 2006, 
Inman et al. 2015)  The placode forms into an epithelium ball that grows in size, 
changes shape and dives deeper into the underlying mesenchyme by E14. In male 
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embryos, testosterone signaling leads to degeneration of the bud, halting the 
formation of ducts. (Watson, Khaled 2008) In females, at E16-E18 the epithelial 
bud’s neck elongates through the mesenchymal cells into the underlying cluster of 
preadipocytes. After the sprouts start initial branching into the future fat pad, they 
open up to create the lumen and nipple sheath, which are necessary for milk 
transport and nursing. (Hogg et al. 1983) Signaling from the fat pad guides the 
growth of the sprouts into 10-15 initial ductal branches, there after the ductal 
development slows down until puberty. (Couldrey et al. 2002) 
2.3.2 Postnatal development 
Postnatally, the mammary gland fat pad continues to grow in size in proportion to 
the body. In comparison to the prenatal regulation, postnatal development of the 
mammary gland ductal system is in larger part orchestrated by systemic hormones 
like estrogen and progesterone which are regulated by the pituitary/hypothalamus 
axis and ovary functions. (Hennighausen and Robinson 2001) In addition, the 
mammary environment and resident cells and their signaling continue to shape the 
developing ductal meshwork. (Gouon-Evans et al. 2000, Fata et al. 2000) During 
the first weeks of postnatal life, the existing rudimentary mammary ducts grow 
slowly. (Watson, Khaled 2008) Once puberty begins, the growth escalates and the 
avidly proliferating terminal end buds (TEBs) at the end of the ducts further invade 
the fat pad, sprouting onwards and laterally, finally filling 60% of the breast with 
the ductal tree. (Macias, Hinck 2012) The ductal branches grow until they have 
reached the fat pad border at around 10-12wks of age. (Watson, Khaled 2008) At 
this point the mammary gland has reached maturity. The size of the ductal network 
in virgin mice fluctuates in response to the cyclical hormonal cues during the 
estrous cycle (menstruation in humans). During pregnancy and lactation, the ductal 
epithelium forms milk-secreting alveoli which disappear during the involution 
phase after weaning. (Förster et al. 2002, Oakes et al. 2006, Joshi et al. 2010) 
2.3.3 Macrophages in the mammary gland 
Macrophages are a part of normal mammary gland stroma and have been detected 
in the mammary gland from 2wk onwards. Macrophages promote the ductal 
growth by clearing the apoptotic epithelial cells in the TEB, stabilizing the 
morphology of the TEB and by rearranging the collagen fibers around the growing 
TEB. Macrophages localize to the neck of the TEB and also close to the nipple. 
(Gouon-Evans et al. 2000, Ingman et al. 2006) The macrophage localization in the 
vicinity of ducts is often attributed to the local chemokines produced by the 
epithelium, such as the CSF1, a major growth factor and chemoattractant for 
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macrophages. (Ryan 2001) CSF1-deficient mice experience reductions in 
macrophage number in the mammary gland. (Gouon-Evans et al. 2000) CSF1 
levels and the macrophage numbers in the wild type (WT) adult mouse fluctuate 
during the different phases of the estrus cycle, however their peaks do not correlate 
with each other. (Dasari et al. 2014, Chua et al. 2010) Van Nguyen et al. showed 
that the CSF1 does recruit macrophages, but is not necessary for their recruitment, 
suggesting that other signals are also responsible for the macrophage presence in 
the mammary gland. (Van Nguyen, Pollard 2002) Ductal epithelium is produced by 
the mammary stem cells and mammary macrophages have been shown to be 
important for the mammary gland stem cell activity and epithelial proliferation. 
(Gyorki et al. 2009) Chakrabarti et al. showed that the close proximity between 
macrophages and mammary gland stem cells can be explained by the contact-
dependent Notch/Wnt signaling loop between the stem cells and macrophages. 
This signaling not only promotes stem cell activity but also maintains the 
macrophage number and activity in the mammary gland. (Chakrabarti et al. 2018)   
2.3.3.1 Mammary macrophages as therapeutic targets 
Breast cancer is the most prevalent cancer among women world-wide and in 
various countries the incidence rates have been rising. Even though there are 
several treatment strategies to tackle breast cancer, it still is the leading cause of 
cancer death. (Bray et al. 2018) In addition to traditional therapy options like 
hormone blocking strategies, surgery, chemotherapy and radiation, new 
unconventional approaches are needed. All the available treatments have undesired 
adverse effects and even though they are effective in many cases, there are still 
many patients who receive little to no benefit from the current methods. 
Immunomodulatory therapies are based on the concept that the patient’s resident 
immune cells can be modulated to recognize and fight off the cancerous cells. 
(Umansky, Sevko 2012) Coissieux et al. used mice and approached the problem by 
curbing the recruitment of CCR2+ monocytes to the mammary tumor by inhibition 
of CCL2 signaling. This led to reduction in macrophages numbers in the primary 
breast cancer tumor, but the cessation of inhibition surprisingly led to increased 
metastasis and accelerated death. Cessation of treatment resulted in the 
macrophage-mediated production of VEGF-A in the metastatic tissue resulting in 
increased angiogenesis in the metastatic tumors. (Bonapace et al. 2014) Thus, 
immunotherapies need to be carefully examined and permanent reprogramming of 
the tumor microenvironment or complete elimination of tumors is necessary to 
avoid a risk of negative rebound. 
So far, there have been some successful attempts in the immunomodulatory 
approaches. Hu et al. showed in vitro that high-intensity focused ultrasound 
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treatment of breast cancer tumors led to tumor cell -derived danger signals, which 
activated macrophages and enhanced anti-tumor immunity. (Hu et al. 2005) 
Blocking of the CSF1/CSF1R signaling in a mouse model of pancreatic ductal 
adenocarcinoma efficiently depleted tumor associated macrophages. The reduction 
of macrophages significantly enhanced the efficacy of immunotherapy which was 
based on the inhibition of T-cell checkpoint with antagonists for cytotoxic T 
lymphocyte antigen 4 (CTLA4) and Programmed cell death-1 (PD1). Combination 
of the two approaches resulted in the successful regression of tumors. (Zhu et al. 
2014) Modulation of the existing immune cells requires a vast amount of detailed 
information on the target tissue stromal cells and the particular primary and 
metastatic cancer cells. It is imperative to understand the steady-state profile of the 
immune cells within the target tissue, before attempting to reinstate the 
homeostasis. 
It is known that the mammary gland harbors macrophages at least throughout 
the postnatal development, but the phenotype of the macrophages is still only 
superficially researched and further investigation with current methods is needed. 
Macrophages are also found in breast cancer both within the tumor and in the 
tumor environment, where they have been extensively studied. However, 
macrophage presence in breast cancer has been linked to positive and negative 
outcomes. (Medrek et al. 2012) This could imply that the macrophages are not 
homogenous in phenotype and that the tumor environment might affect the 
different macrophages in different ways. 
 39 
3 Aims 
Correctly functioning endothelial cells and the vasculature they line are crucial for 
the well-functioning body. Endothelium is involved in embryonic develop-ment, 
maintenance of vessel integrity and cell traffic control. This thesis aims to 
investigate the role of endothelial cell permeability in cell and molecule ex-change 
in physiological state and to elucidate the consequences of perturbed endothelial 
cell function. 
 
The specific aims of the study were: 
1. To explore the role of PLVAP in the lymphatics, especially in the 
endothelial cells of the lymph node sinus. 
2. To learn how the PLVAP expressing lymphatic endothelial cells affect the 
immune response within the lymph node. 
3. To determine how the endothelial protein PLVAP affects migration of 
macrophage precursors during development. 
4. To elucidate the macrophage status of virgin steady-state mammary gland. 
5. To examine the functions of tissue-resident macrophages in the mammary 
gland. 
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4 Materials and Methods 
4.1 Animals (I-III) 
This thesis comprises the results from studies performed on several mouse strains. 
All mice were housed under controlled, specific pathogen free conditions and a 12 
h light-dark cycle at a temperature of 22 °C in the animal facilities of University of 
Turku (Turku, Finland). The mice had ad libitum access to chow (irradiated 
standard pellets) and water. All animal experiments were reviewed and approved 
by the Ethical Committee for Animal Experimentation in Finland. Experiments 
were carried out in adherence with the rules and regulations of the Finnish Act on 
Animal Experimentation (497/2013) and in accordance to the 3R-principle under 
Animal license numbers: 3791/04.10.03/2011 and 5587/04.10.07/2014 and 
6211/04.10.07/2017. Both genders were used in the experiments (except in 
mammary gland analyses) in Publications I and II. In III, only females were used 
unless indicated otherwise. Mice were used at indicated ages. When gene-modified 
mice were used, age-, sex- and strain-matched WTs or littermates were used as 
controls. For embryonic time points, the female was introduced to the male for one 
night and the morning of the vaginal plug detection was considered as embryonic 
day E0.5. 
4.1.1 Wild type strains (I-III) 
Commercially available WT mice C57BL/6J, C57BL/6N, NMRI, F1 hybrid 
C57BL/6;129 and BALB/c mice were from Charles River, The Jackson Laboratory 
or Janvier Labs. 
4.1.2 Knock out strains (I-III) 
Cav1tm1Mls/J (Cav1−/−, stock004585), Ccr2−/− mice (stock 004999) and Nur77−/− 
mice (stock 006187) were purchased from The Jackson Laboratory. Nt5etm1Lft 
(Nt5e−/−) and Aoc3tm1Salm (Aoc3−/−) mice have been described in (Stolen et al. 2005) 
and (Thompson et al. 2004) respectively. 
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4.1.3 Generation of conditional Plvap−/− mice (I) 
PLVAP-deficient mice were generated at Taconic Artemis and thereafter were bred 
in the University of Turku animal facilities. In brief, the Plvap targeting vector was 
constructed with bacterial artificial chromosome clones from the C57BL/6J RPCI-
24 bacterial artificial chromosome clones library. Translation initiation site -
containing exon 1 and approximately 1.5 kb of the sequence upstream of exon 1 
(promoter region) was flanked by loxP-sites. The positive selection marker PuroR 
was inserted into intron 1. The linearized targeting vector was transfected into the 
Taconic Artemis Art B6/3.6 ES cell line on the C57BL/6NTac genetic background. 
The homologous recombinant clones (PuroR+) were isolated and confirmed by 
Southern blot analysis and correct homologous recombination at the 5′ side (5ext1 
probe: sense, TGCTCTGGAAGCTGAGCTTGGCACC, and antisense, 
TGCTGCCACCTAGGCAAGTCTTGG) and 3′ side (3ext2 probe: sense, 
GGGTAGAGGTTCAGGTCTGTCCTC, and antisense, 
AGAGCTGAGTTGTGACCCAGTCACC). The proximal loxP-site was detected 
in all clones. The targeted embryonic stem cells were injected into BALB/c mouse 
blastocysts, and chimeric mice were generated. Highly chimeric male mice were 
bred to deletor (C57BL/6-Tg(CAG-Flpe)2Arte) female mice which expressed Flp 
recombinase in order to confirm the germline transmission and to generate mice 
with conditional deficiency in Plvap (PlvapF/+). Plvap+/− mice were generated by 
breeding PlvapF/+ mice to CAG-Cre (NMRI-Tg(CAG-Cre)) mice. Intercrossing of 
Plvap+/− mice resulted in Plvap−/− mice in addition to the WT littermate controls 
and PlvapF/+ mice. Plvap−/− mice on a mixed background (including BALB/c, 
C57BL/6N and NMRI strains) were used in the experiments in Publications I-III. 
4.1.4 Tamoxifen inducible models (II, III) 
Inducible PlvapF/F; CAGGCre-ERTM mice were produced by crossing conditional 
PlvapF/F mice with a CAGGCre-ERTM (B6.Cg-Tg (CAG-cre/Esr1)5Amc/J deletor Cre 
mouse line (stock 004682, The Jackson Laboratory). Conditional PlvapF/F mice 
were crossed with Lyve-1-Cre mice (Lyve1tm1.1(EGFP/cre)Cys, (stock 012601, The 
Jackson Laboratory)) to generate PlvapF/F; Lyve-1-Cre mice. (II) 
For fate mapping studies, R26R-EYFP mice (stock 006148) were crossed with 
either Cx3cR1Cre/ERT2 (stock 020940) or Csf1r-Mer-iCre-Mer (stock 019098), all 
purchased from The Jackson Laboratory. (III) 
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4.2 Macrophage depletion (I, II) 
4.2.1 Depletion of existing macrophages (I) 
WT mice were injected s.c with clodronate-loaded or control liposomes 
(ClodrodateLiposomes.com). Analysis of the macrophage depleted tissues or 
further experiments were performed seven days after clodronate treatment. 
4.2.2 Depletion of YS-derived macrophages prenatally (II, III) 
Pregnant (E6.5) WT female mice were treated with a single i.p injection of 3 mg of 
the CSF1R blocking antibody (clone AFS98, BE0213 Bio X Cell) or rat IgG2a 
control antibody (clone 2A3, BE0089 Bio X Cell) to deplete the YS-derived 
macrophages in the offspring. 
4.2.3 Depletion of tissue-resident macrophages postnatally 
(III) 
Tissue-resident macrophages were depleted by injecting 2 wk old WT mice 
cyclically with anti-CSF1 antibody and clodronate: three doses of CSF1 
neutralizing antibody (Clone 5A1, BE0204 Bio X cell) or control IgG (clone 
HRPN, BE0088 Bio X cell) were given i.p, followed by three doses of clodronate 
or control liposomes i.v (Liposoma) on the following day. Mice were sacrificed at 
indicated time points after the last clodronate administration. 
4.3 Colony forming assay (II) 
Adult bone marrow from the femur and livers of E12.5 embryos were collected and 
seeded in 1 ml of M3434 Methocult medium (Stem Cell Technologies) into 35-mm 
culture dishes in duplicates. Amount of colonies were counted after 7 day culture at 
37 °C with 5% CO2. 
4.4 Immunoblot analysis (I) 
Spleen stromal elements from mechanically dissociated spleens were lysed for 1 h. 
The sample was centrifuged and aliquots of the lysate were mixed with non-
reduced Laemmli’s sample buffer and resolved by 5–15% SDS-PAGE. PLVAP 
was using with MECA-32 after transfer to nitrocellulose and anti-GAPDH (5G4 
mAb 6C5; Hytest) was used as a loading control. Enhanced chemiluminescence 
detection (ECL) system (Amersham) was used. 
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4.5 Interaction studies (II) 
4.5.1 Generation of PLVAP-Fc fusion protein (II) 
A fusion protein with the extracellular domain of mouse PLVAP fused to a human 
IgG2 Fc-tail was generated. The extracellular domain of mouse PLVAP (amino-
acid residues 48–438) was PCR-cloned (Phusion High-Fidelity DNA Polymerase, 
ThermoFisher Scientific) from a full-length cDNA clone for mouse PLVAP 
(MR206983, Origene) using primers introducing EcoRV and NheI digestion sites. 
The amplified fragment was purified and annealed to EcoRV and NheI digested 
pFUSEN-hG2Fc vector (InvivoGen). Sequencing and immunoblotting were used 
to verify the integrity of the construct. The expression plasmid was transfected into 
HEK293-EBNA cells (CRL-10852, from ATCC) and the cells were cultured for 2-
3 days. CD4–Fc-chimaera was used as a control in the interaction studies. 
4.5.2 Heparin affinity pull down assay (II) 
Heparin- or streptavidin-coupled agarose beads (Sigma or GE Healthcare, 
respectively) were washed, and blocked with TBS with 1% BSA. The beads were 
rocked with either total protein lysates from E14.5 WT livers or the PLVAP–Fc 
and CD4–Fc fusion proteins. After washing, the bead-bound molecules were eluted 
and subjected to SDS–PAGE separation. 
4.5.3 Far western (II) 
Recombinant mouse neuropilin-1 (R&D Systems, 5994-N1) and recombinant 
mouse VEGF164 (R&D Systems, 493-MV) were spotted onto filters. The PLVAP–
Fc fusion protein was allowed to bind to the immobilized proteins in the presence 
or absence of heparin (Leo Pharma) for 2 h. ECL and HRP-conjugated anti human 
IgG antibody was used to visualize the bound fusion protein. 
4.5.4 Proximity ligation assay (II) 
VEGF interaction with PLVAP in fetal livers was evaluated with a proximity 
ligation assay (PLA). Briefly, anti-VEGF (46154, Abcam) or control primary 
antibody were detected by Duolink in situ PLA probe anti-rabbit PLUS 
(DUO92002, Sigma). Anti-PLVAP antibody was directly conjugated to MINUS 
PLA probe with Duolink in situ probemaker MINUS kit (DUO92010, Sigma). 
Detection reagent red (DUO92008, Sigma) was used to detect the ligated probes 
after amplification. Anti-PLVAP was also detected with an additional secondary 
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antibody. Finally, the nuclei were stained with 4′,6-diamidino-2-phenylindole 
(DAPI) and samples were mounted in Mowiol and imaged. 
4.5.5 Co-immunoprecipitation assay (II) 
Freshly isolated WT fetal livers were briefly lysed before pelleting. The 
supernatants were incubated with an anti-VEGFA antibody or a negative control 
for 5 h. Protein G beads were added for 1 h. The beads were washed and the bound 
proteins were eluted in non-reducing Laemmli’s sample buffer. The proteins were 
separated in SDS–PAGE and immunoblotted for VEGF and PLVAP using IRDye-
conjugated second-stage reagents and Odyssey imager. 
4.6 Fluorescence-activated flow cytometry (I-III) 
4.6.1 Isolation of the cells for single-cell suspension (I-III) 
For flow cytometry analyses the excised tissue samples were processed into single-
cell suspension. Briefly, most tissues were first mechanically dissociated, followed 
by a 0,5-2h enzymatic digestion in Hank’s balanced-salt buffer containing 
collagenase D (1 mg/ml) and DNAse I (50 μg/ml). Tissues were then filtered and 
washed before staining for flow cytometry. Some tissues needed a method with 
some exceptions: livers were dissociated using Gentle MACS C-tube (Miltenyi 
Biotech) and immune cells were purified via OptiPrep density gradient 
centrifugation (Sigma D1556). Brains were digested, followed by a Percoll 
gradient isolation of microglia before staining. Bone marrows were isolated by 
gently crushing and extensively filtering the femurs before staining. Lamina 
propria cells from the colon were isolated by an enzymatic digestion. Peritoneal 
cells were collected by gently rinsing the peritoneal cavity with medium containing 
heparin and serum.  Erythrocytes in blood and spleen were lysed by hypotonic 
lysis. (I-III) In some experiments lymph nodes were gently mechanically teased to 
detach the lymphocytes without enzymatic digestion. For LEC analyses, minced 
lymph nodes were digested for 15 min at 37 °C with 25 μg/ml liberase TM and 
100 μg/ml DNase I. Samples were delicately passed through Pasteur pipettes and 
filtered, the remaining undigested fragments were collected and subjected to four 
additional cycles of digestion with fresh enzymes. Cell suspensions from each 
cycle were pooled and stained. (I) 
Total leukocyte numbers were determined by establishing the absolute numbers 
of viable cells in the cell suspension with a cell counter (Cellometer Auto 2000, 
Nexcelcom) and the percentage of CD45+ cells with flow cytometry. Absolute 
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blood leukocyte numbers were determined with a hemocytometer (VetScan HM5, 
Abaxis). (II) 
4.6.2 Staining of cells for flow cytometry (I-III) 
Before staining the single cell suspensions, the Fc-receptors were blocked with 
purified anti-CD16/32 to reduce non-specific binding of the antibodies. Samples 
were then stained with either directly fluorochrome-conjugated antibodies or a 
primary antibody and a fluorochrome-conjugated secondary antibody. Antibodies 
used in the three publications are listed in Table 1. Finally, after washing (and 
when necessary, fixation of the samples) samples were analyzed and collected with 
cell sorters FACSAriaII (BD) (I-III) or Sony SH800Z (Sony Biotechnology) (II), or 
analyzed with LSRII (BD) (I) or LSR Fortessa (BD) (I-III). Results were analyzed 
and visualized using FACSDiva software (I) or FlowJo-software (Tree Star/ 
FlowJo LLC) (I-III). 
Table 1.  Antibodies used in the flow cytometric stainings. 
Antibody Company  Cat# Pub. 
B220-PE BD Biosciences 553089 I, II 
B220-BV421 BD Biosciences 562922 II 
B220-Pacific Blue BD Biosciences 558108 I, II 
CD3-Pacific Blue BD Biosciences 558214 I 
CD4-APC BD Biosciences 552051 I, II 
CD4-APC-CY7 BD Biosciences 561091 I 
CD4-APC-Cy7 BD Biosciences 552051 II 
CD4-A647 BD Biosciences 557681 II 
CD4-PE BD Biosciences 553048 II 
CD8-PerCP-Cy5,5 BD Biosciences 551162 I, II 
CD8-PE BD Biosciences 553032 II 
CD8-BV650 BD Biosciences 563234 II 
CD11b-PE BD Biosciences 553311 I-III 
CD11b-APC-Cy7 BD Biosciences 561039 I, II 
CD11b-APC-Cy7 BD Biosciences 557647 III 
CD11b-BB515 BD Biosciences 564454 II, III 
CD11b-BV786 BD Biosciences 740861 III 
CD11c-BV421 BD Biosciences 562782 I-III 
CD11c-PerCP-Cy5,5 BD Biosciences 560584 I, II 
CD16/CD32 (2.4G2) Bio X Cell CUSTOM24G2 III 
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Antibody Company  Cat# Pub. 
CD25-APC eBiosciences 17-0251-81 I 
CD31-APC BD Biosciences 551262 I 
CD34-PerCP-Cy5,5 BD Biosciences 128607 II 
CD41-PE BD Biosciences 561850 II 
CD41-FITC BD Biosciences 553848 II 
CD42.2 PerCP-Cy5,5 BD Biosciences 552950 I 
CD44-PerCP-Cy5,5 eBiosciences 45-0441-80 I 
CD45-APC-Cy7 BD Biosciences 557659 I, II 
CD45-V500 BD Biosciences 561487 I, II 
CD45-PerCP-Cy5.5 BD Biosciences 550994 II, III 
CD62L-A647 BioLegend 104421 I 
CD64-PE BioLegend 139304 III 
CD115-PE-Cy7 eBioscience 25-1152-80 II, III 
CD117-BV510 Biolegend 135119 II 
CD127 (IL7) -PeCy7 BD Biosciences 560733 II 
CD135 (Flt-3)-BV421 BD Biosciences 562898 II 
CD169-PE BioLegend 142403 I 
CD206-A488 Adb Serotec MCA2235A488 II 
CD206-BV650 BioLegend 141723 III 
CD304-PE eBiosciences 12-3041-82 II 
F4/80-A647 BioLegend 122610 I 
F4/80-PE Abcam Ab105156 II 
F4/80-A488 eBioscience 53-4801-82 III 
F4/80-A647 Bio-Rad/AbdSerotec MCA497A647 III 
CXCR5-APC BD Biosciences 560615 I 
GL7-A647 BD Biosciences 561529 I 
IgD-A647 BioLegend 405708 I 
IgM-APC-A780 eBiosciences 47-5790-80 I 
Ly6C-BV421 BD Biosciences 562727 II, III 
Ly6C-FITC BD Biosciences 553104 II 
Ly6G-BV510 BioLegend 127633 II, III 
Lin-APC BD Biosciences 558074 II 
MerTK-PE BioLegend 151505 III 
MHCII-PE-Cy7 eBioscience 25-5321-82 I-III 
Podoplanin-PE-Cy7 BioLegend 127412 I 
S1P1 Santa Cruz sc25489 I 
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Antibody Company  Cat# Pub. 
Sca-1-PE R&D Systems FAB1226P II 
Siglec - F -PE -CF594 BD Biosciences 562757 II, III 
VEGFR1-PE R&D Systems FAB4711P II 
VEGFR2-PE eBiosciences 12-5821-81 II 
Armenian hamster IgG1 (λ1) -PerCP-Cy5,5 BD Biosciences 560554 I, II 
Armenian hamster IgG1 (λ2) -BV421 BD Biosciences 562919 I, II 
Armenian hamster IgG-PerCP-Cy5,5 Biolegend 400931 II 
Goat anti Rabbit A488 Life Technologies A11008 I 
Hamster IgG-PE-Cy7 BioLegend 402009 I 
Lin-Isot conrol cocktail-APC BD Biosciences 558074 II 
Rat IgG1-APC eBiosciences 17-4301-81 I 
Rat IgG1-FITC BD Biosciences 553924 II 
Rat IgG2a-A488 Adb Serotec MCA1212A488 II 
Rat IgG2a-A647 BD Biosciences 557690 II 
Rat IgG2a-A647 BioLegend 400526 I 
Rat IgG2a-APC BD Biosciences 553932 I 
Rat IgG2a-APC–A780 eBiosciences 47-4321-82 I 
Rat IgG2a-BV421 BD Biosciences 562602 II 
Rat IgG2a-BV510 BD Biosciences 562952 II 
Rat IgG2a-BV650 BD Biosciences 563236 II 
Rat IgG2a-Pacific Blue BD Biosciences 558109 I, II 
Rat IgG2a-PE BD Biosciences 553930 I 
Rat IgG2a-PE-CF594 BD Biosciences 562302 II 
Rat IgG2a-PE-Cy7 eBiosciences 25-4321-81 II 
Rat IgG2a-PerCP-Cy5,5 BD Biosciences 550765 I, II 
Rat IgG2b-APC-Cy7 BD Biosciences 552773 I, II 
Rat IgG2b-A647 Biolegend 400626 II 
Rat IgG2b-BB515 BD Biosciences 564421 II 
Rat IgG2b-BV510 Biolegend 135119 II 
Rat IgG2b-PE BD Biosciences 553989 I 
Rat IgG2b-PE-Cy7 eBiosciences 25-4031-81 I, II 
Rat IgG2b-PerCP-Cy5,5 BD Biosciences 550764 II 
Rat IgG2b-PerCP-Cy5,5 eBiosciences 45-4031-80 I 
Rat IgG2b-V500 BD Biosciences 560784 I, II 
Rat IgM-A647 BD Biosciences 560892 I 
Rat IgM-FITC BD Biosciences 553942 II 
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4.7 In vivo migration assays (I) 
WT donor splenocytes were mechanically isolated and erythrocytes were lysed by 
hypotonic lysis. The cells were labeled with 0.5 μM CFSE (carboxyfluorescein 
diacetate succinimidyl ester) in RPMI-1640 medium, and washed twice after 
15min incubation in +37C. The cells (10 × 106 cells in 20 μl PBS) were injected 
s.c into the hind paws of the recipients. Draining lymph nodes were processed for 
microscopy after 4 or 8 hour migration. 
In certain experiments, the CFSE-labeled cells were injected in combination with a 
PE-conjugated or unconjugated anti-MECA-32 (1µg/mouse). PE-conjugated or 
unconjugated isotype-matched antibodies were used as controls. Lymph nodes 
were collected after 4 h and processed for microscopy. Alternatively, lymph nodes 
were collected after 8 h and analyzed by flow cytometry for quantification of 
immigrated CFSE+ cells and subpopulations. 
4.8 In vitro transmigration assays (I) 
For functional end-point transmigration experiments, confluent human lymph node 
LECs (SciencCell Research Laboratories) were activated for 19 h with human 
recombinant TNF (50 ng/ml; R&D Systems). Cultured, washed mononuclear cells 
from donors were applied to the top of LEC cultures in HBSS medium containing 
1% human serum albumin, and were allowed to interact for 20 min at 37 °C in a 
humidified incubator. Thereafter the adherent cells were fixed with 4% PFA. The 
cells were permeabilized, stained and imaged. 
4.9 In vivo uptake experiments (I, III) 
The antigen up-take by resident macrophages and dendritic cells of the lymph node 
was studied using recombinant AOC3-A647 (180 kDa) and ovalbumin (OVA)-
A488 (45 kDa). Mixture of both conjugated antigen (0,5 µg of each) was injected 
s.c to mice and the draining lymph node was collected 30 min later. The lymph 
node was processed for flow cytometry and the frequency of each cell type 
containing the fluorescent antigens was determined with flow cytometry. (I) 
In other experiments, immune complexes were produced by incubating OVA-
Atto488 (41235 Sigma, 2 mg/ml in PBS) at 5:1 molar ratio with rabbit polyclonal 
anti-OVA IgG for 1h at 4C. 100 μl of OVA-SIC, or PBS as a control, was injected 
i.v. Alternatively, 10 μg of fluorescently labeled acetylated low-density 
lipoprotein (LDL; Alexa Fluor 488 conjugated, L23380 Thermo Fisher Scientific) 
or 0.8 mg of 500 kDa Dextran (fluorescein, D7136 L23380 Thermo Fisher 
Scientific) were administered i.v. After 1 h (dextran) or 2 h (OVA-SIC and LDL) 
the mice were sacrificed and the mammary gland was collected and processed for 
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flow cytometry. The mean fluorescence intensity (MFI) of each label in the PBS-
treated mice was subtracted from MFI for the corresponding label in the test 
compound treated mice to determine the specific MFI for each test compound. (III) 
4.10  In vivo conduit-filling studies (I) 
Recombinant human AOC3 (Peprotech), a mixture of fluorescently labeled 
dextrans of various molecular weights (all from Molecular Probes) or fluorescent 
20 nm quantum dots (QTracker) were injected s.c into the hind paw. After one 
minute (AOC3), two minutes (dextrans) or 10 minutes (quantum dots), the mice 
were sacrificed and the draining lymph node was collected. The sample was fixed 
overnight in 1% PFA or for 2 h at room temperature and for 2 h at 4 °C in 4% PFA. 
Dextran and quantum dot samples were dehydrated overnight in 30% sucrose and 
mounted in Optimal Cutting Temperature compound (OCT). Sections were cut, 
stained and imaged. After fixation with PFA, the AOC3 was detected with a 
polyclonal anti-AOC3 (PAS-2542; Harlan Sera-Lab). 
4.11  Proliferation assay (III) 
Mice were injected i.p with 120 μl of 10 mg/ml solution of bromodeoxyuridine 
(BrdU, BD Bioscience) and sacrificed two hours later. Mammary glands were 
processed for flow cytometry, but after immunofluorescence staining, the cells 
were further stained with FITC–conjugated BrdU antibody (BrdU Flow Kit, BD 
Bioscience) and analyzed with flow cytometry. 
4.12  Mass cytometry (III) 
The cells were isolated in the same manner as for flow cytometry. The cells were 
stained for dead cells with Cell-ID Cisplatin (Fluidigm; cat. 201064). After washing 
and Fc-blocking, the cells were stained with heavy-metal isotope–labelled antibodies. 
Antibodies used for stainings are listed in Table 2. After washings, the cells were 
incubated with DNA intercalation solution (1:1000 Cell ID Intercalator-103Rh in 
MaxPar® Fix and Perm Buffer; cat. 201067; Fluidigm), fixed with 4% PFA 
overnight. The pelleted cells were resuspended to MaxPar Water (cat. 201069; 
Fluidigm) immediately prior to data acquisition with a Cytometry by time of flight 
(CyTOF) mass cytometer (Helios, Fluidigm). The T-distributed Stochastic Neighbor 
Embedding (t-SNE) algorithm was applied for visualization of the multidimensional 
data in two-dimensions (viSNE, Cytobank, https://www.cytobank.org). The distinct 
CD45+ cell populations were manually assigned to different leukocyte 
subpopulations. To allow direct comparison with flow cytometric analyses in certain 
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experiments, the mass cytometry data was manually analyzed using bi-axial blotting. 
Alternatively, the data were uploaded to the VorteX clustering environment 
(https://github.com/nolanlab/vortex/releases/tag/29-Jun-2017). Unsupervised 
hierarchical clustering with X-shift algorithm was performed with 15 selected 
parameters on the datasets from 5wk and 3 month old mice. The default settings were 
used for the clustering, with nearest density estimation (K) from 150 to 10, with 30 
steps. Then, all data sets were selected and the elbow point (K) was calculated. All 
13 clusters were selected and the force-directed layout was created (ForceAtlas2 
algorithm). The distinct CD45+ cell clusters were manually assigned to different 
leukocyte subpopulations. The layout and the visualization were produced with 
Gephi 0.9.1 (https://gephi.org).  
Table 2.  Antibodies used in mass cytometry. 
Antibody Company Cat# 
B220-159Tb Fluidigm 3159015C 
CD4-172Yb Fluidigm 3172003C 
CD8a-168E Fluidigm 3168003C 
CD11b-148Nd Fluidigm 3148003C 
CD11c-142Nd Fluidigm 3142003C 
CD45-175Lu Fluidigm 3175010C 
CD64-151Eu Fluidigm 3151012C 
CD80-171Yb Fluidigm 3171008C 
CD117-173Yb Fluidigm 3173004C 
CD206-169Tm Fluidigm 3169021C 
CD274-153Eu Fluidigm 3153016C 
CX3CR1-164Dy Fluidigm 3164023C 
F4/80-146Nd Fluidigm 3146008C 
Ly6C-162Dy Fluidigm 3162014C 
Ly6G-141Pr Fluidigm 3141008C 
MerTK-PE BioLegend 151505 
MHCII-174Yb Fluidigm 3174003C 
Anti PE (PE004) 158HO Fluidigm 3165015C 
Siglec - 1 -170Er Fluidigm 3170018C 
Siglec - F -PE -CF594 BD Biosciences 562757 
TER -119 -154Sm Fluidigm 3154005C 
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4.13 Cytology (II) 
Sorted F4/80Low and F4/80Hi fetal liver macrophages were spun down onto 
microscopic slides (Shandon cytospin III, Tecan). The cells were stained with Diff-
Quick (REASTAIN) and imaged using Zeiss AxioVert 200M (Zeiss) with a Plan-
Noefluar 40× /0.60 objective. 
4.14 Quantitative PCR (I, II, III) 
Plvap mRNA expression data from sorted CD45–CD31+ podoplanin+ LECs and 
from CD45–CD31+ podoplanin– BECs were obtained with permission from the 
database of the Immunological Genome Project. (I) 
Total RNA from samples was isolated using the Nucleo-Spin RNA kit 
(Macherey–Nagel) (II) or the RNAeasy Plus Micro kit (QIAGEN) (II, III). The 
RNA was reverse-transcribed to cDNA with SuperScript VILO cDNA Synthesis 
kit (ThermoFisher Scientific) (II) or SensiFastTM cDNA Synthesis Kit (Bioline) 
(III) according to the manufacturers’ instructions. Quantitative PCR (qPCR) was 
carried out using Taqman Gene Expression Assays (ThermoFisher Scientific). The 
reactions were run using the 7900HT Fast Real-Time PCR System (Applied Bio-
systems/ ThermoFisher Scientific) (II), QuantStudio 12K Flex Real-Time PCR 
System (Applied Biosystems/ ThermoFisher Scientific) (II, III) or Quant Studio 3 
Real-Time PCR System (Thermo Fisher Scientific) (III) at the Finnish Microarray 
and Sequenc-ing Centre (FMSC), Turku Centre for Biotechnology, Turku, Finland. 
(I) Table 3 lists the genes that the qPCR was carried out for. Relative expression 
levels were calculated using Sequence Detection System (SDS) Software v2.4.1, 
QuantStudio 12 K Flex software, and DataAssist software (all from Applied 
Biosystems/ThermoFisher Scientific) (I) or Applied Biosystems® analysis 
modules in Thermo Fisher Cloud computing platform (ThermoFisher Scientific) 
(III). Results were presented as percentages of the control gene mRNA levels from 
the same samples. 
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Table 3.  The genes of interest and their qPCR primers. 
Gene Primer Pub. 
Plvap Mm00453379_m1 II 
Lyve-1 Mm00475056_m1 II 
Actb (control) Mm00607939_s1 II 
Cx3cr1 Mm00438354_m1 II, III 
Mrc1 Mm00485148_m1 II 
Adgre1/Emr1/F4/80 Mm00802529_m1 II 
Itgam Mm00434455_m1 II, III 
Gata2 Mm00492301_m1 II 
Flt3 Mm00439016_m1 II 
Ccr2 Mm04207877_m1 II, III 
Csf1r Mm01266652_m1 III 
Zbtb46 Mm00511327_m1 III 
C1qa Mm00432142_m1 III 
Spi1 Mm00488142_m1 III 
Itgax Mm00498701_m1 III 
Actb (control) Mm02619580_g1 III 
 
4.15 Electron microscopy (I, II) 
4.15.1 Transmission electron microscopy (I, II) 
Tissue samples were collected and fixed in 5% glutaraldehyde in 0.16 M s-
collidine buffer. After 2 h post-fixation with 2% OsO4 containing 3% potassium 
ferrocyanide, samples were dehydrated with a series of increasing ethanol 
concentrations and embedded in Epoxy Embedding Medium kit (45359 Fluka). 70 
nm sections were cut and stained with 1% uranyl acetate and 0.3% lead citrate. The 
samples were imaged with a JEOL JEM-1400 Plus transmission electron 
microscope. 
4.15.2 Scanning electron microscopy (I) 
Mice were fixed by transcardial perfusion of a solution of 2% glutaraldehyde and 
4% PFA in phosphate buffer before tissue collection. The lymph nodes were 
washed and the capsules of the nodes were peeled off with forceps under a 
stereomicroscope. The samples were post-fixed for 60 min at 20 °C in 1% OsO4 in 
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0.1 M phosphate buffer and dehydrated through a graded ethanol series and dried 
with a critical point dryer (HCP-2, Hitachi). The samples were coated with 250Å 
gold by an ion-sputtering device (IB-3; Eiko) and examined with a scanning 
electron microscope (S-3000H; Hitachi) at an accelerating voltage of 25 kV. 
4.15.3 Immunoelectron microscopy (I) 
Mice were fixed by transcardial perfusion of cold periodate-lysine-PFA and the 
PLNs were collected. Samples were post-fixated with the same fixative, embedded 
in OCT and snap-frozen. Sections were stained by an immunogold method (15-nm 
gold particles) with a MECA-32 first-stage antibody. Thereafter the sections were 
fixed with 1% glutaraldehyde solution and 2% osmium tetroxide solution, 
dehydrated in graded ethanol and embedded in epoxy resin. Ultra-thin sections 
were stained with uranyl acetate and imaged with a JEOL JEM-1400 Plus 
transmission electron microscope. 
4.16 Immunofluorescence staining and imaging of 
sections (I-III) 
In general, immunofluorescence staining and imaging were performed on samples 
that were collected and then frozen to OCT. Sections of desired thickness were cut, 
acetone fixed and stained with directly conjugated antibodies and a combination of 
primary and secondary antibodies. Antibodies that were used are listed on Table 4.  
Stained samples were mounted in Prolong Gold with or without DAPI or the nuclei 
were stained with Hoechst (Thermo Fisher Scientific, Cat. 62249) and then 
mounted with Prolong gold without DAPI. Imaging was performed with an 
appropriate microscope. Images were acquired with a LSM 780 confocal 
microsope (Zeiss) using a Plan-Apochromat 20× /0.8 objective, a C-Apochromat 
40× /1.20 W Korr M27 objective, C-Apochromat 63× /1.2 oil objective or Plan-
Apochromat 100× /1.40 oil DIC objective. A spinning disk confocal microscope 
(Intelligent Imaging Innovations) with a Plan-Apochromat 63× /1.4, 20× /0.8, 10× 
/0.45 or LD c-apochromat 40× /1.1 W objective was also used. Zen 2010 software 
(Zeiss), SlideBook 6 software (Intelligent Imaging Innovations, Inc.) Imaris 8.0 
software (Bitplane) and ImageJ software were used. Subtraction of background 
was used equally for all images. In certain images, brightness was changed in a 
linear way with ImageJ software. Brightness adjustments and thresholds were 
always applied equally to images that were compared. For certain representative 
images, maximal projection was used to generate z-stacks and noise was reduced 
with the mean filter in ImageJ software. 
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Table 4.  Antibodies used in immunofluorescence microscopy 
Antibody Company Cat# Pub. 
αSMA-Cy3 Sigma C6198 I 
αSMA-FITC Sigma F3777-2ML III 
B220-Pacific Blue BD Biosciences 558108 I 
CD4-A647 BD Biosciences 557681 I 
CD8-A488 BD Biosciences 557668 I 
CD11b-eFluor450 eBiosciences 48-0112-80 I 
CD11c-A488 eBiosciences 53-0114-82 I 
CD31-A488 BioLegend 102514 I, III 
CD31-APC BioLegend 102510 I, II 
CD206-A488 Bio-Rad MCA2235A488T III 
CD206-A647 BD Biosciences 565250 III 
F4/80-A488 Invitrogen MF48020 II 
Meca-32-A488 BioLegend 120506 I 
Meca-32-A647 Serotec MCA2539A647 I 
Siglec - F -A647 BD Biosciences 562680 III 
Phalloidin-A546 Life Technologies A22283 I 
Rat IgG2a-A488 BioLegend 400525 I 
AOC3 Harlan Sera-Lab PAS-2542 I 
CD31 BD Biosciences 550274 II 
CD31 BD Biosciences 553370 III 
CD54 (ICAM) BD Biosciences 550287 I 
CD106 (VCAM) BD Biosciences 550547 I 
CD117 BD Biosciences 553352 II 
CD144 (VE-cadherin) Pharmingen/BD Biosciences 550548 I, III 
CD169 Serotec MCA884EL I 
Caveolin Santa-Cruz sc-894 I, II 
CCRL1 Santa Cruz sc-46835 I 
Collagen I Chemicon AB765P I 
ER-TR7 Abcam ab51824 I 
ER-TR7-DyLight 405 Novus Biologicals NB100-649 I 
F4/80 Bio-Rad MCA497R III 
Lyve-1 Reliatech 102-PA50AG/103-PA50 I, II 
MAdCAM-1 E.Butcher Standford   I, II 
MECA-32/Plvap Invivo MECA32-17-8-AK 2028/01 II 
MECA-32/Plvap BD Biosciences 550563 I, II 
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Antibody Company Cat# Pub. 
Mouse anti human Plvap Abcam ab8086 I, II 
Perlecan Acris DM3099P I 
Podoplanin R&D Systems AF3244 I 
Prox-1 R&D Systems AF2727 I 
Rat IgG2a BD Biosciences 553926 I 
VEGF Abcam AB46154 II 
anti Goat IgG-A633 Molecular Probes A21477 I 
Donkey anti Goat IgG-A633 Life Technologies A21082 I 
Donkey anti Rat IgG-A488 Life Technologies A21208 I, II 
Goat anti Mouse IgG-A488 Invitrogen A11029 II 
Goat anti Rat IgG-A546 ThermoFisher A11081 I-III 
Goat anti Rat IgG-A647 Life Technologies A21247 I, II 
Goat anti Rabbit IgG- A405 Life Technologies A31556 I 
Goat anti Rabbit IgG-A546 Invitrogen A11035 II 
Goat anti Rabbit IgG-A633 Invitrogen A21071 I, II 
 
4.16.1 Visualization of luminal PLVAP (I, II) 
For visualization of the luminal location of PLVAP, unconjugated or A488-
conjugated MECA-32 or control antibody was administered to recipient. Injections 
were made either s.c to hind paw (I) or directly to the umbilical and vitelline veins 
of the yolk sac of E12.5 embryos (II). After 5 min (I) or 1 min (II) circulation, the 
recipients were killed and tissues of interest were collected, processed for 
microscopy. 
4.16.2 Whole-mount (I, II) 
Afferent lymphatics were visualized by staining the mechanically separated dorsal 
half of a WT ear with antibodies, followed by extensive washing and imaging the 
next day. The whole-mount staining methodology for PLNs, YS and AGM was 
adapted from a published protocol (Yokomizo et al.2012). Samples were imaged 
and three–dimensional reconstructions were generated from z-stacks, the results 
were converted to QuickTime files with Imaris 8.0 software (Bitplane). 
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4.16.3 PLVAP expression in human samples (I, II) 
PLVAP expression in human tissues was investigated in lymph nodes and liver. 
Peripheral lymph nodes which were macroscopically and microscopically normal, 
originated from surplus tissue from head and neck surgery. Human fetal liver 
sample from pregnancy week 18 was used for human liver analysis. Samples were 
sectioned and stained to determine the PLVAP expression and location using 
microscopy. 
4.17 Histology (II) 
Formalin-fixed, paraffin-embedded sections of embryo livers were cut, 
deparaffinized before antigen retrieval. Endogenous peroxide was quenched with 
3% H2O2 and non-specific immunoglobulin binding was blocked with rabbit 
serum. Endogenous biotin and avidin were blocked using DakoCytomation Biotin 
blocking system (Dako, X0590). Biotin–avidin complexes with the secondary 
antibodies were formed with using Vectastain ABC kit (PK-6100, Vector 
Laboratories). Liquid DAB+ substrate Chromogen System (Dako K3468) was used 
to detect the peroxidase complexes. Samples were stained with haematoxylin, 
dehydrated and mounted before imaging. 
4.18 Iron recycling (II) 
Prussian blue stainin on PFA-fixed, paraffin embedded sections was used to detect 
the ferric iron. The sections were counter-stained with Nuclear Fast Red. The red 
pulp areas of the spleen containing the blue-stained Fe3+-containing cells were 
analyzed using image thresholding. In livers, whole sections were analyzed. 
ImageJ software was used to measure the area fractions. 
4.19 Mammary gland ductal branching (II, III) 
The fourth mammary gland was mounted onto a glass slide and fixed in Carnoy’s 
fixative overnight at +4 °C or for 4 h at room temperature. The sample was 
rehydrated and stained with carmine alum (STEMCELL technologies, cat 07070) 
according to the manufacturer’s instructions. The samples were dehydrated, cleared 
in xylene for 2–3 days, and mounted with DPX Mountant (Sigma-Aldrich). 
Imaging was performed with Zeiss SteREO Lumar V12 stereo microscope using 
NeoLumar 0.8× objective (II) or Axiovert M200 microscope using a 5× /0.25 
objective (III). The mammary gland ductal tree area and the number of ductal 
branches were tracked manually and quantified using ImageJ with 
‘Skeletonize2D/3D’ and ‘AnalyzeSkeleton’ plugins. 
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4.20 Statistical analyses (I-III) 
Sample sizes were based on pilot analyses and published literature. Because mice 
of distinct genotypes were used, no specific randomization methods were 
implemented. During the experimental procedures with embryos, investigators 
were blinded to the genotypes, no other blinding methods were used. Numeric data 
are given as mean ± SEM. Statistical analyses were performed using GraphPad 
Prism software v6 and SAS 9.4. Comparisons between the genotypes were done 
with the Mann-Whitney or Kruskal-Wallis test. P values of <0.05 were considered 
statistically significant. 
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5 Results 
5.1 PLVAP in lymphatic endothelium controls the 
entrance of lymphocytes and antigens into the 
lymph nodes 
5.1.1 Deletion of PLVAP leads to abnormal lymph nodes 
To study the expression and role of PLVAP in lymphatics, a Plvap−/− knockout 
mouse model was generated. A heterozygous × heterozygous breeding and a mixed 
background approach were necessary to ensure that the offspring were born alive 
and that approximately 15% of the expected frequency of homozygous pups 
survived until early adulthood. Deletion of the PLVAP expression was checked 
with immunoblotting and by staining blood endothelium in the peripheral lymph 
nodes (PLN) with MECA-32 (monoclonal antibody to PLVAP). (I: Fig 1a, S1d) 
Comparison to sex matched WT littermates confirmed that the PLVAP protein was 
successfully ablated from the knockout mice. 
PLN:s from the Plvap−/− mice were unmistakably different compared to the 
WT PLN:s. Enlarged B cell follicles were visible with the microscope and further 
studies with flow cytometry showed a normal total lymphocyte count, but reduced 
amounts of CD4+ and CD8+ T cells and an increase of B220+ B cells. (I: Fig 1b-d) 
More B cells positive for the germinal center activation marker GL7 was seen in 
addition to a larger number of activated CD25+ T cells and CD44HiCD62LLow T 
cells among CD3+ cells in the Plvap−/− mice. (I: Fig 1e-g) However, even in the 
absence of PLVAP, the lymphatic vasculature in the PLN seemed normal. (I: Fig 
2a, 2g, 2h) Also the distribution and composition of the reticular conduit network 
which travels along the T cell areas were normal, although the area was diminished 
in size, due to the enlarged B cell follicles. (I: Fig 4i, S5c-f) 
5.1.2 WT subcapsular sinus LECs express PLVAP 
A closer look at the subcapsular sinus of the WT PLN revealed a clear PLVAP 
signal in the sinus lining LECs, both on the floor and ceiling of the sinus. (I: Fig 2a, 
3a) To confirm the unexpected finding of the presumably BEC-specific molecule, 
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several approaches were used. Detection of PLVAP in the draining lymph node 
SCS after s.c administration of MECA-32-A488, together with immunoelectron 
microscopy corroborated the finding. (I: Fig 2e, 3e-f,) A comparison of mRNA 
expression in the BECs and LECs from WT PLN showed obvious transcription of 
Plvap in the LECs, albeit the level being lower in the LECs. (I: Fig 2b, 2f) Finally, 
human PLN also showed expression of PLVAP in the subcapsular sinus. (I: Fig 
S3c) No PLVAP signal was found in the parenchyma of the WT PLN, excluding 
the blood vascular endothelial cells. Also, the afferent lymphatics were devoid of 
PLVAP expression. (I: Fig 2i, S3e, S3f) Much like in the BECs, PLVAP formed 
diaphragms in the endothelium, especially in the sinus floor that is in close contact 
with the underlying parenchymal conduits. (I: Fig 3b) The diaphragms were found 
on TECs and caveolae. Even though the Plvap−/− mice lacked the diaphragms, the 
endothelial structures could still be found on the LECs. (I: Fig 3c-f, S4h-i)  
5.1.3 Lack of PLVAP leads to increased antigen entry and 
enhanced B & T cell activation in the PLN 
The open-ended endothelial channels of the LEC floor in Plvap−/− mice are in close 
proximity of the conduit network, therefore the effect of the missing diaphragms 
was investigated. Fluorescently-labeled molecules (dextrans) with different 
molecular weights (10 kDa, 70 kDa, 500 kDa) were injected s.c into mouse foot 
pad and the conduit filling was analyzed. Normally, molecules of 70 kDa and 
larger molecular weight are excluded from entering the conduit network. In the 
Plvap−/− mice, the smallest molecule crowded the conduits instantly and the 70 
kDa and even 500 kDa molecules entered the network. (I: Fig 4a-d) In the absence 
of PLVAP filters, also a large protein antigen (180 kDa enzyme AOC3) reached 
the parenchyma readily. There, the antigen was taken up by the parenchymal 
macrophages and DCs, which act as antigen presenting cells in the lymph node. (I: 
Fig 4c, 4f, 4h) 
To determine whether the increased antigen-entry was PLVAP-dependent, we 
ruled out some other possibilities. Caveolae are known to facilitate trans-
endothelial passage. (Schubert et al. 2001) Our studies on the Cav−/− mice revealed 
that the PLVAP expression in the SCS LECs was comparable to WT. This 
indicated that the majority of PLVAP is located in non-caveolar structures. Also 
the results from the dextran experiments were similar to WT. (I Fig 5a-c) 
Macrophages participate in antigen transfer from the sinus to the B cell follicles. 
(Junt et al. 2007) To test the macrophage involvement in the antigen transfer into 
the conduits and parenchyma, macrophages were depleted by using clodronate 
containing liposomes. Macrophage-ingested liposomes release the clodronate, a 
bisphosphonate drug, which induces apoptosis of the phagocyte. (Van Rooijen and 
Norma Jäppinen 
60 
Sanders 1994) Depletion of PLN parenchymal CD169+ F4/80+ and sinus-lining 
CD169+ F4/80- macrophages (both PLVAP negative) using clodronate-containing 
liposomes did not affect the PLVAP expression of the LECs, nor the result of the 
dextran assay, i.e. the 70 kDa and 500 kDa molecules were excluded from the 
parenchyma. (I: Fig 5f, S6i) Thus, PLVAP in the LECs regulates the entry of 
lymph borne molecules to the PLN parenchyma, in a size-dependent manner. 
5.1.4 Lymphocytes use PLVAP to transmigrate through the 
lymphatic endothelium 
To study whether the PLVAP diaphragms of the SCS floor affected the migration 
of lymph borne lymphocytes to the parenchyma, lymphocytes from WT donors 
were labeled with a green cytosolic dye CFSE, injected s.c into Plvap−/− and WT 
mice and left to migrate to the draining lymph node. In the absence of PLVAP, the 
transferred lymphocytes entered the lymph node in greater numbers in comparison 
to WT. Blocking the PLVAP filter with a conjugated or unconjugated MECA-32 
antibody led to reduced entry of lymphocytes into the lymph node. (I: Fig 6a-c) 
Electron microscopy analyses showed that the interaction between lymphocytes 
and LECs typically took place where cell surface structures such as caveola and 
TECs located. In vitro -data revealed that 32,3 % ± 5,3% (mean ± sem) of the 
lymphocytes traversed the monolayer of LECs via the transcellular route. 
Immunofluorescence stainings showed the lymphocytes extending F-actin+ 
podosomes to probe the LEC membrane and pushing aside the PLVAP and F-actin. 
PLVAP+ areas were sporadically situated on the peripheral cytoplasm and seemed 
to coincide with F-actinLow expression, but were almost absent in the cell-cell 
junction areas. (I: Fig 7a-f, S7e-g) These data suggest that PLVAP on the 
endothelium facilitates transcellular migration. 
5.2 PLVAP regulates the establishment of tissue-
resident macrophage populations during 
development 
Studying the immune system and immune cells of the adult Plvap−/− mice revealed 
that the absence of PLVAP led to unexpected perturbations in the macrophage 
system. Several tissues lacked macrophages to some extent or almost totally. F4/80 
is often used to differentiate the fetal-derived tissue-resident macrophages (F4/80Hi) 
from monocyte-derived macrophages (F4/80Low). (Schulz et al. 2012, Hashimoto et 
al. 2013) Therefore we used F4/80 (among other markers) to study the macrophage 
biology of the Plvap−/− mouse. 
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5.2.1 Deletion of PLVAP leads to decrease in F4/80Hi tissue-
resident macrophage populations in the adult mice 
Flow cytometry analyses showed that several tissues had significant reductions 
(75%-95%) in embryonic-derived tissue-resident macrophage populations, but 
normal or slightly increased amounts of bone marrow –derived tissue 
macrophages. (II: Fig1a) In the adult mice, the production of monocytes and 
macrophages seemed normal, determined by the fact that frequencies of 
hematopoietic stem cells (HSC), common myeloid and common lymphoid 
progenitor cells were comparable to WT mice. In addition, the frequencies of bone 
marrow and blood monocytes were normal, as were the amount of recently entered 
tissue monocytes in the spleen and liver. (II: Fig 1a, S2b-f) Frequencies of B cells 
and T cells were not affected by the PLVAP deletion, except in the PLNs. (I: Fig 
1d, II: Fig S2g, S3a-b) 
5.2.2 Decreased fetal liver -derived, but not YS-derived 
macrophages in tissues of Plvap−/− mice 
Tissue-resident macrophages originate from the fetal era, so the Plvap−/− mice were 
studied at an embryonic time point. Flow cytometric analyses showed that at E16.5 
the YS-derived macrophage counts in the spleen and lung were not influenced by 
the lack of PLVAP.  Also the number erythro-myeloid progenitors (EMP) and the 
colony forming ability of E10.5 YS cells remained unaffected, as did the microglia 
of both embryonic and adult mice. (II: Fig 2a, S4b-e) However, the frequency of 
liver-derived macrophages in the embryonic spleen and lung were significantly 
reduced. The blood also had significantly fewer liver-derived monocytes. (II: Fig 
1b)  
5.2.3 Macrophage precursors accumulate in fetal liver 
Since the production of fetal macrophages shifts to the liver at E12.5, a closer look 
at the Plvap−/− liver was taken. The lack of PLVAP (which is synthesized in WT 
liver endothelium from E11.5 onwards) did not disturb the overall morphology and 
vasculature of the embryonic liver. (II Fig: 3a-b S7a-c) Flow cytometric analysis 
revealed that the amount of YS-derived macrophages in the liver remained 
unaffected at E12.5-E16.5, but at the same time a clear accumulation of liver-
derived macrophages and especially liver monocytes was seen. (II: Fig 2b-d, S5c) 
The frequencies of monocyte progenitor cell types were comparable between the 
Plvap−/− and WT livers, as were the frequencies of EMPs and HSCs (and their 
colony forming abilities at E12.5). (II: Fig S5c-f) Tamoxifen inducible PlvapF/F; 
CAGCre-ERTM and conditional PlvapF/F; Lyve-1Cre- mouse indicated that PLVAP 
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expression is needed at E13.5-E14.5 for the normal egress of fetal liver monocytes. 
(II: Fig S8a-f) 
5.2.4 PLVAP interacts with heparin and chemotactic 
molecules 
In embryonic WT liver, PLVAP can be found on top of fenestrae, whereas in 
Plvap−/− liver the endothelial structures are formed normally, but remain 
uncovered. (II Fig 3d) We reasoned that if the open-ended fenestrae leave cells 
trapped in the liver, the PLVAP diaphragms might be needed to interact with the 
cells, essentially guiding them out. A series of interaction studies with molecules of 
interest, based on the literature, were conducted. PLVAP (in certain experiments 
endogenous PLVAP from E14.5 liver and in others a PLVAP-IgG Fc fusion 
protein) bound to heparin. PLVAP also bound to the chemotactic molecules 
VEGF-A and neuropilin-1, but only in the presence of heparin. (II Fig 3e-h, S9a-e) 
We also discovered that in the liver, common monocyte progenitors and Ly6C+ and 
Ly6C- monocytes express receptors for VEGF-A and neuropilin-1. (II: Fig S9f-i) 
This supported our theory that the PLVAP may immobilize chemotactic molecules 
which are recognized by fetal monocytes. 
5.2.5 Deficiency of fetal-derived macrophages leads to Fe3+ 
accumulation and altered mammary branching in adult 
Plvap−/− mice 
The deficiency of F4/80Hi macrophages in the Plvap−/− mice was evident in the 
spleen and liver of adult mice. (II: Fig 1a, 2b) To investigate if bone marrow -
derived macrophages can take over the tissue-resident macrophage functions, the 
recycling of iron was studied. Prussian blue staining showed that in the Plvap−/− 
mice Fe3+ accumulated in the red pulp of the spleen and in the liver. (II: Fig 4a-b, 
S10c) Mammary gland branching is partly macrophage dependent and was studied 
in the prepubertal 4,5wk old Plvap−/− female mice. F4/80+ macrophage counts 
within the 4th inguinal mammary glands were reduced, while the other lymphocyte 
counts remained unaffected. The ductal branching was significantly stunted in the 
otherwise proportionally sized mammary gland. (II: Fig 4c-f, S10d-e, III: Fig 5a) 
These results showed that the adult monocyte-derived macrophages cannot fully 
compensate the tissue-resident macrophage functions in the Plvap−/− mice. 
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5.3 Fetal-derived macrophages occupy mammary 
gland throughout adulthood 
The striking under-development of the mammary gland ductal network in the 
Plvap−/− mice prompted us to perform a more detailed investigation of the 
mammary gland macrophage biology. Steady state mammary tissue macrophage 
status has not been thoroughly investigated, as much of the research focuses in 
pathological tumor associated macrophages. 
5.3.1 Macrophages reside in the mammary gland already 
before birth 
Flow cytometric analyses revealed that F4/80+ cells of the 5wk WT mammary 
gland can in fact be divided to F4/80Hi and F4/80Int populations. (II: Fig 4c, III: Fig 
1a) Gene profiling and surface marker analysis of the two mammary gland 
populations supported the different phenotypes of the macrophages. (III: Fig S2c-
d) Two robust populations of macrophages were found in the mammary gland at all 
studied postnatal time points (1wk, 2wk, 5wk and 3 months of ages), with the 
F4/80Hi macrophages composing approx. 50% of total mammary gland 
macrophages. Interestingly, two macrophage populations were present in the 
mammary gland already before and right after birth. This, in addition to reduced 
macrophage counts in the Plvap−/− mammary gland (see 5.2.5) suggested YS-
derived and fetal liver -derived origins to the mammary gland tissue-resident 
macrophages in adulthood. (III: Fig 1a, S2a-b, h) 
5.3.2 Fetal liver -derived macrophages seem to constitute 
the majority of tissue-resident macrophage pool in 
mammary gland 
To further dissect the origin of the embryonic macrophages in the adult mammary 
gland, several mouse models and experimental settings were utilized. Experiments 
with anti CD115 antibody (which blocks the production of YS-derived 
macrophages) showed that the YS-derived macrophages fall into the F4/80Hi 
population in E17.5 WT mice, but the depletion did not affect the mammary gland 
macrophage populations significantly in later time points. Analysis of the 
mammary glands of CX3CR1-YFP and CSF1R-YFP -reporter mice (which label 
the YS-derived macrophages/progenitors and their progeny) showed that the YFP+ 
cells were also F4/80Hi in all time points and that YFP+ F4/80Hi fetal-derived 
macrophages persisted in the adult mammary gland. Plvap−/− mice, which have a 
deficiency of fetal liver -derived macrophages, but normal YS-derived 
macrophages, have a small proportion (12% vs 39% in the WT) of F4/80Hi 
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macrophages in the mammary gland. This small population is most probably from 
YS origin. (III: Fig 1b-d, S2g) These results suggest that the majority of F4/80Hi 
macrophages in the adult mammary gland are originating from the fetal liver, 
rather than the YS. 
5.3.3 CCR2-independent migration of macrophages to 
mammary gland 
To investigate the contribution of adult monocytes to the F4/80Int macrophage 
population in the mammary gland, we studied two commonly used knock out 
mouse models with reductions in mature Ly6C+ and circulating Ly6C- monocytes. 
In breast cancer, monocytes are recruited to the tumor in CCR2-dependent manner. 
(Bonapace et al. 2014) Flow cytometry analysis of Nur77−/− mice mammary glands 
showed no reduction of mammary gland monocytes and Ccr2−/− mice showed only 
a modest reduction in the F4/80Int population of macrophages. (III: Fig 2a, S3d) 
These results suggest that in a healthy mouse the majority of adult monocyte -
derived macrophages migrate to the mammary in a CCR2-independent manner. 
5.3.4 CD206 as a putative marker to define fetal-derived 
macrophages in mammary gland 
Distinguishing the tissue-resident macrophages often relies on the common 
macrophage surface marker F4/80. However, after analyzing the mammary gland 
macrophages with mass cytometry, we observed that CD206 is actually more 
powerful at phenotypically differentiating the fetal-derived and adult monocyte-
derived macrophages in the mammary gland. F4/80Hi macrophages were CD206Hi 
and the deficiency of CD206Hi macrophages in Plvap−/− mice and in clodronate 
treated mice after recovery imply that CD206 does identify fetal macrophages. 
Also, CD206Hi macrophages expressed high levels of typical macrophage markers 
(CD64, F4/80, Siglec-1) in flow cytometric and qPCR analyses. (III: Fig 3d, 4b) 
5.3.5 CD206+ macrophages are associated with ductal 
branching and scavenging in mammary gland 
Macrophages are associated with ductal branching morphogenesis of the mammary 
gland. Mammary gland whole mount stainings showed that the ductal branching 
was comparable to WT mice in the knockout models with defective bone marrow 
monocyte migration (Ccr2−/− and Nur77−/−). However, the ductal morphogenesis 
failed almost completely in the embryonic macrophage -deficient mice (Plvap−/− 
mice, which have normal YS-derived macrophages, see 5.2.2). (III: Fig 5a) 
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In addition to assisting in ductal branching, macrophages are known scavengers 
in many tissues. We studied the scavenging abilities of the mammary macrophages 
and the CD206Hi macrophages showed superior scavenging properties in assays 
where dextran, acetylated LDL or immunocomplexes were injected intravenously 
(i.v) into WT mice. The injected particles were taken up by the CD206Hi 
macrophages much more readily in comparison to the monocyte-derived 
CD206Neg/low macrophages. (III: Fig 5b) Immunofluorescence stainings showed that 
the CD206+ macrophages resided next to the ducts and small vessels of the 
mammary gland, even reaching to the lumen. These locational data support their 
scavenging function. (III: Fig 5d-f, S7b-d) These data show that the CD206+ 
macrophages possibly perform specialized functions in the mammary gland. 
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6 Discussion 
The basis of this thesis was laid by the unexpected discovery of PLVAP in the PLN 
subcapsular sinus. Until then, PLVAP had been studied only in the blood vascular 
endothelium, where it affected endothelial permeability. We reasoned that PLVAP 
in the PLN might serve the same purpose and studied if the absence of PLVAP had 
an effect on the immunological functions of the PLN. While investigating the 
leukocyte populations we noticed that the Plvap−/− mice experienced reduced 
frequencies of macrophages in several tissues. Since the production of macrophage 
precursors in the adult mice seemed unaffected, we reasoned that there must be 
another reason for the diminished macrophage counts. Embryonic macrophages 
had been reported to colonize tissues and remain in them during adulthood. 
PLVAP-deficient mice seemed to have diminished frequencies of tissue-resident 
macrophages in many tissues, especially in the mammary gland. Thus the final step 
was to elaborate the mammary gland macrophage kinetics and inspect the origins 
and functions of the tissue-resident macrophages in the mammary gland. The 
results from this thesis underline the importance of endothelial regulation in the 
developing embryo and in the adult individual. This chapter discusses some of the 
key results and the questions they raise. At the end of this chapter I will discuss 
some potential approaches to utilize the discoveries in this thesis. 
6.1 PLVAP expression in the lymphatics (I) 
The endothelial protein PLVAP has been previously studied in the blood 
vasculature and has been established as a blood endothelium specific marker. 
(Baluk, McDonald 2008) PLVAP is the only known component of the diaphragms 
that overlay caveolae, TECs and fenestrae and no other localization has been found 
for PLVAP. (Tkachenko et al. 2012) It was surprising to detect PLVAP expression 
within the lymph node LECs. The immunofluorescence staining of mouse and 
human peripheral lymph node clearly showed that the lymphatic endothelial cells 
of the subcapsular and medullary sinus expressed PLVAP. Bright staining by the 
MECA-32 antibody in the blood vessels of the PLN combined with the blank 
staining in the Plvap−/− mice corroborated the reliability of the antibody used to 
detect PLVAP. Comparing Plvap mRNA expression in the LECs and BECs 
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showed that the LECs clearly express the mRNA, although in a lower level 
compared to BECs. Co-staining with lymphatic endothelial markers confirmed the 
PLVAP expression within the SCS. Finally, electron microscopy studies suggested 
the existence of the classical cartwheel-like structure that PLVAP forms in other 
tissues, and showed the binding of gold conjugated PLVAP antibody to the 
caveolae, transendothelial channel and fenestrae structures. These results prove that 
the PLVAP, formerly thought to be BEC specific is also expressed by the adult 
mouse and human PLN. The unique expression of PLVAP in the SCS LECs and 
the absence of PLVAP in the afferent lymphatics may point to a specific filtering 
function of the SCS LECs. It is likely that the expression has gone unnoticed by 
researchers because of the lower expression and specific location in the SCS, 
relatively far from the BEC vessels which might be stained with MECA-32 for 
their blood vessel identity.  
6.2 PLVAP mediated regulation of antigen and 
leukocyte migration (I, II) 
6.2.1 Antigen migration (I) 
The lymphatic expression of PLVAP was focused on the SCS floor and the 
absence of expression in the afferent lymphatics led us to hypothesize that the 
diaphragm could serve the same function in the LECs as it does in the blood 
endothelium. Indeed, in the absence of PLVAP, the entry of small and large 
antigens was increased. Several approaches were used to prove that the antigen 
entry is regulated by PLVAP in the LECs. We showed that once the larger (>70 
kDa) molecules gain access through the SCS, like in the case of the Plvap−/− mice, 
they are non-discriminatively transported onwards in the conduit system. Our data 
are supported by the results from Thierry et al. who showed that the conduit system 
is able to transport locally produced large IgM molecules, but they cannot enter the 
LN parenchyma from the blood or lymph, i.e. cross the endothelium layers 
(Thierry et al. 2018). We used Cav−/− mice to show that the endothelial caveolae, 
which are known to facilitate molecule transport, had no effect on the antigen entry 
to the PLN parenchyma. Similarly we showed that the sinus lining macrophages, 
which are known to transport larger antigens trough the SCS (Junt et al. 2007), did 
not affect the conduit filling. The endothelial cells are known to endocytose 
particles and the amount of endothelium-facilitated transport was not quantified. 
However, the efficacy of endothelial transport is small compared to macrophages 
(Anselmo and Mitragotri 2017) and since the macrophages had no significant 
effect on dextran transport, it is unlikely that the LEC transcytosis would account 
for the robust dextran migration to the conduits. These data support our 
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interpretation that the PLVAP diaphragms on LECs have a decisive role in 
regulating the entry of the molecules to the parenchyma. 
6.2.2 Leukocyte migration (I, II) 
Leukocytes can traverse endothelial layers via the transcellular or paracellular 
route. (Carman et al. 2007) The results on CFSE –labeled leukocyte migration 
showed that the absence of PLVAP diaphragms on the SCS led to increased CD4+ 
T lymphocyte (and B220+ B cells, but less so compared to the T cells) entry into 
the parenchyma of the PLN, similarly to the increased antigen entry. Blocking of 
the diaphragm in WT mice using a MECA-32-antibody in turn decreased the 
lymphocyte entry. These results indicate that in steady state, the migrating 
lymphocytes interact with the PLVAP filter and perhaps use it as a sign of a route 
with less resistance. 
Labeling of the lymphocytes with CFSE even at recommended concentrations 
has been shown to negatively affect the migration of B cells to the PLN in vivo, but 
not to affect their ability to respond to chemotactic signals or bind to HEVs in 
vitro. (Nolte et al. 2004) We showed an increase of CFSE-labeled lymphocytes in 
Plvap−/− PLN in comparison to WT, and the blocking of PLVAP with an antibody 
reduced the influx of both T and B cells. PLVAP interactions with chemotactic 
molecules are possibly needed for the monocyte egress in the fetal liver, but we did 
not check the presence of chemokines in the PLN. Thus, blocking of the PLVAP 
diaphragm with an antibody might have hampered the transmigration by preventing 
the migrating lymphocytes from reaching the diaphragm-bound chemokines. 
CFSE-labeling of the cells, rather than differing migration mechanisms between 
the T and B cells, might explain the underrepresentation of B220+ cells in the 
migrated lymphocytes. 
Our results support the in vitro data from Keuschnigg et al. which shows that 
PLVAP is important for the transmigration, more so than for the paracellular 
migration of lymphocytes. (Keuschnigg et al. 2009) Migrating cells made contact 
with PLVAP+ areas which were also F-actinLow. The PLVAP covered TECs and 
fenestra are structures that in essence create a tunnel through the endothelial cells 
and often localize to the thinnest, peripheral part of the cytoplasm. This might 
provide the lymphocyte a sign of easy entry into the parenchyma via the 
transcellular route. Interestingly, the lymphocytes are too big to fit through the 
TECs and fenestra, so it is likely that some remodeling of the endothelial 
architecture takes place. Leukocytes have been shown to extend podosomes to 
palpate endothelial cell surface and induce and expand pores to facilitate migration 
across the endothelium. (Carman et al. 2007) The same techniques could be used to 
push aside or degrade the PLVAP diaphragm and open the pre-existing pore to fit 
Discussion 
 69 
through. Figure 5. summarizes the role of PLVAP in antigen and lymphocyte 
migration from the SCS to the parenchyma of the PLN. 
 
Figure 5.  Summary of the effects of PLVAP in migration of lymphocytes and various sized 
antigens from the SCS to PLN parenchyma. L= Lymphocyte 
However, contrary to the increased lymphocyte migration into the PLN 
(Publication I), the absence of PLVAP filter in the fetal liver led to decreased 
migration of macrophage precursors to the blood stream (Publication II). We and 
others have shown that PLVAP interacts with molecules such as VEGF-A and 
neuropilin-1. (Keuschnigg et al. 2012) Our results showed for the first time the 
interaction between heparin, neuropilin-1, VEGF and PLVAP and that they 
potentially interact with the neuropilin-1 and VEGFR1 in the fetal monocytes, 
guiding the monocytes into the blood stream. The molecular interactions offer a 
possible explanation for the monocyte accumulation within the fetal liver in the 
absence of PLVAP diaphragm (and the subsequent presence of open fenestrae). 
Nevertheless, it is unexpected that the absence of PLVAP filter in the SCS and 
fetal liver affects the migration cascade in opposite ways, as the absence of PLVAP 
has so far only been linked to increased leakiness in all tissues. No other structure 
or function has been reported for PLVAP besides the cart wheel -like diaphragm 
and the gene is well conserved in mouse, rat and human tissues. (Stan et al. 2001) 
Therefore it is unlikely that the PLVAP-diaphragm itself would function differently 
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in PLN and fetal liver. Possible explanations for the opposite effects of absent 
PLVAP on cell migration in the PLN and fetal liver might be: 
Perturbed endothelial cell barrier: The SCS LEC floor could be leaky due to 
the lack of PLVAP or experimental procedures during the cell migration assays, 
allowing the labeled lymphocytes to leak through the SCS. The injection of CFSE-
labeled lymphocytes is not strictly physiological, but others have shown that the 
injection of cells in the periphery (although intralymphatic) does not alter the 
lymph node structure. (Brown et al. 2018) The immunofluorescent stainings also 
showed that the lack of PLVAP did not disturb the overall morphology of either the 
PLN or the fetal liver suggesting it is unlikely that the increased cell migration 
would be the result of perturbed morphology in the PLN. 
Differences in migration routes: The migrating lymphocytes and fetal 
monocytes utilized different routes to migrate to their target tissues (lymphatics in 
Publication I and blood vessels in Publication II). PLVAP is widely expressed in 
the blood vasculature (Stan et al. 2001) and the systemic absence of PLVAP could 
result in leaky vessels outside the liver which would not be able to facilitate fetal 
monocyte migration from the liver to the target tissues. In the lymphatics, PLVAP 
expression has not been reported in the periphery. 
Differences in migrating cells: The migrating cells in Publication I were 
CFSE-labeled adult lymphocytes as opposed to the endogenous, non-manipulated 
fetal monocytes in their native environment in Publication II. The two cell types 
might use differing migration strategies. It is possible that the dependency of a 
certain migration molecule changes between fetal and adult cells. For example, 
adult monocytes typically migrate in a CCR2-dependent manner, whereas fetal 
monocytes have a more progenitor-like phenotype and migrate in a CCR2-
independent manner. (Serbina, Pamer 2006) Similarly, adult lymphocytes could be 
less dependent on PLVAP or PLVAP-associated migration molecules. 
Elucidating the reason for the opposite outcomes for cell migration in the adult 
lymph node and fetal liver requires more investigation of the differences in the 
endothelial cells. However, investigation of cell migration should preferably be 
conducted in a three-dimensional model. It is challenging to draw conclusions of 
cell location in a tissue, based on two-dimensional sections. Nonetheless it seems 
that PLVAP, which so far has mainly been reported to act as a filter, has the ability 
to participate in molecular interactions with chemokines and migrating cells. The 
blocking antibody experiments in PLN suggest that PLVAP is needed for the 
normal migration of cells in the PLN as well as the fetal liver. 
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6.3 PLVAP expression in humans (I, II) 
Others and we have showed that PLVAP is expressed in the human PLN, in 
addition to several other healthy and diseased tissues. (Stan et al. 2001) The reports 
on PLVAP expression in human liver have been inconclusive. Strickland et al. 
reported that they could not detect expression of PLVAP in human fetal liver. 
(Strickland et al. 2005) We however, did see a clear PLVAP expression in the 
human fetal liver at pregnancy week 18. Our report supports the report by Stan et 
al. which shows that Plvap mRNA is expressed in the liver (and many other 
tissues, most abundantly in the kidney and spleen and none in the brain). (Stan et 
al. 2001) Strickland et al. did not specify the age of the fetus or the method of 
detection, so the discrepancy might be due to the use of a fetal liver from a 
different stage of development, analysis of a different localization, differences in 
antibodies or the method of detection. 
6.4 Tissue-resident macrophages (II, III) 
So far, reports on adult tissue-resident macrophages have mainly focused on the 
differences of monocyte-derived macrophages and embryonic macrophages, 
grouping together the YS and fetal liver -derived macrophages. One reason for this 
is likely the scarcity of tools to differentiate the two fetal macrophages from each 
other in the adult tissues. Today, reporter mice are widely used. Others and we 
have used an inducible YFP-reporter mouse under a CSF1R-promoter to track YS-
derived cells and under a CX3CR1- promoter to follow both the YS and fetal liver 
-derived cells. The drawback of the tamoxifen inducible models is that the amount 
of labeled cells is small, because the labeling efficiency with tamoxifen is often 
relatively low. (Yona et al. 2013) Further studies are needed to ascertain that the 
macrophage effect is not related to other perturbations in the Plvap−/− mice. 
However, it is possible that the Plvap−/− mice could provide a useful tool to study 
the functional effects of tissue-resident F4/80Hi macrophages. 
The complete lack of PLVAP leads to a severe phenotype and the subsequent 
low birth rate and short life span of the pups. To counteract the adverse effects of 
systemic PLVAP deletion, we developed a conditional PlvapF/F; Lyve-1-Cre 
knockout. Lyve-1 is expressed in the yolk sac blood vessels at E9.5-E18.5 and in 
the fetal liver sinusoidal endothelium from E9.5 forward (Nonaka et al. 2007, 
Gordon et al. 2008), so we achieved a selective deletion of Plvap only in Lyve-1+ 
cells but not the majority of other vessels in the liver. Also, a tamoxifen inducible 
model PlvapF/F; CAGCre-ERTM was generated to delete Plvap and both were useful 
in determining the crucial time window for the PLVAP expression during 
development for Publication II. However, Lyve-1 is expressed in many blood 
vessels of the embryo and not exclusively in the liver so another promoter would 
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be more suitable for studying the effects of sinusoidal PLVAP expression. So far, 
there are no reports of an exclusively liver endothelium specific promoter, so 
developing a liver specific PLVAP knock out mouse is not plausible. Also, the 
timed deletion of PLVAP in the PlvapF/F; CAGCre-ERTM only inhibits the 
formation of new PLVAP for a short period but does not remove the existing 
protein, so the effects remain modest. In the future, a mouse model which lacks 
PLVAP exclusively and completely in the liver endothelium could be useful for 
studying the functional consequences of tissue macrophage reduction. 
6.4.1 Macrophages are found in the prenatal mammary 
gland (III) 
The significant deficiency of macrophages in the Plvap−/− mammary gland 
prompted us to further study the mammary gland. Most mammary gland studies are 
performed on the 4th inguinal mammary glands. Due to ease of extraction and 
comparativeness with results from others, only the 4th inguinal mammary glands 
were used in the experiments for this thesis. Nevertheless the five pairs of mouse 
mammary glands are known to develop in succession and not simultaneously and 
to be differently differentiated. (Bolander 1990) To ensure that the macrophage 
phenotype that we reported was not unique to only the 4th mammary gland, we also 
analyzed the macrophage statuses of the 2nd, 3rd and 5th mammary glands. The 
different mammary gland pairs closely resemble each other in macrophage 
composition, suggesting a conserved role for macrophages in the mammary glands 
and corroborating the use of the 4th mammary gland for the mammary macrophage 
studies. 
Macrophage presence in the WT mammary gland has not been fully elucidated 
during the different stages of development. In steady state macrophages have been 
reported in the mammary gland beginning from 2wk of age. (Gouon-Evans et al. 
2000) We used the sensitive FACS method to show that two populations of 
macrophages can be found in the mammary gland fat pad precursor tissue already 
before birth at E16.5. Macrophages are often found in the niches of developing 
organs, as has been demonstrated in the PLN development. The inguinal lymph 
node develops in the area where the 4th inguinal mammary gland also forms during 
pregnancy. At E15.5 the inguinal lymph node starts to form and at E18.5 
macrophages are found adjacent to the PLN bud. (Bovay et al. 2018) We did not 
remove the PLN bud for the E16.5 analyses as the PLN was too small. 
Theoretically, at E16.5 the macrophages in our mammary gland analyses could 
originate from the PLN development even though the macrophage numbers are 
considerable. However, the PLN was removed from the newborn mammary gland 
(and from all time points after that) and still the macrophage status of the breast 
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tissue closely resembled the E16.5 status. Our results provide information about the 
early development of the mammary gland cell composition and show that the 
mammary gland harbors sizeable macrophage populations already before birth. Our 
FACS analyses and immunohistochemical stainings compliment and further 
elaborate the data from adult mice reported by Gouon-Evans et al. and Chua et al. 
(Gouon-Evans et al. 2000, Chua et al. 2010) We provide an up-to-date picture of 
the mammary gland macrophage landscape with quantitative and kinetic data about 
the macrophage status within the whole mammary gland. 
6.4.2 Fetal macrophages persist in the adult mammary 
gland (II, III) 
After establishing that the prenatal mammary gland is inhabited by macrophages 
and the reduction in Plvap−/− mice macrophage population in the mammary gland, 
we wanted to investigate if the prenatal macrophages persisted in the adult 
mammary gland and what was their contribution to the whole mammary gland 
tissue macrophage population. Plvap−/− mice showed deficiencies in F4/80Hi tissue-
resident macrophages in many tissues, including the mammary gland. We saw two 
distinct macrophage populations at all stages of the development in the virgin WT 
mice. Chua et al. have reported F4/80Low and F4/80Hi macrophage populations in 
the 9-10 wk old mice, and our data from the 3 month old mice support their results. 
Chua et al. did not study the mammary gland at other ages or the developmental 
origin of the two populations. (Chua et al. 2010) 
So far it has been thought that the adult mammary gland macrophages are 
derived from HSC-precursors in the bone marrow. (Varol et al. 2015) The 
assumption is supported by the report form Gouon-Evans et al. who showed that 
the total body irradiation of mice at 19 days of age reduced the macrophage counts 
around the TEB and led to perturbed mammary gland duct formation. 
Transplantation of bone marrow cell suspension rescued the blood lymphocyte 
counts and the ductal phenotype (Gouon-Evans et al. 2000). The experimental 
setting which has driven the mammary gland macrophage dogma is problematic 
and the results should be cautiously interpreted to steady state. Total body 
irradiation causes inflammation and tissue damage. (Lambert, Moores 1986) 
Hashimoto et al. concluded that lethal irradiation, followed by a bone marrow 
transplantation results in tissue macrophages being repopulated by monocytes, but 
the same does not happen if macrophages are depleted using other methods which 
cause no damage to the tissue environment. (Hashimoto et al. 2013) Lavin et al. 
showed that after irradiation, the monocyte-derived cells, which have gained entry 
to a tissue, acquire 50-90% of the genetic imprint of the original tissue-resident 
macrophages. (Lavin et al. 2014) These results question the monocyte-dependent 
Norma Jäppinen 
74 
replenishment in steady state, since the irradiation might harm the tissue 
environment pat the point that is physiological. Indeed, we saw no replacement of 
the F4/80Hi macrophages after a clodronate and anti-CSF1 antibody treatment, 
which is not likely to damage the tissue environment. We did see an ablation of all 
tissue macrophages and the repopulation of bone marrow -derived macrophages, 
but not the tissue-resident macrophages. This would suggest that the method of 
clearing the tissue affects the capability of monocytes to repopulate the tissue and 
corroborates our results that in steady state the mammary gland hosts a robust adult 
monocyte-independent macrophage population which appears to originate from the 
fetal liver. 
Mass cytometry was used to study the macrophage populations of the 
mammary gland, as we wondered whether a marker could be found to better 
differentiate the fetal and adult macrophage populations, in addition to F4/80. 
CD206 was found to be useful in separating the two populations. Even though the 
CD206Neg/Low and CD206Hi populations remained relatively close to each other in 
flow cytometric analyses, using CD206 has the advantage that it is not expressed 
by the F4/80+ eosinophils, which are found in the mammary gland. (Gouon-Evans 
et al. 2000) Using any markers to stain and detect fetal macrophages has a level of 
uncertainty, as it is possible that the adult monocyte derived macrophages could be 
able to upregulate the same molecules. This methodological problem could be 
resolved with lineage tracking experiments using a powerful and selective reporter 
line under a suitable promoter.   
6.4.3 Monocyte-derived macrophage contribution to the 
mammary gland macrophage pool: CCR2 involvement 
in the F4/80Low population (III) 
We showed that a proportion of the mammary gland macrophages were 
CD11b+F4/80Low, which indicated that they were derived from adult monocytes. 
We used animals with perturbed monocyte migration to further investigate the 
origin of that population. Monocytes require CCR2 to exit from the bone marrow 
and CCR2-dependent monocyte influx to the breast is increased in breast cancer. 
(Bonapace et al. 2014) We however showed that in steady state, adult Ccr2−/− mice 
have only a modest reduction of monocyte-derived macrophages in the mammary 
gland, but normal or increased tissue-resident macrophages compared to WT. 
Newborn Ccr2−/− mice have normal mammary macrophage populations which 
aligns with the results from Hoeffel et al. who show that contrary to the adult 
monocyte migration, fetal monocytopoiesis is not CCR2-dependent. (Hoeffel et al. 
2015) This suggests that the establishment of the F4/80Low macrophages is CCR2-
independent and that by adulthood only a fraction of the F4/80Low macrophages are 
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replaced by CCR2+ bone marrow monocytes. The rest of the F4/80Low macrophages 
are replenished by a mechanism that is yet to be determined. 
Recently, Chakarov et al. reported two monocyte-derived interstitial 
macrophage populations which reside in contact with nerve fibers and blood 
vessels. They showed that the populations originate from Ly6CHi monocytes and 
are identifiable by LyveHiMHCIILo and LYVELowMHCIIHi signatures and evaluated 
that the two are present in several tissues. (Chakarov et al. 2019) We used mass 
cytometry to recognize two CD45+CD11b+Ly6CHiCX3CR1+F4/80+ populations 
which could be divided by their MHCII expression to MHCIILow (monocyte 
population 1, MO1) and MHCIIHi (monocyte population 2, MO2), possibly 
reflecting the two populations that Chakarov et al. reported. They report that unlike 
MHCIILow, only MHCIIHi positive cells appeared to rise from the blood monocytes 
and expressed Ccr2, which could support our data that a small portion of mammary 
macrophages are CCR2-dependent. Interestingly, our studies pointed towards the 
monocyte populations being a continuum of monocytes maturing to tissue 
macrophages, but Chakarov et al. reported that the interstitial macrophage 
populations are separate lineages which arise from tissue-recruited monocytes. We 
had not included Lyve-1 in our marker pattern in mass cytometry or determined the 
location of the MO1 or MO2 population in immunohistochemical stainings, so we 
cannot confirm that they are interstitial macrophages but it is possible and would 
require more research. 
Taken together, our data suggest that in the steady state virgin mouse the major 
mammary macrophage population is fetal-derived and that the bone marrow -
derived monocytes contribute to the mammary macrophage pool in a CCR2-
independent manner. The kinetics of mammary macrophage pool in relation to the 
origins of the population is depicted in Figure 6. 
 
Figure 6.  A relative representation of the suggested macrophage origin in the virgin mouse 
mammary gland at different time points. Red line = fetal liver -derived macrophages, 
black line = adult bone marrow -derived macrophages, orange line = yolk sac -derived 
macrophages 
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6.4.4 Hormonal effects on mammary macrophages (III) 
Chua et al. reported that the macrophage abundancy in the mammary gland of 9-
10wk mice changes during the estrus cycle. (Chua et al. 2010) We did not 
determine the estrus cycle in the adult mice, but all mice in all age points had 
robust macrophage counts in each experiment. The estrus cycle-associated 
fluctuation of the macrophage counts might explain the slightly larger variation of 
total cell amounts in the 3 month old mammary gland. However the frequencies of 
fetal and monocyte-derived macrophages stay similar in the virgin mice in every 
age point from prenatal to adult mice. Also, our results from male mammary tissue 
show comparable macrophage frequencies and phenotypes to females. These data 
may suggest that the macrophage composition in the mammary gland is not 
hormonally regulated. 
6.4.5 Macrophage functions in the mammary gland (III) 
Milk and milk proteins are produced by the alveoli in the mammary gland and 
defects in the ductal formation often lead to perturbed milk production and failed 
lactation. (Pollard Henninghauser 1994) Milk contains a substantial amount of 
macrophages, which are distinctly different from blood monocytes, highly 
phagocytic and linked to transmission of HIV from mother to child. (Ichikawa et 
al. 2003) Studying the effect of the reduced F4/80HiCD206Hi macrophages on milk 
composition would be interesting. The embryonic macrophages seem to reside in 
close contact with the ducts and are clearly phagocytic, so in that sense they 
resemble the macrophages depicted by Pollard et al. and it would be tempting to 
investigate whether the milk macrophages actually are embryonically-derived. 
Unfortunately the Plvap−/− females do not survive long enough to produce and 
nurse offspring, so their milk composition cannot be studied.  
Interestingly, the adult male mouse mammary gland fat pads, which neither 
form ducts or alveoli nor produce milk, have comparable macrophage frequencies 
to females. Macrophages in the healthy mammary gland have been linked to the 
development and cyclic remodeling of the ductal network and the assistance of 
mammary stem cell function (Chua et al. 2010, Chakrabarti et al. 2018). The ductal 
network development has been studied in the CSF1 deficient op/op mice, which 
lack about 50% of F4/80+ macrophages around the TEBs. (Gouon-Evans et al. 
2000) The ductal development in op/op mice is delayed and somewhat perturbed in 
comparison to WT, but the network still fills the whole mammary gland and is able 
to produce milk. (Pollard, Henninghausen 1994) Unlike the development of fetal 
YS macrophages and adult bone marrow –derived macrophages, the development 
of fetal liver –derived macrophages is not CSF1R-dependent. It is possible that the 
fetal macrophages are still present in the op/op mammary gland and assist in the 
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ductal development. However, our data suggest that in addition to supporting the 
ductal remodeling and stem cell function, some of the mammary macrophages also 
serve an immunological role. We showed that the tissue-resident macrophages are 
superior in scavenging blood borne ligands, so it is likely that the tissue-resident 
macrophages are needed for the maintenance of immunological homeostasis of the 
mammaries in both sexes. 
6.5 Future perspectives 
6.5.1 PLVAP as a therapeutic target (I) 
PLVAP is already the target of many researchers as its expression in the blood 
endothelium increases in many pathological conditions. We and others have shown 
that the PLVAP can be targeted and its function modulated by blocking antibodies. 
To evaluate the possible side effects of a new approach, knowledge of the 
expression pattern and kinetics of the target are beneficial. The discovery of 
PLVAP expression in the PLN, a major central for immune responses, could be 
useful for new ways to control inflammation. Excess activation and subsequent 
immune reactions by the PLN lymphocytes could potentially be regulated by 
targeted blocking of PLVAP in the SCS. 
6.5.2 Mammary macrophages as a therapeutic target (III) 
Macrophage presence in breast cancer has been mostly linked to poor prognosis, 
however their location in and around the tumor is clinically more relevant than 
their mere presence. Also, macrophages were not as abundantly present in all 
breast cancer types. (Medrek et al. 2012, Zhao et al. 2017) It is noteworthy that in 
other cancers, results on the macrophage effect on prognosis are both positive and 
negative. (Bingle et al. 2002) It seems that the macrophages in breast cancer (and 
other cancers) are heterogeneous in their phenotype and functions. Investigating 
the behavior of tissue-resident macrophages in breast cancer could produce new 
insight to the macrophage immunology.  
It would be interesting to use the expression pattern to distinguish the 
embryonic macrophages (F4/80HiCD64HiSiglec-1HiCD206Hi) in the mammary gland 
and investigate how they act in the development and progression of breast cancer. 
After carefully elucidating the functions of the resident macrophage populations, 
testing whether they could be modulated seems attractive. The detailed 
investigation of the similarities and differences of macrophage populations are 
warranted, since those factors are not only suitable druggable targets but also key 
points to avoid undesired adverse effects. 
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Macrophages can be used as carriers for drug delivery. (Klyachko et al. 2017) 
We established that the CD206+ macrophages are superior in scavenging blood 
borne molecules. This functional ability that seems to separate the embryonic and 
adult macrophages in the mammary gland could potentially be utilized for the 
design of cell type specific, targeted therapies. Whether the therapy would be 
intended to eliminate the specific macrophages or to use them as carriers of 
medicine to the breast cancer, targeting the drug exposure could limit the systemic 
exposure to the drug, reduce the drug concentrations and thus limit adverse effects.  
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7 Conclusions 
Collectively, the results in this thesis study show the decisive role of endothelium 
(and the protein PLVAP) in cell traffic and molecule exchange. We also show that 
the endothelium plays an important role in the formation of tissue-resident 
macrophage population in the mammary gland during embryogenesis. 
Disturbances, even transient ones, in the integrity of the endothelium can have 
serious and long lasting adverse effects in immune responses and immune cell 
composition of tissues. 
 
The main conclusions of the study are the following 
1. PLVAP is expressed in the lymphatic endothelium of the lymph node and 
regulates endothelial permeability in the sub capsular sinus and the 
activation of parenchymal lymphocytes. 
2. In addition to forming physical sieve-like structures, PLVAP has the 
capability to participate in several molecular interactions.  
3. PLVAP expression during embryogenesis is important for the emergence of 
F4/80Hi tissue-resident macrophages in several tissues. 
4. Mammary gland harbors a large macrophage population already before birth. 
In adulthood, F4/80Hi macrophages constitute the major macrophage 
population in the mammary gland. 
5. Tissue-resident macrophages perform unique scavenging functions in the 
mammary glands. 
 
 80 
Acknowledgements 
The work described in this thesis was carried out in the MediCity Research 
Laboratory, Institute of Biomedicine, University of Turku, Finland. 
I wish to thank my supervisors Academician Sirpa Jalkanen, Professor Marko 
Salmi and Docent Pia Rantakari for providing me the opportunity to do my PhD 
here. You have showed me three outlooks on scientific research and the academic 
life. Sirpa, your enthusiasm and drive, Marko, your calm rationality and endless 
knowledge and Pia, your creativity and ambition have guided me through these 
years. The most important lesson I learned from you all is the passion for science. 
Professor Risto Renkonen and Docent Marja Mikkola are warmly thanked for 
reviewing this thesis. Discussing the thesis with you was a pleasure and your 
comments and insight helped me improve this thesis. 
Professor Ulla Pirvola, I thank you for being a part of my steering committee. 
Unfortunately we did not get together too often, but your input is still much 
appreciated. 
The projects and publications in this thesis are products of intense 
collaboration. Therefore I thank all my co-authors for their efforts. With some we 
have worked side by side around the clock and shared the ups and downs of 
research life. PLVAP posse is thanked for the supportive and fun everyday work 
environment: Heidi Gerke, Emmi Lokka, Heli Jokela, Ines Felix, and Etta-Liisa 
Väänänen and the visiting students made sure that not only we got the job done, but 
we also had fun doing it. Fellow doctoral students Laura Kähäri and Ruth Fair-
Mäkelä, thank you for the laughs and lively discussions about science and 
everything but science. I would also like to thank all the past and present people in 
the groups as well as the Maritta Pohjansalo, Riikka Sjöroos, Sari Mäki, Teija 
Kanasuo and Mari Parsama for their technical expertise. Jouko Sandholm, Ketlin 
Adel and Markku Saari, thank you for brightening my day each time we worked 
together, none of our projects would have been finished without you! 
I thank Elina Wiik and Katri Kulmala for secretarial assistance and Antti-Pekka 
Laine for helping me when my IT skills weren’t enough. 
I am fortunate to have shared my journey to a PhD with so many friends. It has 
been wonderful to be able to discuss and get peer support and advice from my 
Acknowledgements 
 81 
friends (and fellow PhDs) Matias Knuuttila, Janne Hakkarainen, Juhani Aakko, and 
Sofia Aakko. I warmly thank the other friends from Terbio-years: Lauri 
Saastamoinen, Joona Valtonen, Jussi Jalonen, Tiia Asukas, Mia Ståhle, Riikka 
Siitonen and Mari Linhala. You have been a great peer support during this journey. 
Anna and the Lemberg family are thanked for the friendship and support over the 
years. 
Kiitos äidilleni Mariannelle sekä Jarille, te olette kannustaneet minua jo ennen 
väitöskirjaurakkaani, mutta varsinkin sen aikana. Olette olleet ilahduttavan ylpeitä 
onnistumisistani ja myös tukeneet kun sen aika on ollut. Kiitokset myös veljilleni 
Jerrylle ja Lukelle, sekä Narikolle ja Yoritolle, muille sukulaisilleni, sekä Mallalle. 
Kiitos ”appivanhemmilleni” Marja-Tertulle ja Heikille mielenkiinnosta uraani 
kohtaan, kannustuksesta sen suhteen. Kiitos koko Sahan perheelle ja suvulle 
lämpimästä vastaanotosta joukkoonne. 
Lopuksi, tahdon kiittää pientä perhettäni. Matti, ei ole itsestään selvää että 
löytää rinnalleen ihmisen, joka varauksetta kannustaa ja rakastaa. Sinä olet juuri 
sellainen minulle ja kanssasi on helppo olla onnellinen. Poikamme Ahto, olet 
mahtava ja rakas pieni ukkeli! Valaiset jokaisen päivän vilpittömällä hymylläsi ja 
toohotustasi on ilahduttava seurata. Odotan innolla tulevia kikkailujamme 
perheenä, kiitos että olette osa elämääni. 
I want to acknowledge the TuDMM doctoral programme, Finnish Cultural 
Foundation – Satakunta Regional Fund, Turun Yliopistosäätio, Emil Aaltonen 
Foundation, Orion research Foundation, Instrumentarium Science foundation and 
Alfred Kordelin Foundation for financially supporting this thesis. 
 
 
 82 
References 
Aird WC (2012) Endothelial Cell Heterogeneity. Cold Spring Harbor perspectives in medicine, 2(1). 
Ajami B, Bennet JL, Krieger C, Tetzlaff W, Rossi FMV (2007) Local self-renewal can sustain CNS 
microglia maintenance and function throughout adult life. Nature Neuroscience, 10(12), 1538-43. 
Ålgars A, Karikoski M, Yegutkin GG, Stoitzner P, Niemelä J, Salmi M, Jalkanen S (2011) Different 
role of CD73 in leukocyte trafficking via blood and lymph vessels. Blood, 117(16), 4387-93. 
Allan RS, Waithman J, Bedoui S, Jones CM, Villadangos JA, Zhan Y, Lew AM, Shortman K, Heath 
WR, Carbone FR (2006) Migratory Dendritic Cells Transfer Antigen to a Lymph Node-Resident 
Dendritic Cell Population for Efficient CTL Priming. Immunity, 25(1), 153-62. 
Allende ML, Lesneski MJ, Xu Y, Brinkmann V, Cyster JG, Lo CG, Proia RL, Matloubian M, 
Cinamon G (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is 
dependent on S1P receptor 1. Nature, 427(6972), 355-60. 
Anselmo AC, Mitragotri S (2017) Impact of particle elasticity on particle-based drug delivery 
systems. Advanced Drug Delivery Reviews, 108, 51-67. 
Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M, Wiig H, Alitalo K (2015) A 
dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. Journal 
of Experimental Medicine, 212(7), 991-9. 
Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, Leibowitch J 
(1997) Positive Effects of Combined Antiretroviral Therapy on CD4+ T Cell Homeostasis and 
Function in Advanced HIV Disease. Science, 277(5322), 112-6. 
Bain CC, Bravo-Blas A, Scott CL, Perdiguero EG, Geissmann F, Henri S, Malissen B, Osborne LC, 
Artis D, Mowat AM (2014) Constant replenishment from circulating monocytes maintains the 
macrophage pool in adult intestine. Nature immunology, 15(10), 929-37. 
Bajénoff M, Egen JG, Koo LY, Laugier J, Brau F, Glaichenhaus N, Germain RN (2006) Stromal Cell 
Networks Regulate Lymphocyte Entry, Migration, and Territoriality in Lymph Nodes. Immunity, 
25(6), 989-1001. 
Baluk P, McDonald DM (2008) Markers for Microscopic Imaging of Lymphangiogenesis and 
Angiogenesis. Annals of the New York Academy of Sciences, 1131(1), 1-12. 
Baluk P, Fuxe J, Hashizume H, Romano T, Lashnits E, Butz S, Vestweber D, Corada M, Molendini 
C, Dejana E, McDonald DM (2007) Functionally specialized junctions between endothelial cells 
of lymphatic vessels. Journal of Experimental Medicine, 204(10), 2349-62. 
Batista FD, Iber D, Neuberger MS (2001) B cells acquire antigen from target cells after synapse 
formation. Nature, 411(6836), 489-94. 
Bearer EL, Orci L (1985) Endothelial fenestral diaphragms: a quick-freeze, deep-etch study. The 
Journal of cell biology, 100(2), 418-28. 
Berney C, Herren S, Power CA, Gordon S, Martinez-Pomares L, Kosco-Vilbois MH (1999) A 
member of the dendritic cell family that enters B cell follicles and stimulates primary antibody 
responses identified by a mannose receptor fusion protein. The Journal of experimental medicine, 
190(6), 851-60. 
References 
 83 
Bingle L, Brown NJ, Lewis CE (2002) The role of tumour‐associated macrophages in tumour 
progression: implications for new anticancer therapies. The Journal of Pathology, 196(3), 254-
65. 
Bolander FF (1990) Differential characteristics of the thoracic and abdominal mammary glands from 
mice. Experimental Cell Research, 189(1), 142-4. 
Bonapace L, Coissieux M, Wyckoff J, Mertz KD, Varga Z, Junt T, Bentires-Alj M (2014) Cessation 
of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature. 515, 
pages 130–133. 
Boring L, Gosling J, Cleary M, Charo I (1998) Decreased lesion formation in CCR2−/− mice reveals a 
role forchemokines in the initiation of atherosclerosis. Nature, 894-7. 
Bosma EK, van Noorden, Cornelis J. F, Schlingemann RO, Klaassen I (2018) The role of 
plasmalemma vesicle-associated protein in pathological breakdown of blood–brain and blood–
retinal barriers: potential novel therapeutic target for cerebral edema and diabetic macular edema. 
Fluids and Barriers of the CNS, 15(1), 1-17. 
Bovay E, Sabine A, Prat-Luri B, Kim S, Son K, Willrodt A, Olsson C, Halin C, Kiefer F, Betsholtz C, 
Jeon NL, Luther SA, Petrova TV (2018) Multiple roles of lymphatic vessels in peripheral lymph 
node development. The Journal of experimental medicine, 215(11), 2760-77. 
Braun A, Worbs T, Moschovakis GL, Halle S, Hoffmann K, Bölter J, Münk A, Förster R (2011) 
Afferent lymph–derived T cells and DCs use different chemokine receptor CCR7–dependent 
routes for entry into the lymph node and intranodal migration. Nature Immunology, 12(9), 879-
87. 
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 
2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 
countries. CA: A Cancer Journal for Clinicians, 68(6), 394-424. 
Broekaert IJ, Becker K, Gottschalk I, Körber F, Dötsch J, Thiele H, Altmüller J, Nürnberg P, 
Hünseler C, Cirak S (2018) Mutations in plasmalemma vesicle-associated protein cause severe 
syndromic protein-losing enteropathy. Journal of Medical Genetics, 55(9), 637-40. 
Brown M, Assen FP, Leithner A, Abe J, Schachner H, Asfour G, Bago-Horvath Z, Stein JV, Uhrin P, 
Sixt M, Kerjaschki D (2018) Lymph node blood vessels provide exit routes for metastatic tumor 
cell dissemination in mice. Science, 359(6382), 1408-11. 
Buckley RH, Schiff SE, Schiff RI, Markert ML, Williams LW, Roberts JL, Myers LA, Ward FE 
(1999) Hematopoietic Stem-Cell Transplantation for the Treatment of Severe Combined 
Immunodeficiency. The New England Journal of Medicine, 340(7), 508-16. 
Carman CV, Sage PT, Sciuto TE, de la Fuente, Miguel A., Geha RS, Ochs H, Dvorak HF, Dvorak 
AM, Springer TA (2007) Transcellular Diapedesis Is Initiated by Invasive Podosomes. Immunity, 
26(6), 784-97. 
Carrasco YR, Batista FD (2007) B Cells Acquire Particulate Antigen in a Macrophage-Rich Area at 
the Boundary between the Follicle and the Subcapsular Sinus of the Lymph Node. Immunity, 
27(1), 160-71. 
Chakarov S, Lim HY, Tan L, Lim SY, See P, Lum J, Zhang X, Foo S, Nakamizo S, Duan K, Kong 
WT, Gentek R, Balachander A, Carbajo D, Bleriot C, Malleret B, Tam JKC, Baig S, Shabeer M, 
Toh SES, Schlitzer A, Larbi A, Marichal T, Malissen B, Chen J, Poidinger M, Kabashima K, 
Bajenoff M, Ng LG, Angeli V, Ginhoux F (2019) Two distinct interstitial macrophage 
populations coexist across tissues in specific subtissular niches. Science, 363(6432), eaau0964. 
Chi J, Chang H, Y, Haraldsen G, Jahnsen FL, Troyanskaya OG, Chang DS, Wang Z, Rockson SG, 
Van de Rijn M, Botstein D, O. Brown P (2003) Endothelial Cell Diversity Revealed by Global 
Expression Profiling. Proceedings of the National Academy of Sciences of the United States of 
America, 100(19), 10623-8. 
Cho K, Morris D, DelProposto J, Geletka L, Zamarron B, Martinez-Santibanez G, Meyer K, Singer 
K, O’Rourke R, Lumeng C (2014) An MHC II-Dependent Activation Loop between Adipose 
Norma Jäppinen 
84 
Tissue Macrophages and CD4+ T Cells Controls Obesity-Induced Inflammation. Cell Reports, 
9(2), 605-17. 
Chu EY, Hens J, Andl T, Kairo A, Yamaguchi TP, Brisken C, Glick A, Wysolmerski JJ, Millar SE 
(2004) Canonical WNT signaling promotes mammary placode development and is essential for 
initiation of mammary gland morphogenesis. Development, 131(19), 4819-29. 
Chua ACL, Hodson LJ, Moldenhauer LM, Robertson SA, Ingman WV (2010) Dual roles for 
macrophages in ovarian cycle-associated development and remodelling of the mammary gland 
epithelium. Development, 137(24), 4229-38. 
Clarke EL, Connell AJ, Six E, Kadry NA, Abbas AA, Hwang Y, Everett JK, Hofstaedter CE, Marsh 
R, Armant M, Kelsen J, Notarangelo LD, Collman RG, Hacein-Bey-Abina S, Kohn DB, 
Cavazzana M, Fischer A, Williams DA, Pai S, Bushman FD (2018) T cell dynamics and 
response of the microbiota after gene therapy to treat X-linked severe combined 
immunodeficiency. Genome Medicine, 10(1), 1-14. 
Cleaver O, Krieg PA (2010) Chapter 8.2 - Vascular Development. Heart Development and 
Regeneration, 487-528. 
Cohen JN, Guidi CJ, Tewalt EF, Qiao H, Rouhani SJ, Ruddell A, Farr AG, Tung KS, Engelhard VH 
(2010) Lymph node–resident lymphatic endothelial cells mediate peripheral tolerance via Aire-
independent direct antigen presentation. The Journal of experimental medicine, 207(4), 681-8. 
Couldrey C, Moitra J, Vinson C, Anver M, Nagashima K, Green J (2002) Adipose tissue: A vital in 
vivo role in mammary gland development but not differentiation. Developmental Dynamics, 
223(4), 459-68. 
Croxtall J, Van Hal P, Choudhury Q, Gilroy D, Flower R (2002) Different glucocorticoids vary in 
their genomic and non‐genomic mechanism of action in A549 cells. British Journal of 
Pharmacology, 135(2), 511-9. 
Dasari P, Sharkey DJ, Noordin E, Glynn DJ, Hodson LJ, Chin PY, Evdokiou A, Robertson SA, 
Ingman WV (2014) Hormonal regulation of the cytokine microenvironment in the mammary 
gland. Journal of Reproductive Immunology, 106, 58-66. 
Davies LC, Rosas M, Smith PJ, Fraser DJ, Jones SA, Taylor PR (2011) A quantifiable proliferative 
burst of tissue macrophages restores homeostatic macrophage populations after acute 
inflammation. European Journal of Immunology. 
Dick SA, Macklin J, A, Nejat S, Momen A, Clemente-Casares X, Althagafi MG, Chen J, Kantores C, 
Hosseinzadeh S, Aronoff L, Wong A, Zaman R, Barbu I, Besla R, Lavine KJ, Razani B, Ginhoux 
F, Husain M, Cybulsky MI, Robbins CS, Epelman S (2019) Self-renewing resident cardiac 
macrophages limit adverse remodeling following myocardial infarction. Nature Immunology, 
20(1), 29-39. 
Dini L, Lentini A, Diez GD, Rocha M, Falasca L, Serafino L, Vidal-Vanaclocha F (1995) 
Phagocytosis of apoptotic bodies by liver endothelial cells. Journal of Cell Science, 108(3), 967. 
Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, Hoogeveen R, Folsom AR, 
Heiss G (2003) Low-Grade Systemic Inflammation and the Development of Type 2 Diabetes: 
The Atherosclerosis Risk in Communities Study. Diabetes, 52(7), 1799-805. 
Elgueta R, Tse D, Deharvengt SJ, Luciano MR, Carriere C, Noelle RJ, Stan RV (2016) Endothelial 
Plasmalemma Vesicle–Associated Protein Regulates the Homeostasis of Splenic Immature B 
Cells and B-1 B Cells. Journal of Immunology, 197(10), 3970-81. 
Elkadri A, Thoeni C, Deharvengt SJ, Murchie R, Guo C, Stavropoulos JD, Marshall CR, Wales P, 
Bandsma RHJ, Cutz E, Roifman CM, Chitayat D, Avitzur Y, Stan RV, Muise AM (2015) 
Mutations in Plasmalemma Vesicle Associated Protein Result in Sieving Protein-Losing 
Enteropathy Characterized by Hypoproteinemia, Hypoalbuminemia, and Hypertriglyceridemia. 
Cellular and Molecular Gastroenterology and Hepatology, 1(4), 394.e7. 
Ensan S, Li A, Besla R, Degousee N, Cosme J, Roufaiel M, Shikatani EA, El-Maklizi M, Williams 
JW, Robins L, Li C, Lewis B, Yun TJ, Lee JS, Wieghofer P, Khattar R, Farrokhi K, Byrne J, 
Ouzounian M, Zavitz CCJ, Levy GA, Bauer CMT, Libby P, Husain M, Swirski FK, Cheong C, 
References 
 85 
Prinz M, Hilgendorf I, Randolph GJ, Epelman S, Gramolini AO, Cybulsky MI, Rubin BB, 
Robbins CS (2015) Self-renewing resident arterial macrophages arise from embryonic CX3CR1+ 
precursors and circulating monocytes immediately after birth. Nature Immunology, 17(2),159-68 
Escobedo N, Oliver G (2016) Lymphangiogenesis: Origin, Specification, and Cell Fate 
Determination. Annual Review of Cell and Developmental Biology, 32(1), 677-91. 
Fata JE, Kong Y, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey 
DL, Boyle WJ, Khokha R, Penninger JM (2000) The Osteoclast Differentiation Factor 
Osteoprotegerin-Ligand Is Essential for Mammary Gland Development. Cell, 103(1), 41-50. 
Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea SK, Powell-Braxton L, Hillan KJ, 
Moore MW (1996) Heterozygous embryonic lethality induced by targeted inactivation of the 
VEGF gene. Nature. 
Fletcher AL, Malhotra D, Acton SE, Lukacs-Kornek V, Bellemare-Pelletier A, Curry M, Armant M, 
Turley SJ (2011) Reproducible Isolation of Lymph Node Stromal Cells Reveals Site-Dependent 
Differences in Fibroblastic Reticular Cells. Frontiers in immunology, 2, 35. 
Forabosco P, Bouzigon E, Ng MY, Hermanowski J, Fisher SA, Criswell LA, Lewis CM (2009) Meta-
analysis of genome-wide linkage studies across autoimmune diseases. European Journal of 
Human Genetics, 17(2), 236-43. 
Förster C, Mäkelä S, Wärri A, Kietz S, Becker D, Hultenby K, Warner M, Gustafsson J (2002) 
Involvement of Estrogen Receptor β in Terminal Differentiation of Mammary Gland Epithelium. 
Proceedings of the National Academy of Sciences of the United States of America, 99(24), 
15578-83. 
Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S, Helft J, Chow A, Elpek KG, 
Gordonov S, Mazloom AR, Ma'ayan A, Chua W, Hansen TH, Turley SJ, Merad M, Randolph GJ 
(2012) Gene-expression profiles and transcriptional regulatory pathways that underlie the 
identity and diversity of mouse tissue macrophages. Nature Immunology, 13(11), 1118. 
Chakrabarti R, Celià-Terrassa T, Kumar S, Hang X, Wei Y, Choudhury A, Hwang J, Peng J, Nixon 
B, Grady JJ, DeCoste C, Gao J, van Es JH, Li MO, Aifantis I, Clevers H, Kang Y (2018) Notch 
ligand Dll1 mediates cross-talk between mammary stem cells and the macrophageal niche. 
Science, 360(6396), eaan4153. 
Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Guan Ng L, 
Stanley ER, Samokhvalov IM, Merad M (2010) Fate Mapping Analysis Reveals That Adult 
Microglia Derive from Primitive Macrophages. Science, 330(6005), 841-5. 
Ginhoux F, Schultze JL, Murray PJ, Ochando J, Biswas SK (2016) New insights into the 
multidimensional concept of macrophage ontogeny, activation and function. Nature Immunology, 
17(1), 34-40. 
Ginhoux F, Guilliams M (2016) Tissue-Resident Macrophage Ontogeny and Homeostasis. Immunity, 
44(3), 439-49. 
Girard J, Moussion C, Förster R (2012) HEVs, lymphatics and homeostatic immune cell trafficking in 
lymph nodes. Nature Reviews. Immunology, 12(11), 762-73. 
Gomez Perdiguero E, Klapproth K, Schulz C, Busch K, Azzoni E, Crozet L, Garner H, Trouillet C, de 
Bruijn MF, Geissmann F, Rodewald H (2015) Tissue-resident macrophages originate from yolk-
sac-derived erythro-myeloid progenitors. Nature, 518(7540), 547-51. 
Gordon EJ, Gale NW, Harvey NL (2008) Expression of the hyaluronan receptor LYVE-1 is not 
restricted to the lymphatic vasculature; LYVE-1 is also expressed on embryonic blood vessels. 
Developmental Dynamics, 237(7), 1901-9. 
Gorelik L, Gilbride K, Dobles M, Kalled SL, Zandman D, Scott ML (2003) Normal B Cell 
Homeostasis Requires B Cell Activation Factor Production by Radiation-resistant Cells. Journal 
of Experimental Medicine, 198(6), 937-45. 
Gouon-Evans V, Rothenberg ME, Pollard JW (2000) Postnatal mammary gland development requires 
macrophages and eosinophils. Development, 127(11), 2269. 
Norma Jäppinen 
86 
Gouon-Evans V, Pollard JW (2002) Unexpected Deposition of Brown Fat in Mammary Gland During 
Postnatal Development. Molecular Endocrinology, 16(11), 2618-27. 
Gretz JE, Norbury CC, Anderson AO, Proudfoot AE, Shaw S (2000) Lymph-borne chemokines and 
other low molecular weight molecules reach high endothelial venules via specialized conduits 
while a functional barrier limits access to the lymphocyte microenvironments in lymph node 
cortex. The Journal of experimental medicine, 192(10), 1425-40. 
Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of cancers in people with 
HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet, 
370(9581), 59-67. 
Guilliams M, Kleer I, Henri S, Post S, Vanhoutte L, Prijck S, Deswarte K, Malissen B, Hammad H, 
Lambrecht B (2013) Alveolar macrophages develop from fetal monocytes that differentiate into 
long-lived cells in the first week of life via GM-CSF. The Journal of Experimental Medicine, 
210(10), 1977-92. 
Gyorki D, Lindeman G, Visvader J (2009) Resident Macrophages Influence Stem Cell Activity in the 
Mammary Gland. Cancer Research, 69(24 Supplement), 49. 
Haldar M, Kohyama M, So A, KC W, Wu X, Briseño C, Satpathy A, Kretzer N, Arase H, 
Rajasekaran N, Wang L, Egawa T, Igarashi K, Baltimore D, Murphy T, Murphy K (2014) Heme-
Mediated SPI-C Induction Promotes Monocyte Differentiation into Iron-Recycling 
Macrophages. Cell, 156(6), 1223-34. 
Hammarlund E, Thomas A, Poore EA, Amanna IJ, Rynko AE, Mori M, Chen Z, Slifka MK (2016) 
Durability of Vaccine-Induced Immunity Against Tetanus and Diphtheria Toxins: A Cross-
sectional Analysis. Clinical Infectious Diseases, 62(9), 1111-8. 
Hashimoto D, Chow A, Noizat C, Teo P, Beasley M, Leboeuf M, Becker C, See P, Price J, Lucas D, 
Greter M, Mortha A, Boyer S, Forsberg E , Tanaka M, van Rooijen N, García-Sastre A, Stanley 
E , Ginhoux F, Frenette P, Merad M (2013) Tissue-Resident Macrophages Self-Maintain Locally 
throughout Adult Life with Minimal Contribution from Circulating Monocytes. Immunity, 38(4), 
792-804. 
Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, Hicklin DJ, Zhu Z, Witte L, Crystal 
RG, Moore M, Rafii S (2001) Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate 
Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells. 
Journal of Experimental Medicine, 193(9), 1005-14. 
Hennighausen L, Robinson GW (2001) Signaling Pathways in Mammary Gland Development. 
Developmental Cell, 1(4), 467-75. 
Herrnberger L, Seitz R, Kuespert S, Bösl M, Fuchshofer R, Tamm E (2012) Lack of endothelial 
diaphragms in fenestrae and caveolae of mutant Plvap-deficient mice. Histochemistry and Cell 
Biology, 138(5), 709-24. 
Hnasko R, McFarland M, Ben-Jonathan N (2002) Distribution and characterization of plasmalemma 
vesicle protein-1 in rat endocrine glands. Journal of Endocrinology, 175(3), 649-61. 
Hoeffel G, Chen J, Lavin Y, Low D, Almeida F, See P, Beaudin A, Lum J, Low I, Forsberg E , 
Poidinger M, Zolezzi F, Larbi A, Ng L, Chan JY, Greter M, Becher B, Samokhvalov I, Merad M, 
Ginhoux F (2015) C-Myb+ Erythro-Myeloid Progenitor-Derived Fetal Monocytes Give Rise to 
Adult Tissue-Resident Macrophages. Immunity, 42(4), 665-78. 
Hogg NAS, Harrison CJ, Tickle C (1983) Lumen formation in the developing mouse mammary 
gland. Journal of Embryology and Experimental Morphology, 73(1), 39. 
Howard B, Gusterson B (2000) Human Breast Development. Journal of Mammary Gland Biology 
and Neoplasia, 5(2), 119-37. 
Hu Z, Yang XY, Liu Y, Morse MA, Lyerly HK, Clay TM, Zhong P (2005) Release of endogenous 
danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs. 
Biochemical and Biophysical Research Communications, 335(1), 124-31. 
Ichikawa M, Sugita M, Takahashi M, Satomi M, Takeshita T, Araki T, Takahashi H (2003) Breast 
milk macrophages spontaneously produce granulocyte–macrophage colony-stimulating factor 
References 
 87 
and differentiate into dendritic cells in the presence of exogenous interleukin-4 alone. 
Immunology, 108(2), 189-95. 
Ichimura K, Stan RV, Kurihara H, Sakai T (2008) Glomerular Endothelial Cells Form Diaphragms 
during Development and Pathologic Conditions. Journal of the American Society of Nephrology: 
JASN, 19(8), 1463-71. 
Iftakhar-E-Khuda I, Fair-Mäkelä R, Kukkonen-Macchi A, Elima K, Karikoski M, Rantakari P, 
Miyasaka M, Salmi M, Jalkanen S (2016) Gene-expression profiling of different arms of 
lymphatic vasculature identifies candidates for manipulation of cell traffic. Proceedings of the 
National Academy of Sciences of the United States of America, 113(38), 10643-8. 
Ingerman-Wojenski C, Silver MJ, Smith JB, Macarak E (1981) Bovine endothelial cells in culture 
produce thromboxane as well as prostacyclin. The Journal of clinical investigation, 67(5), 1292-
6. 
Ingman WV, Wyckoff J, Gouon-Evans V, Condeelis J, Pollard JW (2006) Macrophages promote 
collagen fibrillogenesis around terminal end buds of the developing mammary gland. 
Developmental Dynamics, 235(12), 3222-9. 
Inman JL, Robertson C, Mott JD, Bissell MJ (2015) Mammary gland development: cell fate 
specification, stem cells and the microenvironment. Development (Cambridge, England), 142(6), 
1028-42. 
Iwasaki A, Medzhitov R (2015) Control of adaptive immunity by the innate immune system. Nature 
Immunology, 16(4), 343-53. 
Janeway CA (1992) The immune system evolved to discriminate infectious nonself from 
noninfectious self. Immunology Today, 13(1), 11-6. 
Jerome-Majewska L, Jenkins GP, Ernstoff E, Zindy F, Sherr CJ, Papaioannou VE (2005) Tbx3, the 
ulnar-mammary syndrome gene, and Tbx2 interact in mammary gland development through a 
p19Arf/p53-independent pathway. Developmental Dynamics, 234(4), 922-33. 
Jones D, Min W (2011) An overview of lymphatic vessels and their emerging role in cardiovascular 
disease. Journal of cardiovascular disease research, 2(3), 141-52. 
Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD, 
Khokha R (2010) Progesterone induces adult mammary stem cell expansion. Nature, 465(7299), 
803-7. 
Jubinville É, Routhier J, Maranda-Robitaille M, Pineault M, Milad N, Talbot M, Beaulieu M, Aubin 
S, Paré M, Laplante M, Morissette MC (2019) Pharmacological activation of liver X receptor 
during cigarette smoke exposure adversely affects alveolar macrophages and pulmonary 
surfactant homeostasis. American journal of physiology. Lung cellular and molecular 
physiology, 316(4), L678. 
Junt T, Moseman EA, Iannacone M, Massberg S, Lang PA, Boes M, Fink K, Henrickson SE, 
Shayakhmetov DM, Di Paolo NC, Van Rooijen N, Mempel TR, Whelan SP, Von Andrian UH 
(2007) Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present 
them to antiviral B cells. Nature. 
Keuschnigg J, Henttinen T, Auvinen K, Karikoski M, Salmi M, Jalkanen S (2009) The prototype 
endothelial marker PAL-E is a leukocyte trafficking molecule. Blood, 114(2), 478-84. 
Keuschnigg J, Tvorogov D, Elima K, Salmi M, Alitalo K, Salminen T, Jalkanen S (2012) PV-1 is 
recognized by the PAL-E antibody and forms complexes with NRP-1. Blood, 120(1), 232-5. 
Klyachko NL, Polak R, Haney MJ, Zhao Y, Gomes Neto RJ, Hill MC, Kabanov AV, Cohen RE, 
Rubner MF, Batrakova EV (2017) Macrophages with cellular backpacks for targeted drug 
delivery to the brain. Biomaterials, 140, 79-87. 
Koh TJ, DiPietro LA (2011) Inflammation and wound healing: the role of the macrophage. Expert 
Reviews in Molecular Medicine, 13, e23. 
Kurolap A, Eshach-Adiv O, Gonzaga-Jauregui C, Dolnikov K, Mory A, Paperna T, Hershkovitz T, 
Overton JD, Kaplan M, Glaser F, Zohar Y, Shuldiner AR, Berger G, Baris HN (2018) 
Norma Jäppinen 
88 
Establishing the role of PLVAP in protein-losing enteropathy: a homozygous missense variant 
leads to an attenuated phenotype. Journal of medical genetics, 55(11), 779-84. 
Lambert BE, Moores SR (1986) Radiation Effects in the Lung. Environmental Health Perspectives., 
70, 261-91. 
Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H, Merad M, Jung S, Amit I (2014) 
Tissue-Resident Macrophage Enhancer Landscapes Are Shaped by the Local Microenvironment. 
Cell, 159(6), 1312-26. 
Lee SL, Wesselschmidt RL, Linette GP, Kanagawa O, Russell JH, Milbrandt J (1995) Unimpaired 
thymic and peripheral T cell death in mice lacking the nuclear receptor NGFI-B (Nur77). 
Science, 269(5223), 532-5. 
Lerner A, Jeremias P, Matthias T (2016) The World Incidence and Prevalence of Autoimmune 
Diseases is Increasing. International Journal of Celiac Disease, 3(4), 151-5. 
Lim HS, Blann AD, Chong AY, Freestone B, Lip GYH (2004) Plasma Vascular Endothelial Growth 
Factor, Angiopoietin-1, and Angiopoietin-2 in Diabetes: Implications for cardiovascular risk and 
effects of multifactorial intervention. Diabetes care, 27(12), 2918-24. 
Link A, Vogt TK, Favre S, Britschgi MR, Acha-Orbea H, Hinz B, Cyster JG, Luther SA (2007) 
Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. Nature 
Immunology, 8(11), 1255-65. 
Liu K, Victora G, Schwickert T, guermonprez P, Meredith M, Yao K, Chu F, Randolph G, Rudensky 
A, Nussenzweig M (2009) In Vivo Analysis of Dendritic Cell Development and Homeostasis. 
Science, 324, 392-7. 
Loannidou S, Deinhardt K, Miotla J, Bradley J, Cheung E, Samuelsson S, Ng Y, Shima DT (2006) 
An in vitro Assay Reveals a Role for the Diaphragm Protein PV-1 in Endothelial Fenestra 
Morphogenesis. Proceedings of the National Academy of Sciences of the United States of 
America, 103(45), 16770-5. 
Macias H, Hinck L (2012) Mammary gland development. Wiley Interdisciplinary Reviews: 
Developmental Biology, 1(4), 533-57. 
Martinez FO, Gordon S (2014) The M1 and M2 paradigm of macrophage activation: time for 
reassessment. F1000prime reports, 6, 13. 
Martinez-Corral I, Ulvmar M, Stanczuk L, Tatin F, Kizhatil K, John S, Alitalo K, Ortega S, Makinen 
T (2015) Nonvenous Origin of Dermal Lymphatic Vasculature. Circulation Research, 116(10), 
1649-54. 
Martínez-González J, Badimon L (2005) The NR4A subfamily of nuclear receptors: new early genes 
regulated by growth factors in vascular cells. Cardiovascular research, 65(3), 609-18. 
Massberg S, Schaerli P, Knezevic-Maramica I, Köllnberger M, Tubo N, Moseman EA, Huff IV, Junt 
T, Wagers AJ, Mazo IB, von Andrian UH (2007) Immunosurveillance by Hematopoietic 
Progenitor Cells Trafficking through Blood, Lymph, and Peripheral Tissues. Cell, 131(5), 994-
1008. 
McGrath KE, Koniski AD, Malik J, Palis J (2003) Circulation is established in a stepwise pattern in 
the mammalian embryo. Blood, 101(5), 1669-75. 
McHeyzer-Williams L, McHeyzer-Williams M (2005) Antigen- Specific Memory B cell 
Development. Annual Review of Immunology, 23(1), 487-513. 
Medrek C, Pontén F, Jirström K, Leandersson K (2012) The presence of tumor associated 
macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer, 
12(1), 306. 
Melton DA, Cleaver O (2003) Endothelial signaling during development. Nature Medicine, 9(6), 661-
8. 
Mempel TR, Henrickson SE, Andrian U (2004) T-cell priming by dendritic cells in lymph nodes 
occurs in three distinct phases. Nature, 427(6970), 154-9. 
Menconi F, Monti MC, Greenberg DA, Oashi T, Osman R, Davies TF, Ban Y, Jacobson EM, 
Concepcion ES, Li CW, Tomer Y (2008) Molecular Amino Acid Signatures in the MHC Class II 
References 
 89 
Peptide-Binding Pocket Predispose to Autoimmune Thyroiditis in Humans and in Mice. 
Proceedings of the National Academy of Sciences of the United States of America, 105(37), 
14034-9. 
Millán J, Hewlett L, Glyn M, Toomre D, Clark P, Ridley AJ (2006) Lymphocyte transcellular 
migration occurs through recruitment of endothelial ICAM-1 to caveola- and F-actin-rich 
domains. Nature Cell Biology, 8(2), 113-23. 
Morris L, Graham CF, Gordon S (1991) Macrophages in haemopoietic and other tissues of the 
developing mouse detected by the monoclonal antibody F4/80. Development, 112(2), 517-26. 
Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, O'Hagan D, Rappuoli R, De Gregorio 
E (2008) Molecular and Cellular Signatures of Human Vaccine Adjuvants. Proceedings of the 
National Academy of Sciences of the United States of America, 105(30), 10501-6. 
Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nature 
Reviews, 8. 
Moussion C, Girard J (2011) Dendritic cells control lymphocyte entry to lymph nodes through high 
endothelial venules. Nature, 479(7374), 542-6. 
M'Rini C, Cheng G, Schweitzer C, Cavanagh LL, Palframan RT, Mempel TR, Warnock RA, Lowe 
JB, Quackenbush EJ, von Andrian UH (2003) A Novel Endothelial L-Selectin Ligand Activity in 
Lymph Node Medulla That Is Regulated by α(1,3)-Fucosyltransferase-IV. Journal of 
Experimental Medicine, 198(9), 1301-12. 
Mullican SE, Zhang S, Ruvolo V, Andreeff M, Conneely OM, Milbrandt J, Konopleva M (2007) 
Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid 
leukemia. Nature Medicine, 13(6), 730-5. 
Nackiewicz D, Hanna RN, Hubbeling HG, Punt JA, Green AM, Hedrick CC, Geissmann F, Carlin 
LM (2011) The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and 
the survival of Ly6C − monocytes. Nature Immunology, 12(8), 778-85. 
Naik S, Bouladoux N, Wilhelm C, Molloy MJ, Salcedo R, Kastenmuller W, Deming C, Quinones M, 
Koo L, Conlan S, Spencer S, Hall JA, Dzutsev A, Kong H, Campbell DJ, Trinchieri G, Segre JA, 
Belkaid Y (2012) Compartmentalized Control of Skin Immunity by Resident Commensals. 
Science, 337(6098), 1115-9. 
Nakagami Y, Hatano E, Chayama Y, Inoue T (2019) An anti-PLVAP antibody suppresses laser-
induced choroidal neovascularization in monkeys. European Journal of Pharmacology, 854, 
240-6. 
Newton K, Dixit VM (2012) Signaling in Innate Immunity and Inflammation. Cold Spring Harbor 
Perspectives in Biology, 4(3), a006049. 
Niemelä H, Elima K, Henttinen T, Irjala H, Salmi M, Jalkanen S (2005) Molecular identification of 
PAL-E, a widely used endothelial-cell marker. Blood, 106(10), 3405-9. 
Nolte MA, Kraal G, Mebius RE (2004) Effects of fluorescent and nonfluorescent tracing methods on 
lymphocyte migration in vivo. Cytometry. Part A, 61(1), 35-44. 
Nonaka H, Tanaka M, Suzuki K, Miyajima A (2007) Development of murine hepatic sinusoidal 
endothelial cells characterized by the expression of hyaluronan receptors. Developmental 
dynamics : an official publication of the American Association of Anatomists, 236(8), 2258-67. 
Oakes SR, Hilton HN, Ormandy CJ (2006) Key stages in mammary gland development - The alveolar 
switch: coordinating the proliferative cues and cell fate decisions that drive the formation of 
lobuloalveoli from ductal epithelium. Breas Cancer Research, 8(2), 207. 
Okabe Y, Medzhitov R (2014) Tissue-Specific Signals Control Reversible Program of Localization 
and Functional Polarization of Macrophages. Cell, 157(4), 832-44. 
Palis J, Robertson S, Kennedy M, Wall C, Keller G (1999) Development of erythroid and myeloid 
progenitors in the yolk sac and embryo proper of the mouse. Development, 126(22), 5073. 
Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, Giustetto M, Alves Ferreira T, 
Guiducci E, Dumas L, Ragozzino D, Gross CT (2011) Synaptic Pruning by Microglia Is 
Necessary for Normal Brain Development. Science, 333(6048), 1456-8. 
Norma Jäppinen 
90 
Park EJ, Lee JH, Yu G, He G, Ali SR, Holzer RG, Österreicher CH, Takahashi H, Karin M (2010) 
Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 
and TNF Expression. Cell, 140(2), 197-208. 
Parmar H, Cunha GR (2004) Epithelial–stromal interactions in the mouse and human mammary gland 
in vivo. Endocrine-Related Cancer, 11(3), 437-58. 
Pato E, Muñoz-Fernández S, Francisco F, Abad MA, Maese J, Ortiz A, Carmona L (2011) Systematic 
Review on the Effectiveness of Immunosuppressants and Biological Therapies in the Treatment 
of Autoimmune Posterior Uveitis. Seminars in Arthritis and Rheumatism, 40(4), 314-23. 
Petrova TV, Koh GY (2018) Organ-specific lymphatic vasculature: From development to 
pathophysiology. Journal of Experimental Medicine, 215(1), 35-49. 
Pollard JW, Henninghausen L (1994) Colony stimulating factor 1 is required for mammary gland 
development during pregnancy. Proceedings of the National Academy of Sciences of the United 
States of America, 91, 9312-6. 
Predescu SA, Predescu DN, Palade GE (1997) Plasmalemmal vesicles function as transcytotic 
carriers for small proteins in the continuous endothelium. American Journal of Physiology, 
41(2), H937. 
Rafii S, Mohle R, Shapiro F, Frey BM, Moore MAS (1997) Regulation of Hematopoiesis by 
Microvascular Endothelium. Leukemia & Lymphoma, 27(5-6), 375-86. 
Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li 
M, Pestell RG, Di Vizio D, Hou HJ, Kneitz B, Lagaud G, Christ GJ, Edelmann W, Lisanti MP 
(2001) Caveolin-1 Null Mice Are Viable but Show Evidence of Hyperproliferative and Vascular 
Abnormalities. Journal of Biological Chemistry, 276(41), 38121. 
Reynoso GV, Weisberg AS, Shannon JP, McManus DT, Shores L, Americo JL, Stan RV, Yewdell 
JW, Hickman HD (2019) Lymph node conduits transport virions for rapid T cell activation. 
Nature immunology. 
Rhodin JAG (1962) The diaphragm of capillary endothelial fenestrations. Journal of Ultrastructure 
Research, 6(2), 171-85. 
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, Aspirin, and 
the Risk of Cardiovascular Disease in Apparently Healthy Men. The New England Journal of 
Medicine, 336(14), 973-9. 
Risau W, Sariola H, Zerwes HG, Sasse J, Ekblom P, Kemler R, Doetschman T (1988) Vasculogenesis 
and angiogenesis in embryonic-stem-cell-derived embryoid bodies. Development, 102(3), 471. 
Risau W (1995) Differentiation of endothelium. The FASEB Journal, 9(10), 926-33. 
Risau W, Flamme I (1995) Vasculogenesis. Annual Review of Cell and Developmental Biology, 
11(1), 73-91. 
Risau W (1998) Development and differentiation of endothelium. Kidney International, 54(S67), S6. 
Roozendaal R, Mempel TR, Pitcher LA, Gonzalez SF, Verschoor A, Mebius RE, von Andrian UH, 
Carroll MC (2009) Conduits Mediate Transport of Low-Molecular-Weight Antigen to Lymph 
Node Follicles. Immunity, 30(2), 264-76. 
Ryan GR (2001) Rescue of the colony-stimulating factor 1 (CSF-1)-nullizygous mouse 
(Csf1op/Csf1op) phenotype with a CSF-1 transgene and identification of sites of local CSF-1 
synthesis. Blood, 98(1), 74-84. 
Salomon B, Cohen JL, Masurier C, Klatzmann D (1998) Three Populations of Mouse Lymph Node 
Dendritic Cells with Different Origins and Dynamics. The Journal of Immunology, 160(2), 708-
17. 
Schlingemann RO, Dingjan GM, Emeis JJ, Blok J, Warnaar SO, Ruiter DJ (1985) Monoclonal 
antibody PAL-E Specific for endothelium. Laboratory Investigation. 
Schubert W, Frank PG, Razani B, Park DS, Chow C, Lisanti MP (2001) Caveolae-deficient 
Endothelial Cells Show Defects in the Uptake and Transport of Albumin in Vivo. Journal of 
Biological Chemistry, 276(52), 48619. 
References 
 91 
Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, Prinz M, Wu B, 
Jacobsen SEW, Pollard JW, Frampton J, Liu KJ, Geissmann F (2012) A Lineage of Myeloid 
Cells Independent of Myb and Hematopoietic Stem Cells. Science, 336(6077), 86-90. 
Serbina NV, Pamer EG (2006) Monocyte emigration from bone marrow during bacterial infection 
requires signals mediated by chemokine receptor CCR2. Nature Immunology, 7(3), 311-7. 
Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu X, Breitman ML, Schuh AC (1995) 
Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature, 376(6535), 
62-6. 
Shetty S, Weston CJ, Oo YH, Westerlund N, Stamataki Z, Youster J, Hubscher SG, Salmi M, 
Jalkanen S, Lalor PF, Adams DH (2011) Common Lymphatic Endothelial and Vascular 
Endothelial Receptor-1 Mediates the Transmigration of Regulatory T Cells across Human 
Hepatic Sinusoidal Endothelium. Journal of Immunology, 186(7), 4147-55. 
Shuvaev VV, Kiseleva RY, Arguiri E, Villa CH, Muro S, Christofidou-Solomidou M, Stan RV, 
Muzykantov VR (2018) Targeting superoxide dismutase to endothelial caveolae profoundly 
alleviates inflammation caused by endotoxin. Journal of Controlled Release, 272, 1-8. 
Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. The Journal of 
clinical investigation, 122(3), 787-95. 
Sindrilaru A, Peters T, Wieschalka S, Baican C, Baican A, Peter H, Hainzl A, Schatz S, Qi Y, 
Schlecht A, Weiss JM, Wlaschek M, Sunderkötter C, Scharffetter-Kochanek K (2011) An 
unrestrained proinflammatory M1 macrophage population induced by iron impairs wound 
healing in humans and mice. The Journal of clinical investigation, 121(3), 985-97. 
Sixt M, Kanazawa N, Selg M, Samson T, Roos G, Reinhardt DP, Pabst R, Lutz MB, Sorokin L 
(2005) The Conduit System Transports Soluble Antigens from the Afferent Lymph to Resident 
Dendritic Cells in the T Cell Area of the Lymph Node. Immunity, 22(1), 19-29. 
Soucie EL, Weng Z, Geirsdóttir L, Molawi K, Maurizio J, Fenouil R, Mossadegh-Keller N, Gimenez 
G, VanHille L, Beniazza M, Favret J, Berruyer C, Perrin P, Hacohen N, Andrau J, Ferrier P, 
Dubreuil P, Sidow A, Sieweke MH (2016) Lineage-specific enhancers activate self-renewal 
genes in macrophages and embryonic stem cells. Science, 351(6274), aad5510. 
Stan RV, Ghitescu L, Jacobson BS, Palade GE (1999) Isolation, Cloning, and Localization of Rat PV-
1, a Novel Endothelial Caveolar Protein. The Journal of cell biology, 1189-98. 
Stan RV, Kubitza M, Palade GE (1999) PV-1 Is a Component of the Fenestral and Stomatal 
Diaphragms in Fenestrated Endothelia. Proceedings of the National Academy of Sciences of the 
United States of America, 96(23), 13203-7. 
Stan RV, Arden KC, Palade GE (2001) cDNA and Protein Sequence, Genomic Organization, and 
Analysis of cis Regulatory Elements of Mouse and Human PLVAP Genes. Genomics, 72(3), 
304-13. 
Stan RV (2007) Endothelial stomatal and fenestral diaphragms in normal vessels and angiogenesis. 
Journal of Cellular and Molecular Medicine, 11(4), 621-43. 
Stan RV, Tse D, Deharvengt S, Smits N, Xu Y, Luciano M, McGarry C, Buitendijk M, Nemani K, 
Elgueta R, Kobayashi T, Shipman S, Moodie K, Daghlian C, Ernst P, Lee H, Suriawinata A, 
Schned A, Longnecker D, Fiering S, Noelle R, Gimi B, Shworak N, Carrière C (2012) The 
Diaphragms of Fenestrated Endothelia: Gatekeepers of Vascular Permeability and Blood 
Composition. Developmental Cell, 23(6), 1203-18. 
Stein JV, Soriano SF, M'rini C, Nombela-Arrieta C, de Buitrago GG, Rodríguez-Frade JM, Mellado 
M, Girard J, Martínez-A C (2003) CCR7-mediated physiological lymphocyte homing involves 
activation of a tyrosine kinase pathway. Blood, 101(1), 38-44. 
Streeten EA, Brandi ML (1990) Biology of bone endothelial cells. Bone and Mineral, 10(2), 85-94. 
Sternlicht MD (2006) Key stages in mammary gland development: The cues that regulate ductal 
branching morphogenesis. Breast cancer research : BCR, 8(1), 201. 
Norma Jäppinen 
92 
Stolen CM, Marttila-Ichihara F, Koskinen K, Yegutkin GG, Turja R, Bono P, Skurnik M, Hänninen 
A, Jalkanen S, Salmi M (2005) Absence of the Endothelial Oxidase AOC3 Leads to Abnormal 
Leukocyte Traffic In Vivo. Immunity, 22(1), 105-15. 
Strickland LA, Jubb AM, Hongo J, Zhong F, Burwick J, Fu L, Frantz GD, Koeppen H (2005) 
Plasmalemmal vesicle‐associated protein (PLVAP) is expressed by tumour endothelium and is 
upregulated by vascular endothelial growth factor‐A (VEGF). The Journal of Pathology, 206(4), 
466-75. 
Thierry GR, Kuka M, De Giovanni M, Mondor I, Brouilly N, Iannacone M, Bajénoff M (2018) The 
conduit system exports locally secreted IgM from lymph nodes. The Journal of experimental 
medicine, 215(12), 2972-83. 
Thompson LF, Eltzschig HK, Ibla JC, Van De Wiele C, Justin, Resta R, Morote-Garcia JC, Colgan 
SP (2004) Crucial Role for Ecto-5 -Nucleotidase (CD73) in Vascular Leakage during Hypoxia, 
200. 
Tkachenko E, Tse D, Sideleva O, Deharvengt SJ, Luciano MR, Xu Y, McGarry CL, Chidlow J, Pilch 
PF, Sessa WC, Toomre DK, Stan RV (2012) Caveolae, Fenestrae and Transendothelial Channels 
Retain PV1 on the Surface of Endothelial Cells. PLoS One, 7(3), e32655. 
Tsou C, Peters W, Si Y, Slaymaker S, Aslanian AM, Weisberg SP, Mack M, Charo IF (2007) Critical 
roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to 
inflammatory sites. Journal of Clinical Investigation, 117(4), 902-9. 
Umansky V, Sevko A (2012) Overcoming immunosuppression in the melanoma microenvironment 
induced by chronic inflammation. Cancer Immunology, Immunotherapy, 61(2), 275-82. 
Van de Laar L, Saelens W, De Prijck S, Martens L, Scott C, Van Isterdael G, Hoffmann E, Beyaert R, 
Saeys Y, Lambrecht B, Guilliams M (2016) Yolk Sac Macrophages, Fetal Liver, and Adult 
Monocytes Can Colonize an Empty Niche and Develop into Functional Tissue-Resident 
Macrophages. Immunity, 44(4), 755-68. 
Van Nguyen A, Pollard JW (2002) Colony Stimulating Factor-1 Is Required to Recruit Macrophages 
into the Mammary Gland to Facilitate Mammary Ductal Outgrowth. Developmental Biology, 
247(1), 11-25. 
Van Rooijen N, Sanders A (1994) Liposome mediated depletion of macrophages: mechanism of 
action, preparation of liposomes and applications. Journal of Immunological Methods, 174(1), 
83-93 
Varol C, Mildner A, Jung S (2015) Macrophages: Development and Tissue Specialization. Annual 
Review of Immunology, 33(1), 643-75. 
Veerman K, Tardiveau C, Martins F, Coudert J, Girard J (2019) Single-Cell Analysis Reveals 
Heterogeneity of High Endothelial Venules and Different Regulation of Genes Controlling 
Lymphocyte Entry to Lymph Nodes. Cell Reports, 26(11), 3131.e5. 
Veltmaat JM, Relaix F, Le LT, Kratochwil K, Sala FG, van Veelen W, Rice R, Spencer-Dene B, 
Mailleux AA, Rice DP, Thiery JP, Bellusci S (2006) Gli3-mediated somitic Fgf10 expression 
gradients are required for the induction and patterning of mammary epithelium along the 
embryonic axes. Development, 133(12), 2325. 
Vestweber D (2015) How leukocytes cross the vascular endothelium. Nature Reviews. Immunology, 
15(11), 692-704. 
Wang Y, Cheng T, Chen T, Chang K, Chuang VP, Kao K (2014) Plasmalemmal Vesicle Associated 
Protein (PLVAP) as a therapeutic target for treatment of hepatocellular carcinoma. BMC Cancer, 
14(1), 815. 
Wang Y, Jin Y, Mäe M, Zhang Y, Ortsäter H, Betsholtz C, Mäkinen T, Jakobsson L (2017) Smooth 
muscle cell recruitment to lymphatic vessels requires PDGFB and impacts vessel size but not 
identity. Development (Cambridge, England), 144(19), 3590. 
Watson CJ, Khaled WT (2008) Mammary development in the embryo and adult: a journey of 
morphogenesis and commitment. Development, 135(6), 995-1003. 
References 
 93 
Wigle JT, Oliver G (1999) Prox1 Function Is Required for the Development of the Murine Lymphatic 
System. Cell, 98(6), 769-78. 
Wilson JC, Sarsour K, Gale S, Pethö‐Schramm A, Jick SS, Meier CR (2019) Incidence and Risk of 
Glucocorticoid‐Associated Adverse Effects in Patients With Rheumatoid Arthritis. Arthritis Care 
& Research, 71(4), 498-511. 
Wisniewska-Kruk J, van der Wijk A, van Veen HA, Gorgels, Theo G. M. F., Vogels IMC, Versteeg 
D, Van Noorden, Cornelis J. F., Schlingemann RO, Klaassen I (2016) Plasmalemma Vesicle–
Associated Protein Has a Key Role in Blood-Retinal Barrier Loss. The American Journal of 
Pathology, 186(4), 1044-54. 
Wolber FM, Leonard E, Michael S, Orschell-Traycoff CM, Yoder MC, Srour EF (2002) Roles of 
spleen and liver in development of the murine hematopoietic system. Experimental Hematology, 
30(9), 1010-9. 
Wood PJ (2015) Immunological response to infection: inflammatory and adaptive immune responses. 
Anaesthesia & Intensive Care Medicine, 16(7), 349-52. 
Xu H, Guan H, Zu G, Bullard D, Hanson J, Slater M, Elmets CA (2001) The role of ICAM-1 
molecule in the migration of Langerhans cells in the skin and regional lymph node. European 
Journal of Immunology, 31(10), 3085-93. 
Yona S, Kim K, Wolf Y, Mildner A, Varol D, Breker M, Strauss-Ayali D, Viukov S, Guilliams M, 
Misharin A, Hume D, Perlman H, Malissen B, Zelzer E, Jung S (2013) Fate Mapping Reveals 
Origins and Dynamics of Monocytes and Tissue Macrophages under Homeostasis. Immunity, 
38(1), 79-91. 
Young AJ (1999) The physiology of lymphocyte migration through the single lymph node in vivo. 
Seminars in Immunology, 11(2), 73-83. 
Zhao X, Qu J, Sun Y, Wang J, Liu X, Wang F, Zhang H, Wang W, Ma X, Gao X, Zhang S (2017) 
Prognostic significance of tumor-associated macrophages in breast cancer: a meta-analysis of the 
literature. Oncotarget, 8(18), 30576-86. 
Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure 
SP, Linehan DC, DeNardo DG (2014) CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating 
Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer 
Models. Cancer research, 74(18), 5057-69.  
 
 
A
N
N
A
LES U
N
IV
ERSITATIS TU
RK
U
EN
SIS
N
orm
a Jäppinen
D
 1445
ISBN 978-951-29-7780-2 (PRINT)
ISBN 978-951-29-7781-9 (PDF)
ISSN 0355-9483 (PRINT) ISSN 2343-3213 (ONLINE)
Pa
in
os
al
am
a 
O
y, 
Tu
rk
u 
, F
in
la
nd
  2
01
9
PLVAP AS THE 
GATEKEEPER OF 
ENDOTHELIAL CELL 
PERMEABILITY AND 
LEUKOCYTE MIGRATION
Norma Jäppinen
TURUN YLIOPISTON JULKAISUJA – ANNALES UNIVERSITATIS TURKUENSIS
SARJA – SER. D OSA – TOM. 1445 | MEDICA – ODONTOLOGICA | TURKU 2019
